{"title":"Medicinal chemistry Books","description":"","products":[{"product_id":"periodic-tales-9780141041452","title":"Periodic Tales","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cb\u003eTHE PHENOMENAL \u003ci\u003eSUNDAY TIMES\u003c\/i\u003e BESTSELLER\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e  \u003cb\u003e''Science writing at its best. If only chemistry had been like this at school'' Matt Ridley\u003c\/b\u003e\u003cbr\u003e  ____________________\u003cbr\u003e\u003cbr\u003e Everything in the universe is made of them, including you. Like you, \u003cu\u003ethe elements\u003c\/u\u003e have personalities, attitudes, talents, shortcomings, stories rich with meaning.\u003cbr\u003e\u003cbr\u003e Here you''ll meet iron that rains from the heavens and noble gases that light the way to vice. You''ll learn how lead can tell your future while zinc may one day line your coffin. You''ll discover what connects the bones in your body with the Whitehouse in Washington, the glow of a streetlamp with the salt on your dinner table.\u003cbr\u003e\u003cbr\u003e Unlocking their astonishing secrets and colourful pasts, \u003ci\u003ePeriodic Tales \u003c\/i\u003eis a voyage of wonder and discovery, showing that their stories are inextricable from the stories of our own lives.\u003cbr\u003e  ____________________\u003cbr\u003e\u003cbr\u003e \u003cb\u003e''A love letter to the chemical elements. Aldersey-Williams is full of good stories and he knows how to tell them well'' \u003ci\u003eSunday Telegraph\u003c\/i\u003e\u003cbr\u003e\u003cbr\u003e ''The history, science, art, literature and everyday applications of all the elements from aluminium to zinc'' \u003ci\u003eThe Times\u003c\/i\u003e\u003cbr\u003e \u003c\/b\u003e\u003cbr\u003e  \u003cb\u003e''Great fun to read and an endless fund of unlikely and improbable anecdotes'' \u003c\/b\u003e\u003cb\u003e\u003ci\u003eFinancial Times\u003c\/i\u003e\u003c\/b\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003eScience writing at its best ... fascinating and beautiful ... if only chemistry had been like this at school ... to meander through the periodic table with him ... is like going round a zoo with Gerald Durrell ... a rich compilation of delicious tales, but it offers greater rewards, too -- Matt Ridley\u003cbr\u003eImmensely engaging and continually makes one sit up in ­surprise * Sunday Times *\u003cbr\u003eSplendid ... enjoyable and polished * Observer *\u003cbr\u003eFull of good stories and he knows how to tell them well ... an agreeable jumble of anecdote, reflection and information * Sunday Telegraph *\u003cbr\u003eGreat fun to read and an endless fund of unlikely and improbable anecdotes ... sharp and often witty * Financial Times *\u003cbr\u003eA joyous romp through the chemical elements * Today, BBC Radio 4 *\u003cbr\u003eNot only a cultural history of the elements, it is also a lament to the loss of science as a hobby * Economist *\u003cbr\u003eA flashily brainy book, crammed with literary references and held together by a personal quest to collect as many elements as possible * Telegraph *\u003cbr\u003e'Elements are fun' is the essential premise of Hugh Aldersey-Williams's new book and by heck he's right ... Aldersey-Williams mourns the fact chemistry isn't really sexy any more; \u003ci\u003ePeriodic Tales\u003c\/i\u003e is a step towards it getting its mojo back * Metro **** *\u003cbr\u003eImaginative and fun ... almost every page yields a nugget * Nature *","brand":"Penguin Books Ltd","offers":[{"title":"Default Title","offer_id":48732407038295,"sku":"9780141041452","price":11.69,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780141041452.jpg?v=1719996743"},{"product_id":"an-introduction-to-medicinal-chemistry-9780198866664","title":"An Introduction to Medicinal Chemistry","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThe market-leader in medicinal chemistry: clear, supportive, and practical. It helps students to effortlessly make the link from theory to real-life applications using practical and focused coverage alongside a package of supportive online resources.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003eThe best general undergraduate textbook on medicinal chemistry. This new edition retains the accessible style of writing, but provides important updates on the topics. * Dr Mark Ashton, School of Pharmacy, Newcastle University, UK *\u003cbr\u003eI read this masterpiece to build a strong knowledge of medicinal chemistry and it has helped me a lot. I would definitely recommend it to others. Detailed explanations of enzyme-substrate interactions and much more are very useful. * Jinkal Gondaria, MChem student, Manchester Metropolitan University, UK *\u003cbr\u003eA very useful medical chemistry book and teaching tool. Great learning resources and easy to digest content. * Dr Silvia M.M.A. Pereira-Lima, Department of Chemistry, University of Minho, Portugal *\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e1: Drugs and Drug Targets 2: Protein Structure and Function 3: Enzymes: Structure and Function 4: Receptors: Structure and Function 5: Receptors and Signal Transduction 6: Nucleic Acids: Structure and Function 7: Enzymes as Drug Targets 8: Receptors as Drug Targets 9: Nucleic Acids as Drug Targets 10: Miscellaneous Drug Targets 11: Pharmacokinetics and Related Topics Case Study 1: Statins 12: Drug Discovery: Finding a Lead 13: Drug Design: Optimizing Target Interactions 14: Drug Design: Optimizing Access to the Target 15: Getting the Drug to Market Case Study 2: The Design of ACE Inhibitors Case Study 3: Artemisinin and Related Antimalarial Drugs Case Study 4: The Design of Oxamni Case Study 5: Fosfidomycin as an Antimalarial Agent 16: Combinatorial and Parallel Synthesis 17: In Silico Drug Design 18: Quantitative Structure-Activity Relationships Case Study 6:  De Novo Design of a Thymidylate Synthase Inhibitor 19: Antibacterial Agents 20: Antiviral Agents 21: Anticancer Agents 22: Protein Kinase Inhibitors as Anticancer Agents 23: Antibodies and Other Biologics 24: Cholinergics, Anticholinergics, and Anticholinestarases 25: Drugs Acting on the Adrenergic Nervous System 26: The Opioid Analgesics 27: Anti-Ulcer Agents 28: Cardiovascular Drugs Case Study 7: Steroidal Anti-Inflammatory Agents Case Study 8: Design of a Novel Antidepressant Case Study 9: The Design and Development Of Aliskiren Case Study 10: Factor Xa Inhibitors Case Study 11: Reversible Inhibitors of HCV NS-34A Protease","brand":"Oxford University Press","offers":[{"title":"Default Title","offer_id":48732821717335,"sku":"9780198866664","price":52.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780198866664.jpg?v=1719998543"},{"product_id":"impacts-of-the-covid19-pandemic-9781119812159","title":"Impacts of the Covid19 Pandemic","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eIMPACTS OF THE COVID-19 PANDEMIC\u003c\/b\u003e \u003cp\u003e\u003cb\u003eEnables Readers to Understand the Impact of International Legislative and Policy Responses to the COVID-19 Pandemic\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eThe wide array of legal and policy responses to the COVID-19 pandemic have significant implications regarding the functioning of countries and their respective societies. This book addresses the impact of international legislative and policy responses to the COVID-19 pandemic in a range of countries. \u003c\/p\u003e\u003cp\u003eTo aid the reader in understanding country-specific developments, each chapter focuses on a specific country and addresses the legal frameworks and policy approaches used to support measures to prevent transmission and otherwise reduce the impact of the virus on society and the economy. Sample topics discussed in the work include: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eThe effect certain policies may have on civil liberties, such as due process, and the right to privacy in specific countries\u003c\/li\u003e \u003cli\u003eThe provision of public goods in the face of the pa\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eNotes on Contributors xiii\u003c\/p\u003e \u003cp\u003eForeword xv\u003c\/p\u003e \u003cp\u003ePreface xix\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 1 Countries with a Focus on the Rule of Law and Legal Protections of Civil Liberties 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 The Netherlands: Dutch COVID-19 Policy Viewed from a Fundamental Rights Perspective 3\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eAdriaan J. Wierenga and Jorrit Westerhof\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 3\u003c\/p\u003e \u003cp\u003e1.2 Disaster Management in the Netherlands 4\u003c\/p\u003e \u003cp\u003e1.2.1 Functional and General Chain of Command 4\u003c\/p\u003e \u003cp\u003e1.2.2 The COVID-19 Crisis 5\u003c\/p\u003e \u003cp\u003e1.3 The Public Health Act 2008 (Functional Chain of Command) 5\u003c\/p\u003e \u003cp\u003e1.3.1 National Crisis Structure 6\u003c\/p\u003e \u003cp\u003e1.3.2 Measures 7\u003c\/p\u003e \u003cp\u003e1.4 Municipal Emergency Powers (General Chain of Command) 8\u003c\/p\u003e \u003cp\u003e1.4.1 Areas of Tension 8\u003c\/p\u003e \u003cp\u003e1.4.2 Debatable Limitations of Fundamental Rights 9\u003c\/p\u003e \u003cp\u003e1.4.3 Democratic Control and Administrative Supervision 10\u003c\/p\u003e \u003cp\u003e1.5 Interim COVID-19 Measures Act (Addition to the Functional Chain of Command) 11\u003c\/p\u003e \u003cp\u003e1.5.1 Improvements and Shortcomings 12\u003c\/p\u003e \u003cp\u003e1.5.2 Legitimate Limitation of Fundamental Rights 12\u003c\/p\u003e \u003cp\u003e1.5.3 Stricter Democratic Control 13\u003c\/p\u003e \u003cp\u003e1.6 National Emergency Law 14\u003c\/p\u003e \u003cp\u003e1.6.1 Separate Implementation 15\u003c\/p\u003e \u003cp\u003e1.6.2 Criticism 16\u003c\/p\u003e \u003cp\u003e1.6.3 The Curfew Case 17\u003c\/p\u003e \u003cp\u003e1.7 Conclusion 18\u003c\/p\u003e \u003cp\u003eReferences 19\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Emergencies, Executive Power, and Ireland’s Response to the Covid-19 Pandemic 23\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eAlan Greene\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 23\u003c\/p\u003e \u003cp\u003e2.2 Ireland’s Constitutional Emergency Framework 24\u003c\/p\u003e \u003cp\u003e2.2.1 International Human Rights Law 26\u003c\/p\u003e \u003cp\u003e2.3 Ireland’s Pandemic Response and Constitutional Constraints 27\u003c\/p\u003e \u003cp\u003e2.3.1 Pandemic Rent Controls and Constitutional Constraints 28\u003c\/p\u003e \u003cp\u003e2.3.2 Executive Supremacy and the COVID-19 Pandemic 29\u003c\/p\u003e \u003cp\u003e2.4 Ireland’s Pandemic Response and Human Rights 31\u003c\/p\u003e \u003cp\u003e2.4.1 The Pandemic and the Right to Liberty 31\u003c\/p\u003e \u003cp\u003e2.4.1.1 Mandatory Hotel Quarantine 32\u003c\/p\u003e \u003cp\u003e2.4.2 Quarantine and Detention at Home 34\u003c\/p\u003e \u003cp\u003e2.5 Data Protection, Surveillance, and Discrimination Issues 36\u003c\/p\u003e \u003cp\u003e2.5.1 Vaccination and Vaccine Passports 37\u003c\/p\u003e \u003cp\u003e2.6 COVID-19 and the Rule of Law in Ireland 38\u003c\/p\u003e \u003cp\u003e2.7 Conclusions 39\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 COVID-19: Legal Lessons Learned in Switzerland 41\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eFelix Uhlmann\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 41\u003c\/p\u003e \u003cp\u003e3.2 Legal Framework 41\u003c\/p\u003e \u003cp\u003e3.2.1 Legal Framework before COVID-19 (Swiss Epidemics Act) 41\u003c\/p\u003e \u003cp\u003e3.2.1.1 Scope and Goals 41\u003c\/p\u003e \u003cp\u003e3.2.1.2 Normal, Particular, and Extraordinary Situations 42\u003c\/p\u003e \u003cp\u003e3.2.1.3 Measures 44\u003c\/p\u003e \u003cp\u003e3.2.2 Legal Framework Under COVID-19 45\u003c\/p\u003e \u003cp\u003e3.2.2.1 First and SecondWave 45\u003c\/p\u003e \u003cp\u003e3.2.2.2 Financial Aid 47\u003c\/p\u003e \u003cp\u003e3.2.2.3 The Federal Council and Other Actors 48\u003c\/p\u003e \u003cp\u003e3.3 Contact Tracing App 48\u003c\/p\u003e \u003cp\u003e3.4 Fundamental Rights (Civil Liberties) 50\u003c\/p\u003e \u003cp\u003e3.4.1 Restrictions on Daily Life 50\u003c\/p\u003e \u003cp\u003e3.4.2 Vaccinations 52\u003c\/p\u003e \u003cp\u003e3.5 Assessment 53\u003c\/p\u003e \u003cp\u003eReferences 54\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Not Dead Yet: Protest, Process, and Germany’s Constitutional Democracy Amid the Coronavirus Response 59\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eCarolyn Halladay\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 The FirstWave: So Far, So Good 60\u003c\/p\u003e \u003cp\u003e4.2 Proportionality and its Discontents 65\u003c\/p\u003e \u003cp\u003e4.3 Summer in the City 67\u003c\/p\u003e \u003cp\u003e4.4 Is it an Emergency Yet? 71\u003c\/p\u003e \u003cp\u003e4.5 Second Guessing the SecondWave 75\u003c\/p\u003e \u003cp\u003e4.6 Happily Ever After? 77\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 The United Kingdom Legislative Response to Coronavirus: Shotgun or Machine Gun 79\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRonan Cormacain and Duncan Fairgrieve\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction 79\u003c\/p\u003e \u003cp\u003e5.2 Reliance Upon Law 79\u003c\/p\u003e \u003cp\u003e5.3 Nature of the Legal Framework 80\u003c\/p\u003e \u003cp\u003e5.3.1 Machine Gun Legislative Response 80\u003c\/p\u003e \u003cp\u003e5.3.2 Devolution and the Legislative Response 80\u003c\/p\u003e \u003cp\u003e5.3.3 Overview of the Legislative Framework 81\u003c\/p\u003e \u003cp\u003e5.3.4 Pre-existing Laws or New Laws 84\u003c\/p\u003e \u003cp\u003e5.3.5 Use of Emergency\/Urgency Powers and Procedures or Use of Regular Powers and Procedures 84\u003c\/p\u003e \u003cp\u003e5.3.6 Sunset Clauses\/Expiry Dates 86\u003c\/p\u003e \u003cp\u003e5.4 Substance of the Legal Response 86\u003c\/p\u003e \u003cp\u003e5.4.1 Restrictions on Individual Liberties 86\u003c\/p\u003e \u003cp\u003e5.4.2 Travel Restrictions 87\u003c\/p\u003e \u003cp\u003e5.4.3 Vaccination Policy 87\u003c\/p\u003e \u003cp\u003e5.4.4 Track and Trace 90\u003c\/p\u003e \u003cp\u003e5.4.5 Support Measures – Furlough Payments, no Evictions 90\u003c\/p\u003e \u003cp\u003e5.5 Problems\/Analysis of the Legal Response 91\u003c\/p\u003e \u003cp\u003e5.5.1 Reliance upon Emergency Procedures and Processes to Make Law in a Rush 91\u003c\/p\u003e \u003cp\u003e5.5.2 Lack of Effective Parliamentary Scrutiny 92\u003c\/p\u003e \u003cp\u003e5.5.3 Conflation of Law with Guidance 93\u003c\/p\u003e \u003cp\u003e5.5.4 Inaccessible and Unintelligible Legislation 94\u003c\/p\u003e \u003cp\u003e5.5.5 Risk of Creep of Emergency Practices into Normal Lawmaking 95\u003c\/p\u003e \u003cp\u003e5.5.6 Compliance with the Rules by Those in Power 96\u003c\/p\u003e \u003cp\u003e5.6 Conclusion 96\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 2 Countries making Extensive use of Emergency Laws and Securitization 99\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 The State of Exception and its Effects on Civil Liberties in Italy During the COVID-19 Crisis 101\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eAnna Malandrino, Margherita Paola Poto, and Elena Demichelis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 101\u003c\/p\u003e \u003cp\u003e6.2 Defining the Elements of States of Exception (SoE) 103\u003c\/p\u003e \u003cp\u003e6.2.1 States of Exception in the General Context 103\u003c\/p\u003e \u003cp\u003e6.2.2 Italy 103\u003c\/p\u003e \u003cp\u003e6.3 States of Exception During the Pandemic: Declaration, Implementation, and Effects 108\u003c\/p\u003e \u003cp\u003e6.3.1 Establishing and Implementing the States of Exception 108\u003c\/p\u003e \u003cp\u003e6.3.2 The Potential Effects of States of Exception on Civil Liberties 109\u003c\/p\u003e \u003cp\u003e6.4 States of Exception and Containment Measures during the COVID-19 Pandemic in Italy: Regulatory Aspects 110\u003c\/p\u003e \u003cp\u003e6.5 States of Exception and Containment Measures During the COVID-19 Pandemic in Italy: Implementation 112\u003c\/p\u003e \u003cp\u003e6.6 The Effects of States of Exception Measures on Civil Liberties 113\u003c\/p\u003e \u003cp\u003e6.7 Conclusions 116\u003c\/p\u003e \u003cp\u003eReferences 116\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Praise the Alarm: Spain’s Coronavirus Approach 121\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eCarolyn Halladay, Florina C. Matei, and Andres de Castro\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 \u003ci\u003eQuien aprisa juzgó, despacio se arrepintió\u003c\/i\u003e: The Early Days of COVID and the Spanish Response 123\u003c\/p\u003e \u003cp\u003e7.2 \u003ci\u003eCulpa no tiene, quien hace lo que debe: \u003c\/i\u003eThe FirstWave and the First Lockdown 125\u003c\/p\u003e \u003cp\u003e7.3 \u003ci\u003eCada uno quiere justiciar, mas no por su casa: \u003c\/i\u003eThe SecondWave and the Second Lockdown 130\u003c\/p\u003e \u003cp\u003e7.4 \u003ci\u003eCon necesidad, no hay ley? \u003c\/i\u003eStates of Emergency in Spain and Beyond 133\u003c\/p\u003e \u003cp\u003e7.5 \u003ci\u003eHasta que pruebes, no absuelvas ni condenes: \u003c\/i\u003eCOVID and the Law Amid Spanish Tensions 137\u003c\/p\u003e \u003cp\u003e7.6 \u003ci\u003eEl fin veremos; hasta entonces no hablemos: \u003c\/i\u003eConclusion 139\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Pandemic Pangs and Fangs: Romania’s Public Safety and Civil Liberties in the COVID-19 Era 141\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eFlorina C. Matei\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Legal Framework and Policy Approaches Vis-À-Vis Quarantine, Isolation, and Other Social Distancing Measures 141\u003c\/p\u003e \u003cp\u003e8.2 Quarantine, Isolation, and Other Social Distancing Measures During the Covid-19 Pandemic 144\u003c\/p\u003e \u003cp\u003e8.2.1 From a State of Emergency amidst a Political Crisis… 144\u003c\/p\u003e \u003cp\u003e8.2.2 …To a State of Alert: Anachronistic Legislation Meets Ebbing and Flowing Restrictions 150\u003c\/p\u003e \u003cp\u003e8.2.2.1 Vaccination Campaign: Needles for Fangs 153\u003c\/p\u003e \u003cp\u003e8.2.3 Transparency During the Pandemic: Between Thought Police, Strategic “Mis” Communications, and Conspiracy Theories 154\u003c\/p\u003e \u003cp\u003e8.2.3.1 Civil Society: A Tamed yet Clamorous Cerberus? 157\u003c\/p\u003e \u003cp\u003e8.2.4 A “Plagued” Executive–Legislative–Judiciary Trifecta 159\u003c\/p\u003e \u003cp\u003e8.3 Conclusion: Civil Liberties and Freedoms 161\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Policymaking and Liberty Restrictions in the Covid-19 Crisis, the Case of France 165\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eAngelique Palle, Lisa Carayon, François Delerue, Florian Opillard, and Christelle Chidiac \u003c\/i\u003eDisclaimer 165\u003c\/p\u003e \u003cp\u003e9.1 Introduction 165\u003c\/p\u003e \u003cp\u003e9.2 Policymaking and Liberty Restrictions in France During Covid-19 Crisis, Research Questions and Methodology 166\u003c\/p\u003e \u003cp\u003e9.3 Regulation and Policymaking in France During Covid-19, Context and Background 167\u003c\/p\u003e \u003cp\u003e9.4 “State of Emergency Related to the Sanitary Situation\/Etat d’Urgence Sanitaire”: The Recourse to an Exceptional Legal Framework 169\u003c\/p\u003e \u003cp\u003e9.5 The Involvement of the Armed Forces in France in the Covid-19 Crisis Management, Between Political Display and Response to the Crisis 170\u003c\/p\u003e \u003cp\u003e9.6 Perception by the French Population of the Missions Performed by the Armed Forces and of the Nature of the Covid-19 Crisis 172\u003c\/p\u003e \u003cp\u003e9.7 Analyzing Local and Regional Measures of Civil Liberties’s Restrictions in the Context of the “State of Emergency Related to the Sanitary Situation” (\u003ci\u003eétat d’urgence sanitaire\u003c\/i\u003e), the Case of the Freedom of Movement throughout the First to the Second Confinement 173\u003c\/p\u003e \u003cp\u003e9.8 Legitimizing Civil Liberties Restrictions and Shaping the Governance of Policymaking, Comparison of the Two Cities of Rennes and Nice 175\u003c\/p\u003e \u003cp\u003e9.9 Conclusion 179\u003c\/p\u003e \u003cp\u003eReferences 179\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 3 Countries Focused on Population Monitoring and Restrictions 181\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Policy Measures, Information Technology, and People’s Collective Behavior in Taiwan’s COVID-19 Response 183\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eCheryl Lin, Pikuei Tu, Wendy E. Braund, Jewel Mullen, and Georges C. Benjamin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 183\u003c\/p\u003e \u003cp\u003e10.2 A Snapshot of Taiwan 184\u003c\/p\u003e \u003cp\u003e10.2.1 The Legal Framework Pertaining to Pandemic Response 184\u003c\/p\u003e \u003cp\u003e10.2.1.1 Epidemic Control and Public Health Emergency 184\u003c\/p\u003e \u003cp\u003e10.2.1.2 Personal Information 186\u003c\/p\u003e \u003cp\u003e10.3 The Ominous Beginning of the Pandemic 186\u003c\/p\u003e \u003cp\u003e10.3.1 Swift Responses Early On 187\u003c\/p\u003e \u003cp\u003e10.4 Blocking Infection Importation and Local Transmission 188\u003c\/p\u003e \u003cp\u003e10.4.1 Tightened Border Control 188\u003c\/p\u003e \u003cp\u003e10.4.2 Rigorous Contact Tracing 189\u003c\/p\u003e \u003cp\u003e10.4.2.1 Augmentation with Information Technology (IT) 189\u003c\/p\u003e \u003cp\u003e10.4.3 Enforcing Quarantine – Operations and Mechanism 190\u003c\/p\u003e \u003cp\u003e10.4.3.1 Provisions, Compensation, and Penalties During Quarantine 190\u003c\/p\u003e \u003cp\u003e10.5 Active Participatory Role of the Public – Awareness and Preventive Behavior 192\u003c\/p\u003e \u003cp\u003e10.5.1 Common Use of Masks and Response to Shortage 192\u003c\/p\u003e \u003cp\u003e10.5.2 Promoting and Self-Adhering to Social Distancing 192\u003c\/p\u003e \u003cp\u003e10.6 Healthcare System and Capacity 193\u003c\/p\u003e \u003cp\u003e10.6.1 National Health Insurance (NHI) and Data Integration 193\u003c\/p\u003e \u003cp\u003e10.6.2 Infectious Disease Control Medical Network 194\u003c\/p\u003e \u003cp\u003e10.6.3 Assuring Care and Support for the Providers 195\u003c\/p\u003e \u003cp\u003e10.7 The Heights of Cases, Anxiety, and Dilemmas 195\u003c\/p\u003e \u003cp\u003e10.7.1 The Surge of Spring\/Summer 2021 196\u003c\/p\u003e \u003cp\u003e10.7.2 Amended Policies and Reflections of the Surge 197\u003c\/p\u003e \u003cp\u003e10.8 Vaccine Supply, Hesitancy, and Distribution 198\u003c\/p\u003e \u003cp\u003e10.8.1 Slow Delivery and Shortage of Supply 198\u003c\/p\u003e \u003cp\u003e10.8.2 Vaccine Hesitancy and Demand 199\u003c\/p\u003e \u003cp\u003e10.8.3 Vaccine Prioritization and Administration 200\u003c\/p\u003e \u003cp\u003e10.9 Reflections and Conclusions 200\u003c\/p\u003e \u003cp\u003eReferences 201\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 The Legislative and Political Responses of Viet Nam to the Covid-19 Pandemic: The Balancing of Public Health and Collective Civil Liberties 209\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eNguyen T. Trung and Nguyen Q. Duong\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eDisclaimer 209\u003c\/p\u003e \u003cp\u003e11.1 Introduction 209\u003c\/p\u003e \u003cp\u003e11.2 Background: The FourWaves of Covid-19 in Viet Nam 211\u003c\/p\u003e \u003cp\u003e11.2.1 The FirstWave (23 January–19 April 2020) 211\u003c\/p\u003e \u003cp\u003e11.2.2 The SecondWave (25 July–2 September 2020) 212\u003c\/p\u003e \u003cp\u003e11.2.3 The ThirdWave (28 January–13 March 2021) 213\u003c\/p\u003e \u003cp\u003e11.2.4 The FourthWave (27 April–15 July 2021) 214\u003c\/p\u003e \u003cp\u003e11.3 The Legislative Framework in Combating Infectious Disease 215\u003c\/p\u003e \u003cp\u003e11.3.1 Legislative and Administrative Documents in Vietnam 215\u003c\/p\u003e \u003cp\u003e11.3.2 The Constitution 215\u003c\/p\u003e \u003cp\u003e11.3.3 The 2007 Law on Prevention and Control of Infectious Diseases 216\u003c\/p\u003e \u003cp\u003e11.3.3.1 Prevention Measures 217\u003c\/p\u003e \u003cp\u003e11.3.3.2 Combating Measures 217\u003c\/p\u003e \u003cp\u003e11.3.3.3 Prohibited Activities and Fines for Failures to Implement Prevention and Combating Measures 218\u003c\/p\u003e \u003cp\u003e11.3.4 The Criminal Code 219\u003c\/p\u003e \u003cp\u003e11.3.5 Three Directives of the Prime Minister 220\u003c\/p\u003e \u003cp\u003e11.4 The Policy Responses of the Vietnamese Government During the Pandemic 221\u003c\/p\u003e \u003cp\u003e11.4.1 The Contact Tracing System 222\u003c\/p\u003e \u003cp\u003e11.4.2 Quarantine Regulation 223\u003c\/p\u003e \u003cp\u003e11.4.3 Social Distancing Measures 224\u003c\/p\u003e \u003cp\u003e11.5 The Paradigm Shift in the Legal and Political Responses and the Balancing of Public Health and Civil Liberties 224\u003c\/p\u003e \u003cp\u003e11.5.1 The Paradigm Shift in the Legal and Political Responses 225\u003c\/p\u003e \u003cp\u003e11.5.2 The Balancing of Public Health and Civil Liberties 226\u003c\/p\u003e \u003cp\u003e11.6 Conclusion 228\u003c\/p\u003e \u003cp\u003eReferences 230\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Singapore United 235\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJacinta I-Pei Chen, Sharon H.X. Tan, Peak Sen Chua, Jeremy Lim, and Jason Chin-Huat Yap\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Governing Philosophy and Laws 235\u003c\/p\u003e \u003cp\u003e12.2 Early Response to Circuit Breaker (February–May 2020) 237\u003c\/p\u003e \u003cp\u003e12.2.1 Enforcement Approach 242\u003c\/p\u003e \u003cp\u003e12.2.2 Financial and Other Supportive Resources 243\u003c\/p\u003e \u003cp\u003e12.2.3 Religion, Marriage, and Family Life 244\u003c\/p\u003e \u003cp\u003e12.2.4 Communications 245\u003c\/p\u003e \u003cp\u003e12.3 Relaxation of Measures (June 2020–April 2021) 246\u003c\/p\u003e \u003cp\u003e12.3.1 Prioritizing Sectors 251\u003c\/p\u003e \u003cp\u003e12.3.2 Strengthening Outbreak Control Capabilities 251\u003c\/p\u003e \u003cp\u003e12.3.3 General Elections 2020 253\u003c\/p\u003e \u003cp\u003e12.4 Heightened Alert (May 2021–June 2021) 254\u003c\/p\u003e \u003cp\u003e12.5 Leveraging Technology 261\u003c\/p\u003e \u003cp\u003e12.5.1 Data Privacy, Security, and Governance 263\u003c\/p\u003e \u003cp\u003e12.5.2 What Next? 264\u003c\/p\u003e \u003cp\u003e12.6 MigrantWorker Dormitories 264\u003c\/p\u003e \u003cp\u003e12.6.1 The Regulatory Regime 265\u003c\/p\u003e \u003cp\u003e12.6.2 The Dormitory Outbreaks 265\u003c\/p\u003e \u003cp\u003e12.6.3 Reflections 266\u003c\/p\u003e \u003cp\u003e12.7 Discussion 271\u003c\/p\u003e \u003cp\u003e12.8 Conclusion 272\u003c\/p\u003e \u003cp\u003eAcknowledgements 273\u003c\/p\u003e \u003cp\u003eReferences 273\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 4 Countries Focused on Fostering Popular Trust in Government, Emphasizing Social Welfare, and Limiting Sanctions and Restrictions 301\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Sweden and Covid-19: A (Mainly) Recommendary Approach 303\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eIain Cameron and Anna Jonsson Cornell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 303\u003c\/p\u003e \u003cp\u003e13.2 Setting the Stage – The Initial Swedish Response to the Pandemic 303\u003c\/p\u003e \u003cp\u003e13.3 The Constitutional Context 305\u003c\/p\u003e \u003cp\u003e13.4 The Legislative Procedure, Delegation of Powers, and Rights Protection 308\u003c\/p\u003e \u003cp\u003e13.5 The Public Health Agency and the Act on Protection Against Contagious Diseases 309\u003c\/p\u003e \u003cp\u003e13.6 Legal Measures Taken to Counter the Spread of Covid-19 311\u003c\/p\u003e \u003cp\u003e13.7 Vaccination and Exit Strategies 312\u003c\/p\u003e \u003cp\u003e13.8 Putting the Swedish Soft Power Strategy in Context 313\u003c\/p\u003e \u003cp\u003e13.9 Evaluating the Swedish Measures from a Rule of Law Perspective 315\u003c\/p\u003e \u003cp\u003e13.10 Concluding Remarks 319\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Administrative Guidance in Coronavirus Special Measures Act in 2021 in Japan 323\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eYuichiro Tsuji\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 The 2020 CSMA 323\u003c\/p\u003e \u003cp\u003e14.1.1 2021 CSMA and Administrative Guidance 323\u003c\/p\u003e \u003cp\u003e14.1.2 How CSMA was Amended 325\u003c\/p\u003e \u003cp\u003e14.1.3 How CSMA was Amended, and Why 326\u003c\/p\u003e \u003cp\u003e14.1.4 Legalization of the Self-restraint Order 326\u003c\/p\u003e \u003cp\u003e14.1.5 Sanctions, not Penal but Administrative 327\u003c\/p\u003e \u003cp\u003e14.1.6 Revision of the Infectious Diseases Act 328\u003c\/p\u003e \u003cp\u003e14.2 Administrative Guidance and COVID-19 in 2021 329\u003c\/p\u003e \u003cp\u003e14.2.1 Traditional Theory in Japanese Administrative Law 330\u003c\/p\u003e \u003cp\u003e14.2.2 Legal Control of Administrative Guidance 330\u003c\/p\u003e \u003cp\u003e14.2.3 Art. 33 of APA When a Citizen does not Follow Administrative Guidance 331\u003c\/p\u003e \u003cp\u003e14.2.4 Public Announcement 332\u003c\/p\u003e \u003cp\u003e14.2.5 Public Announcement in TMG 332\u003c\/p\u003e \u003cp\u003e14.2.6 Merits and Demerits of Administrative Guidance 333\u003c\/p\u003e \u003cp\u003e14.2.7 How to Impose Administrative Fine Procedural Requirement 334\u003c\/p\u003e \u003cp\u003e14.2.8 APA Ordinance and TMG 334\u003c\/p\u003e \u003cp\u003e14.3 Conclusion 335\u003c\/p\u003e \u003cp\u003eReferences 336\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Canada’s Fight Against COVID-19: Constitutionalism, Laws, and the Global Pandemic 339\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eIffath U. Syed\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Non-Pharmaceutical Intervention (NPI) Measures 340\u003c\/p\u003e \u003cp\u003e15.2 COVID-19 Special Acts for Relief and Compensatory Measures 341\u003c\/p\u003e \u003cp\u003e15.3 Long-Term Care Crisis 346\u003c\/p\u003e \u003cp\u003e15.4 Research and Vaccine Development Initiatives 347\u003c\/p\u003e \u003cp\u003e15.5 Other Policies and Governmental Actions to Dampen the Pandemic 347\u003c\/p\u003e \u003cp\u003e15.6 New Year, But Pandemic Looms 350\u003c\/p\u003e \u003cp\u003e15.7 Summary, Limitations, and Concluding Remarks 351\u003c\/p\u003e \u003cp\u003eReferences 351\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Coronavirus and the Social State: Austria in the Pandemic 359\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eDonald Abenheim and Carolyn Halladay\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 The \u003ci\u003eImpfpflicht \u003c\/i\u003e361\u003c\/p\u003e \u003cp\u003e16.2 The Freedom Party’s Liberties 363\u003c\/p\u003e \u003cp\u003e16.3 A Bundle of Measures 364\u003c\/p\u003e \u003cp\u003e16.4 A Decade or More of Crises 367\u003c\/p\u003e \u003cp\u003e16.5 The \u003ci\u003eSozialstaat \u003c\/i\u003eStrikes Back 371\u003c\/p\u003e \u003cp\u003e16.6 Protest, Rhetoric, and the Law 373\u003c\/p\u003e \u003cp\u003e16.7 Conclusion: Community, Communicability, and the Constitution 376\u003c\/p\u003e \u003cp\u003eAfterword 379\u003c\/p\u003e \u003cp\u003eIndex 381\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":48738367963479,"sku":"9781119812159","price":68.88,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781119812159.jpg?v=1723811983"},{"product_id":"cannabis-is-medicine-9781472276629","title":"Cannabis is Medicine","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eIn \u003ci\u003eCannabis Is Medicine\u003c\/i\u003e, medical cannabis specialist Bonni Goldstein, MD, explains the science behind the use of this \u003cb\u003eamazingly therapeutic plan\u003c\/b\u003et and describes in easy-to-understand detail the recently discovered endocannabinoid system, involved in almost every human physiological process. Over 4 million people in the US are \u003cb\u003ehealing difficult-to-treat illnesses with cannabis\u003c\/b\u003e medicine, and although 33 states have medical cannabis laws, many physicians remain reluctant to discuss how this plant may be beneficial to health. this book is the comprehensive resource for patients and their loved ones who have not found answers with conventional medicines.\u003cbr\u003e\u003cbr\u003eDr Goldstein has helped thousands of suffering patients -- including children -- find relief with cannabis. In her revelatory book, she explains the current state of scientific research on more than 28 chronic medical conditions that have responded positively to treatment with cannabis, and offers actionable ad\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003eDr. Goldstein sets the record straight on cannabis, offering an in-depth, scientific look at the potent healing power of this much-maligned plant. Anyone considering cannabis medicine for themselves or a loved one needs to read this book. * Mark Hyman, MD, author of Food: What the Heck Should I Eat? *\u003cbr\u003e\u003ci\u003eCannabis Is Medicine\u003c\/i\u003e tells it like it is. For far too long the important medicinal potential of the cannabis plant has been at least overlooked, and at worst, aggressively stigmatized. The incredible potential of cannabis derivatives across a wide panorama of medical conditions is now widely embraced by highly respected science. And Dr. Bonni Goldstein has done a magnificent job of eloquently presenting this science to augment our tools as healthcare providers as well as for consumers at large. A powerful validation of the healing properties of cannabis. * David Perlmutter, MD, bestselling author of Grain Brain and Brain Wash *\u003c\/p\u003e","brand":"Headline Publishing Group","offers":[{"title":"Default Title","offer_id":48739451634007,"sku":"9781472276629","price":999.99,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781472276629.jpg?v=1720052285"},{"product_id":"dopeworld-adventures-in-drug-lands-9781529378030","title":"Dopeworld: Adventures in Drug Lands","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cb\u003eWelcome to Dopeworld. \u003cbr\u003e\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eEcstasy in London, crack in Los Angeles, LSD in Tokyo, heroin in Sofia, cocaine in Medellin, bounty hunting in Manilla, opium in Tehran. \u003c\/i\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eGet ready for your next fix. \u003c\/b\u003e\u003cbr\u003e\u003cb\u003e__________\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003ci\u003eDopeworld\u003c\/i\u003e is a bold and intoxicating journey into the world of drugs. From the cocaine farms in South America to the streets of Manila, we trace the emergence of psychoactive substances and our intimate relationship with them. With unparalleled access to drug lords, cartel leaders, street dealers and government officials, Niko Vorobyov attempts to shine a light on the dark underbelly drug world.\u003cbr\u003e\u003cbr\u003eAt once a bold piece of reportage and a hugely entertaining and perverse travelogue, \u003ci\u003eDopeworld\u003c\/i\u003e reveals how drug use is at the heart of our history, our lives, and our world.\u003cbr\u003e__________ \u003cbr\u003e\u003cbr\u003eWith echoes of \u003ci\u003eGomorrah\u003c\/i\u003e and \u003ci\u003eFear and Loathing in Last Vegas\u003c\/i\u003e, \u003ci\u003eDopeworld\u003c\/i\u003e is a brilliant and enlightening journey across the world, examining every angle of the drug war.\u003c\/p\u003e","brand":"Hodder \u0026 Stoughton","offers":[{"title":"Default Title","offer_id":48740241539415,"sku":"9781529378030","price":10.44,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781529378030.jpg?v=1720054207"},{"product_id":"cannabis-laboratory-fundamentals-9783030627157","title":"Cannabis Laboratory Fundamentals","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThe legislative requirement for cannabis to undergo laboratory testing has followed legalization of medical and recreational use in every U.S. state to date.  Cannabis safety testing is a new investment opportunity within the emerging cannabis market that is separate from cultivation, processing, and distribution, allowing individuals and organizations who may have been reluctant to enter previously a new entry route to the cannabis space. However, many of the costs, timelines, operational requirements, and compliance issues are overlooked by people who have not been exposed to regulated laboratory testing.\u003c\/p\u003e  \u003cp\u003eCannabis Laboratory Fundamentals provides an in-depth review of the key issues that impact cannabis testing laboratories and provides recommendations and solutions to avoid common – but expensive – mistakes. The text goes beyond methodology to include sections on economics, regulation, and operational challenges, making it useful for both new and experienced cannabis laboratory operators, as well as all those who want to understand the opportunities and risks of this industry.\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e1.       An Introduction to Cannabis Laboratory Safety and Compliance Testing\u003c\/p\u003e  \u003cp\u003e2.       Cannabis Safety Testing Laboratory Floor Planning \u0026amp; Design\u003c\/p\u003e  \u003cp\u003e3.       Laboratory Safety from Site Selection to Daily Operation\u003c\/p\u003e  \u003cp\u003e4.       Preparing Cannabis Laboratory Business License Applications\u003c\/p\u003e  \u003cp\u003e5.       Quality Assurance and the Cannabis Analytical Laboratory\u003c\/p\u003e  \u003cp\u003e6.       Cannabis Laboratory Management: Staffing, Training and Quality\u003c\/p\u003e  \u003cp\u003e7.       Laboratory Information Management Systems (LIMS)\u003c\/p\u003e  \u003cp\u003e8.       Pesticide and Mycotoxin Detection and Quantitation\u003c\/p\u003e  \u003cp\u003e9.       Cannabinoid Detection and Quantitation\u003c\/p\u003e  \u003cp\u003e10.   Utilizing GC-MS and GC Instrumentation for Residual Solvents in Cannabis and Hemp\u003c\/p\u003e  \u003cp\u003e11.   Elemental Analysis of Cannabis and Hemp – Regulations, Instrumentation, and Best Practices\u003c\/p\u003e  \u003cp\u003e12.   Quantitative Terpene Profiling from Cannabis Samples\u003c\/p\u003e  \u003cp\u003e13.   Laboratory Safety and Compliance Testing for Microorganism Contamination in Marijuana\u003c\/p\u003e","brand":"Springer Nature Switzerland AG","offers":[{"title":"Default Title","offer_id":48743042941271,"sku":"9783030627157","price":71.24,"currency_code":"GBP","in_stock":true}]},{"product_id":"physicians-guide-to-the-diagnosis-treatment-and-follow-up-of-inherited-metabolic-diseases-9783030677268","title":"Physician's Guide to the Diagnosis, Treatment,","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThis updated and enlarged second edition is a unique source of information on the diagnosis, treatment, and follow-up of metabolic diseases.\u003c\/p\u003e  The clinical and laboratory data characteristic of rare metabolic conditions can be bewildering for clinicians and laboratory personnel alike – reference laboratory data is scattered, and clinical descriptions can be obscure. The new Physician’s Guide with the additional more than 600 diseases now featured, documents 1200 conditions grouped according to type of disorder, organ system affected (e.g. liver, kidney, etc) or phenotype (e.g. neurological, hepatic, etc). It includes relevant clinical findings and highlights the pathological values for diagnostic metabolites. Guidance on appropriate biochemical genetic testing is also provided and established experimental therapeutic protocols are described, with recommendations on follow-up and monitoring.  \u003cp\u003eThe authors are acknowledged experts, and the book is a valuable desk reference for all who deal with inherited metabolic diseases.\u003c\/p\u003e\u003cp\u003eChapter 73 is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003ePart 1. GENERAL SUBJECTS AND PROFILES.- 1. Newborn Screening for Inborn Errors of Metabolism.- 2. Simple Tests and Routine Chemistry.- 3. Amino Acids.- 4. Organic Acids.- 5 .Acylcarnitines.- 6. Lysosomals.- 7. Untargeted Metabolomics – Next Generation Metabolic Screening.- 8. MRI and In Vivo Spectroscopy of the Brain.- 9. Genomic Approaches for the Diagnosis of Inborn Errors of Metabolism.- 10. Other-omics Approaches and Their Integration for the Diagnosis and Treatment of Inborn Errors of Metabolism.- 11. Emergency Diagnostic Procedures and Emergency Treatment.- 12. Nosology of Inborn Errors of Metabolism.- Part 2. DISORDERS OF NITROGEN-CONTAINING COMPOUNDS.- 13. Purine and Pyrimidine Disorders.- 14. Disorders of nucleotide metabolism.- 15. Disorders of Creatine Metabolism.- 16. Disorder of Glutathione Metabolism.- 17. Disorders of Ammonia Detoxification.- 18. Amino Acid Transport Defects.- 19. Disorders of Monoamine Metabolism.- 20. Disorders of Phenylalanine and Tetrahydrobiopterin Metabolism.- 21. Disorders of Tyrosine Metabolism.- 22. Disorders of Sulfur Amino Acid and Hydrogen Sulfide Metabolism.- 23. Disorders of Branched-Chain Amino Acid Metabolism.- 24. Disorders of Beta and Gamma Amino Acids.- 25. Amino Acid Synthesis Deficiencies.- 26. Disorders of Glycine Metabolism.- 27. Disorders of Lipoic Acid and Iron-Sulfur Protein Metabolism.- Part 3. DISORDERS OF VITAMINS, COFACTORS, METALS AND MINERALS.- 28. Disorders of Cobalamin Metabolism.- 29. Disorders of Folate Metabolism and Transport.- 30. Disorders of Biotin Metabolism.- 31. Thiamine Disorders.- 32. Disorders of Riboflavin Metabolism.- 33. Disorders of Niacin, NAD and Panthotenate Metabolism.- 34. Vitamin B6-Dependent and Responsive Disorders.- 35. Molybdenum Cofactor Disorders.- 36. Disorders of Copper, Zinc and Selenium Metabolism.- 37. Disorders of Iron Metabolism.- 38. Disorders of Manganese Metabolism.- Part 4. DISORDERS OF CARBOHYDRATES.- 39. Disorders of Carbohydrate Absorption, Transmembrane Transport and Metabolism.- 40. Disorders of the Pentose Phosphate Pathway and Polyol Metabolism.-  41. Hyperinsulinism.- Part 5. MITOCHONDRIAL DISORDERS OF ENERGY METABOLISM.- 42. Disorders of the Pyruvate Metabolism and the Krebs Cycle.- 43. Disorders of Mitochondrial Carriers.- 44. Isolated Mitochondrial Complex Deficiencies.- 45. Disorders of Replication, Transcription and Translation of Mitochondrial DNA.- 46. Disorders of mitochondrial homeostasis, dynamics, protein import and quality control.- 47. Primary Coenzyme Q10 Deficiencies.- Part 6. DISORDERS OF LIPIDS.- 48. Mitochondrial Fatty Acid Oxidation Disorders.- 49. Disorders of Glycerol Metabolism.- 50. Disorders of Ketone Body Metabolism and Transport.- 51. Disorders of Complex Lipids.- 52. Disorders of Eicosanoid Metabolism.- 53. Disorders of Lipoprotein Metabolism.- 54. Disorders of Cholesterol Biosynthesis.- 55. Disorders of Adrenals and Gonads.- 56. Disorders of Bile Acid Synthesis. Part 7. DISORDERS OF TETRAPYRROLES.- 57. Disorders of Heme Metabolism.- 58. Inherited Disorders of Bilirubin Metabolism.- Part 8. STORAGE DISORDERS.- 59. Disorders of Autophagy.- 60. Lipidoses: The Sphingolipidoses, Lysosomal Acid Lipase Deficiency and Niemann Pick type C.- 61. The Neuronal Ceroid Lipofuscinoses.-62. Mucolipidoses, Multiple Sulfatase deficiency, Cathepsin K and C Deficiency.- 63. Oligosaccharidoses and Sialic Acid Disorders.- 64. The Mucopolysaccharidoses.- 65. Cystinosis.- Part 9. DISORDERS OF PEROXISOMES AND OXALATE.- 66. Peroxisomal Disorders.- 67. Disorders for Oxalate Metabolism.- Part 10. CONGENITAL DISORDERS OF GLYCOSYLATION.- 68. Congenital Disorders of Glycosylation.- Part 11. VARIOUS.- 69. Cerebral Organic Acidurias.- 70. 3-Methylglutaconic acidurias.- 71. Biochemical Phenotypes of Questionable Clinical Significance.- 72. Knowledgebase of Inborn Errors of Metabolism (IEMbase): A Practical Approach.- 73. WikiPathways: Integrating Pathway Knowledge with Clinical Data.\u003c\/p\u003e","brand":"Springer Nature Switzerland AG","offers":[{"title":"Default Title","offer_id":48743044743511,"sku":"9783030677268","price":179.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783030677268.jpg?v=1720063867"},{"product_id":"principles-and-practices-of-lyophilization-in-product-development-and-manufacturing-9783031126338","title":"Principles and Practices of Lyophilization in","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThe biotechnology\/biopharmaceutical sector has tremendously grown which led to the invention of engineered antibodies such as Antibody Drug Conjugates (ADCs), Bispecific T cell engager ( BITES), Dual Variable Domain ( DVD), Chimeric Antigen Receptor  - Modified Tcells (CART) that are currently being used as therapeutic agents for immunology and oncology disease conditions.  In addition to other pharmaceuticals and biopharmaceuticals, all these novel formats are fragile with respect to  their stability\/structure under processing conditions meaning marginal stability in the liquid state and often require lyophilization to enhance their stability and shelf-life. This book contains chapters\/topics that will describe every aspect of the lyophilization process and product development and manufacturing starting from the overview of lyophilization process, equipment required, characterization of the material, design and development of the formulation and lyophilization process, various techniques for\u003cb\u003e \u003c\/b\u003echaracterization of the product, scale-up\/tech-transfer and validation.  It also describes the application of CFD coupled with mathematical modeling in the lyophilization process and product development, scale-up, and manufacturing.  Additionally, \u003ci\u003ePrinciples and Practice of Lyophilization Process and Product Development\u003c\/i\u003e contains an entire dedicated section on “Preservation of Biologicals” comprised of nine chapters written by experts and including case studies.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e1. Overview of Freeze Drying\u003cbr\u003e2. Characterization and Determination of Freeze Drying Properties of Frozen Formulations- Case Studies\u003cbr\u003e3. Beyond pH: Acid\/base relationships in frozen and freeze-dried pharmaceuticals\u003cbr\u003e4. Concepts and Strategies in the Design of Formulation for Freeze Drying\u003cbr\u003e5. Formulation Design for Freeze Drying - Case studies of Stabilization of Proteins\u003cbr\u003e6. Challenges and Considerations in the Development of a High Protein Concentration Lyophilized Drug Product\u003cbr\u003e7. Freeze-drying of thermosensible pharmaceuticals with organic co-solvent + water formulations\u003cbr\u003e8. Primary container closure system selection for lyophilized drug products\u003cbr\u003e9. Vial Breakage During Lyophilization\u003cbr\u003e10. The Nucleation of Ice\u003cbr\u003e11. Stresses, Stabilization, and Recent Insights in Freezing of Biologics\u003cbr\u003e12. Lyophilization Process Understanding and Scale-up using ab initio Vial Heat Transfer Modeling\u003cbr\u003e13. Secondary drying: Challenges and Considerations\u003cbr\u003e14. Design and Process Considerations in Spray Freeze Drying\u003cbr\u003e15. LyoPRONTO: Deterministic and Probabilistic Modeling. Tutorial and Case Study\u003cbr\u003e16. Utilizing Solid-State NMR Spectroscopy to Assess Properties of Lyophilized Formulations\u003cbr\u003e17. Design of Moisture Studies for a Lyophilized Product\u003cbr\u003e18. Laser-Based Headspace Moisture Analysis for Rapid Nondestructive Moisture Determination of Lyophilized Products\u003cbr\u003e19. Application of PAT in Real-time Monitoring and Controlling of Lyophilization Process\u003cbr\u003e20. Process Analytical Technology (PAT) for Lyophilization Process Monitoring and End Point Detection\u003cbr\u003e21. Advances in Process Analytical Technology – A Small Scale Freeze-Dryer for Process Analysis, Optimization, and Transfer Advances in Process Analytical Technology – A Small Scale Freeze-Dryer for Process Analysis, Optimization, and Transfer\u003cbr\u003e22. Overview of Heat and Mass Transfer Modeling in Lyophilization to Create Design Spaces and Improve Process Analytical Tool (PAT) Capability\u003cbr\u003e23. Application of QbD elements in the Development and Manufacturing of a Lyophilized product.- Characterization of Freeze Dryer\u003cbr\u003e24. Characterization of Freeze Dryer\u003cbr\u003e25. Scale-up and Technology Transfer of a Lyophilization Process\u003cbr\u003e26.  Lyophilization Validation: Process Design and Modeling\u003cbr\u003e27. Lyophilization Validation: Process Qualification and Continued Process Verification\u003cbr\u003e28. Homogeneity Assessment of Lyohilized Biological Drug Products During Process Performance Qualification\u003cbr\u003e29. Informed Manufacturing through the use of Big Data Analytics for Freeze Drying Process \u0026amp; Equipment\u003cbr\u003e30. Multivariate Analysis for Process Understanding, Continuous Process Verification and Condition Monitoring of Lyophilization Processes\u003cbr\u003e31.  Lyophilized Drug Product Cake Appearance: What Is Acceptable?\u003cbr\u003e​","brand":"Springer International Publishing AG","offers":[{"title":"Default Title","offer_id":48743071646039,"sku":"9783031126338","price":999.99,"currency_code":"GBP","in_stock":false}]},{"product_id":"antibiotic-pharmacokinetic-pharmacodynamic-considerations-in-the-critically-ill-9789811053351","title":"Antibiotic Pharmacokinetic\/Pharmacodynamic","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThis book provides unique insights into the issues that drive modified dosing regimens for antibiotics in the critically ill. Leading international authors provide their commentary alongside a summary of existing evidence on how to effectively dose antibiotics.\u003c\/p\u003e  \u003cp\u003eSevere infection frequently necessitates admission to the intensive care unit (ICU). Equally, nosocomial sepsis often complicates the clinical course in ICU.  Early, appropriate application of antibiotic therapy remains a cornerstone of effective management. However, this is challenging in the critical care environment, given the significant changes in patient physiology and organ function frequently encountered. Being cognisant of these factors, prescribers need to consider modified dosing regimens, not only to ensure adequate drug exposure, and therefore the greatest chance of clinical cure, but also to avoid encouraging drug resistance.\u003cbr\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e1. Basic Pharmacokinetic Principles.- 2. Antibiotic Pharmacodynamics.- 3. Physiological Manifestations of Critical Illness.- 4. Dosing in Obese Critically Ill Patients.- 5. Hypoalbuminemia and Altered Protein Binding.- 6. Antibacterial Pharmacokinetic\/Pharmacodynamic Considerations in the Critically ill.- 7. Augmented Renal Clearance.- 8. Antibiotic Dosing During Extracorporeal Membrane Oxygenation.- 9. Therapeutic Drug Monitoring: More than Avoiding Toxicity.- 10. Generic and Optimised Antibacterial Dosing Strategies in the Critically Ill.- 11. Antifungal PK\/PD in the Critically Ill.- 12. Antibiotic Dosing in Pediatric Critically Ill Patients.- 13. Antibiotic Stewardship in the Intensive Care Unit.\u003cp\u003e\u003c\/p\u003e","brand":"Springer Verlag, Singapore","offers":[{"title":"Default Title","offer_id":48743274119511,"sku":"9789811053351","price":98.99,"currency_code":"GBP","in_stock":false}]},{"product_id":"advanced-organic-chemistry-9780387683461","title":"Advanced Organic Chemistry","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e1: Chemical Bonding and Molecular Structure.- 2: Stereochemistry, Conformation, and Stereoselectivity.- 3: Structural Effects on Stability and Reactivity.- 4: Nucleophilic Substitution.- 5: Polar Addition and Elimination Reactions.- 6: Carbanions and Other Carbon Nucleophiles.- 7: Addition, Condensation and Substitution Reactions of Carbonyl Compounds.- 8: Aromaticity.- Aromatic Substitution.- 9: Concerted Pericyclic Reactions.- 10: Free Radical Reactions.- 11: Photochemistry.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eFrom the reviews of the fifth edition:\u003c\/p\u003e“Carey and Sundberg had written the most detailed and briliant account in the subject of organic chemistry. … The book provides an abundance of reaction examples organized in schemes. It makes studying very effective and helpful. … Advanced undergraduates and graduate students will welcome this new edition and the depth of materials covered.” (Philosophy, Religion and Science Book Reviews, bookinspections.wordpress.com, May, 2014)\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eChemical Bonding and Molecular Structure.- Stereochemistry, Conformation, and Stereoselectivity.- Structural Effects on Stability and Reactivity.- Nucleophilic Substitution.- Polar Addition and Elimination Reactions.- Carbanions and Other Carbon Nucleophiles.- Addition, Condensation and Substitution Reactions of Carbonyl Compounds.- Aromaticity.- Aromatic Substitution.- Concerted Pericyclic Reactions.- Free Radical Reactions.- Photochemistry.","brand":"Springer-Verlag New York Inc.","offers":[{"title":"Default Title","offer_id":48864540295511,"sku":"9780387683461","price":71.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780387683461.jpg?v=1722272387"},{"product_id":"essentials-of-pharmaceutical-chemistry-9780853699798","title":"Essentials of Pharmaceutical Chemistry","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eEssentials of Pharmaceutical Chemistry is an introduction to pharmaceutical chemistry for undergraduate pharmacy, chemistry and medicinal chemistry students. It covers all of the core material necessary to provide an understanding of the basic chemistry of drug molecules.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e \"...Donald Cairns is a well-known educator, mentor, and researcher...this is an excellent resource for pharmacy students taking pharmaceutical chemistry and for individuals who intend to pursue a career in the pharmaceutical industry...Readers will find this as a useful reference.\" Rahmat M Talukder, Ph.D.,Doody's Notes, May 2012.\u003c\/p\u003e -- Rahmat M Talukder * Doody's Notes *\u003cbr\u003e\u003cp\u003e\"This is a great book detailing the basic chemistry of drugs...Throughout the book there are problems that can be worked, and it includes the answers at the end of the book. It is very easy-to-read and has very good graphics to support the discussions. In addition to being a good text, it is a good refresher for those that would like to review this topic.\"\u003cbr\u003eCompounding Today, 27 Jan 2012.\u003c\/p\u003e * Compounding Today *\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e1. Chemistry of Acids and Bases; 2. Partition Coefficient and Biopharmacy; 3. Physicochemical Properties of Drugs; 4. Stereochemistry; 5. Drug Metabolism; 6. Volumetric Analysis of Drugs; 7. Analytical Spectroscopy; 8. Chromatographic Methods of Analysis; 9. Stability of Drugs and Medicines; 10. Kinetics of Drug Stability; 11. Licensing of Drugs and the British Pharmacopoeia; 12. Medicinal Chemistry - the Science of Rational Drug Design; 13. Answers to Problems","brand":"Pharmaceutical Press","offers":[{"title":"Default Title","offer_id":48866059321687,"sku":"9780853699798","price":40.85,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780853699798.jpg?v=1722276851"},{"product_id":"burnt-human-remains-9781119682608","title":"Burnt Human Remains","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eBURNT HUMAN REMAINS\u003c\/b\u003e \u003cp\u003e\u003cb\u003eAn all-encompassing reference and guide designed for professionals involved in the forensic analysis of burnt remains\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003e\u003ci\u003eBurnt Human Remains: Recovery, Analysis and Interpretation \u003c\/i\u003epresents an in-depth multidisciplinary approach to the detection, recovery, analysis, and identification of thermally altered remains. Bridging the gap between research and practice, this invaluable one-stop reference\u003cb\u003e \u003c\/b\u003eprovides detailed coverage of analytical techniques in forensic medicine and pathology, forensic anthropology, forensic odontology, and forensic chemistry and forensic biology. Contributions from a panel of expert authors review the newest findings in forensics research and discuss their applicability to forensic case work. \u003c\/p\u003e\u003cp\u003eOpening with a historical overview of the discipline, the book covers the search and recovery aspects of burnt human remains, medico-legal investigations, determination of the post mortem interval of burnt remains, structu\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eAbout the Editors xiii\u003c\/p\u003e \u003cp\u003eList of Contributors xv\u003c\/p\u003e \u003cp\u003ePreface xxvii\u003c\/p\u003e \u003cp\u003eSeries Preface xxix\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 History of the Study of Burnt Remains 1\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eDouglas H. Ubelaker and Austin A. Shamlou\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Early Developments Prior to 1980 1\u003c\/p\u003e \u003cp\u003e1.2 Post-1980 Advanced Experimentation and Casework 3\u003c\/p\u003e \u003cp\u003e1.3 The 1990s: New Methods and Case Applications 4\u003c\/p\u003e \u003cp\u003e1.4 Summary and Conclusions 6\u003c\/p\u003e \u003cp\u003eReferences 7\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1 Search and Recovery of Burnt Human Remains from the Fire Scene\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Fire Environments and Characteristic Burn Patterns of Human Remains from Four Common Types of Fatal Fire Scenes 13\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eElayne Pope\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 13\u003c\/p\u003e \u003cp\u003e2.2 Experimental Research of Fire and Human Bodies 14\u003c\/p\u003e \u003cp\u003e2.3 How the Human Body Burns 14\u003c\/p\u003e \u003cp\u003e2.4 Variables of Fire Environments 17\u003c\/p\u003e \u003cp\u003e2.5 Structure Fires 18\u003c\/p\u003e \u003cp\u003e2.6 Burning Directly on the Floor 19\u003c\/p\u003e \u003cp\u003e2.7 The Body on Furnishings: Couches and Chairs 19\u003c\/p\u003e \u003cp\u003e2.8 The Body on Furnishings: Bed 21\u003c\/p\u003e \u003cp\u003e2.9 Loss of the Floor 22\u003c\/p\u003e \u003cp\u003e2.10 Collapse into a Lower Level 23\u003c\/p\u003e \u003cp\u003e2.11 Vehicle Fires 24\u003c\/p\u003e \u003cp\u003e2.12 Driver and Passenger Space 25\u003c\/p\u003e \u003cp\u003e2.13 Rear Passenger Space with Bench Seats 26\u003c\/p\u003e \u003cp\u003e2.14 Trunk Environment 26\u003c\/p\u003e \u003cp\u003e2.15 Confined Space Fires 28\u003c\/p\u003e \u003cp\u003e2.16 Outdoor Space Fires 29\u003c\/p\u003e \u003cp\u003e2.17 Ignitable Liquids on Bodies 29\u003c\/p\u003e \u003cp\u003e2.18 Burning Outdoor Debris Piles 30\u003c\/p\u003e \u003cp\u003e2.19 Post-Fire Fragmentation of Burnt Bones 31\u003c\/p\u003e \u003cp\u003e2.20 Suppression 32\u003c\/p\u003e \u003cp\u003e2.21 Recovery and Transport from Fatal Fire Scenes 33\u003c\/p\u003e \u003cp\u003e2.22 Conclusions 35\u003c\/p\u003e \u003cp\u003eReferences 35\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Recovery and Interpretation of Human Remains from Fatal Fire Scenes\u003c\/b\u003e \u003cb\u003e37\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eAlexandra R. Klales; Allison Nesbitt; Dennis C. Dirkmaat and Luis L. Cabo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 37\u003c\/p\u003e \u003cp\u003e3.2 Summary of Fires in the USA 39\u003c\/p\u003e \u003cp\u003e3.3 Statement of the Problem 39\u003c\/p\u003e \u003cp\u003e3.4 Current Fatal Fire Victim Recovery Protocols 42\u003c\/p\u003e \u003cp\u003e3.5 NIJ Protocols 43\u003c\/p\u003e \u003cp\u003e3.6 Special Circumstances 51\u003c\/p\u003e \u003cp\u003e3.7 Conclusions 55\u003c\/p\u003e \u003cp\u003eReferences 55\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Considerations to Maximize Recovery of Post-mortem Dental Information to Facilitate Identification of Severely Incinerated Human Remains 59\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJohn Berketa and Denice Higgins\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 59\u003c\/p\u003e \u003cp\u003e4.2 Identification 59\u003c\/p\u003e \u003cp\u003e4.3 Documentation 60\u003c\/p\u003e \u003cp\u003e4.4 Preparation 61\u003c\/p\u003e \u003cp\u003e4.5 Prepacked Scene Equipment 61\u003c\/p\u003e \u003cp\u003e4.6 Scene Arrival 63\u003c\/p\u003e \u003cp\u003e4.7 Safety Issues 63\u003c\/p\u003e \u003cp\u003e4.8 Overall Scene Evaluation 65\u003c\/p\u003e \u003cp\u003e4.9 Considerations Regarding DNA Evidence 66\u003c\/p\u003e \u003cp\u003e4.10 Considerations Regarding Dental Evidence 67\u003c\/p\u003e \u003cp\u003e4.11 Moving the Victim 69\u003c\/p\u003e \u003cp\u003e4.12 Conclusions 71\u003c\/p\u003e \u003cp\u003eReferences 71\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2 Examination and Identification of Burnt Human Remains\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Methods for Analyzing Burnt Human Remains 75\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eAmanda N. Williams\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Anthropological Methods for Classifying Burnt Remains 76\u003c\/p\u003e \u003cp\u003e5.2 Medicolegal Classification Methods 78\u003c\/p\u003e \u003cp\u003e5.3 Need for New Model within the Forensic Sciences 79\u003c\/p\u003e \u003cp\u003e5.4 A New Classification System 80\u003c\/p\u003e \u003cp\u003e5.5 Best Practices in Applying this New Model 83\u003c\/p\u003e \u003cp\u003e5.6 Case Study #1 83\u003c\/p\u003e \u003cp\u003e5.7 Case Study #2 86\u003c\/p\u003e \u003cp\u003e5.8 Case Study #3 88\u003c\/p\u003e \u003cp\u003e5.9 Case Study #4 90\u003c\/p\u003e \u003cp\u003e5.10 Case Study #5 92\u003c\/p\u003e \u003cp\u003e5.11 Broader Implications 95\u003c\/p\u003e \u003cp\u003e5.12 Conclusions 95\u003c\/p\u003e \u003cp\u003eAcknowledgments 96\u003c\/p\u003e \u003cp\u003eReferences 96\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Burnt Human Remains and Forensic Medicine 99\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSarah Ellingham; Joe Adserias-Garriga and Peter Ellis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Fire Death Statistics 99\u003c\/p\u003e \u003cp\u003e6.2 Statistics of Manner of Fire-Related Deaths 100\u003c\/p\u003e \u003cp\u003e6.2.1 Prevalence of Self-Immolation 100\u003c\/p\u003e \u003cp\u003e6.2.2 Prevalence of Criminal Immolation 101\u003c\/p\u003e \u003cp\u003e6.3 Fire Damage to the Body 102\u003c\/p\u003e \u003cp\u003e6.4 Classification of the Degree of Fire Damage 103\u003c\/p\u003e \u003cp\u003e6.5 Medicolegal Determination of Cause of Death 105\u003c\/p\u003e \u003cp\u003e6.6 Medicolegal Determination of Manner of Death 106\u003c\/p\u003e \u003cp\u003e6.7 The Use of Post-Mortem Imaging for the Analysis of Burn Victims 108\u003c\/p\u003e \u003cp\u003e6.8 Conclusion 110\u003c\/p\u003e \u003cp\u003eAcknowledgments 110\u003c\/p\u003e \u003cp\u003eReferences 110\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Skeletal Alteration of Burnt Remains through Fire Exposure 113\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJoe Adserias-Garriga\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Assessment of the Severity of the Thermal Damage in the Forensic Context 114\u003c\/p\u003e \u003cp\u003e7.2 Soft Tissue Alterations by Fire Exposure 115\u003c\/p\u003e \u003cp\u003e7.3 Bone Alteration by Fire Exposure 116\u003c\/p\u003e \u003cp\u003e7.4 Teeth Alteration by Fire Exposure 120\u003c\/p\u003e \u003cp\u003e7.5 Signature Changes in Skeletal Elements after Cremation 122\u003c\/p\u003e \u003cp\u003e7.6 Conclusions 129\u003c\/p\u003e \u003cp\u003eReferences 130\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Challenges of Biological Profile Estimation from Burnt Remains 133\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eTim J.U. Thompson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Why Does Burning Affect Methods of Identification? 134\u003c\/p\u003e \u003cp\u003e8.2 How Does the Context of Burning Impede the Creation of Biological Profiles? 135\u003c\/p\u003e \u003cp\u003e8.3 Challenges of Biological Profile Estimation of Burnt Remains 137\u003c\/p\u003e \u003cp\u003e8.3.1 Morphological Methods 137\u003c\/p\u003e \u003cp\u003e8.3.2 Metric Methods 139\u003c\/p\u003e \u003cp\u003e8.3.3 Other Approaches to Biological Profile Estimation 140\u003c\/p\u003e \u003cp\u003e8.4 Conclusions 142\u003c\/p\u003e \u003cp\u003eReferences 142\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Victim Identification: The Role of Incinerated Dental Materials 147\u003cbr\u003e\u003c\/b\u003e\u003ci\u003ePeter J. Bush; Mary A. Bush and Raymond Miller\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction 147\u003c\/p\u003e \u003cp\u003e9.2 Microstructural Changes in Teeth after Incineration 148\u003c\/p\u003e \u003cp\u003e9.3 Structural Changes Due to Restorative Procedures 149\u003c\/p\u003e \u003cp\u003e9.4 Case Reports 151\u003c\/p\u003e \u003cp\u003e9.4.1 Case Report 1: Airline Crash 151\u003c\/p\u003e \u003cp\u003e9.4.2 Case Report 2: Double Homicide 161\u003c\/p\u003e \u003cp\u003e9.5 Conclusions 165\u003c\/p\u003e \u003cp\u003eReferences 166\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Techniques for the Differentiation of Blunt Force Sharp Force and Gunshot Traumas from Heat Fractures in Burnt Remains 167\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eHanna Friedlander; Megan Moore and Pamela Mayne Correia\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 167\u003c\/p\u003e \u003cp\u003e10.2 Bone Fracture Biomechanics: Fresh Bone 168\u003c\/p\u003e \u003cp\u003e10.3 Bone Fracture Biomechanics: Stages of Thermal Damage 170\u003c\/p\u003e \u003cp\u003e10.4 Heat Fractures 171\u003c\/p\u003e \u003cp\u003e10.5 Blunt Force Trauma in Burnt Remains 172\u003c\/p\u003e \u003cp\u003e10.6 Sharp Force Trauma in Burnt Remains 175\u003c\/p\u003e \u003cp\u003e10.7 Gunshot Trauma in Burnt Remains 177\u003c\/p\u003e \u003cp\u003e10.8 Case Study: 3D Modelling of Traumatic and Heat Fractures in Cranial and Irregular Bone 179\u003c\/p\u003e \u003cp\u003e10.9 Discussion 182\u003c\/p\u003e \u003cp\u003e10.10 Conclusions 184\u003c\/p\u003e \u003cp\u003eAcknowledgments 185\u003c\/p\u003e \u003cp\u003ePermissions 185\u003c\/p\u003e \u003cp\u003eReferences 185\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3 Analytical Approaches to the Analysis of Burnt Bone\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Biochemical Alterations of Bone Subjected to Fire 193\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSarah Ellingham and Sara C. Zapico\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 The Biological and Chemical Makeup of Fresh Bone 193\u003c\/p\u003e \u003cp\u003e11.1.1 Introduction 193\u003c\/p\u003e \u003cp\u003e11.2 Bone Transformation When Subjected to Heat 195\u003c\/p\u003e \u003cp\u003e11.3 Analytical Approaches to Observing Bone Transformation 196\u003c\/p\u003e \u003cp\u003e11.3.1 Colorimetry 196\u003c\/p\u003e \u003cp\u003e11.3.2 SEM-EDX 196\u003c\/p\u003e \u003cp\u003e11.3.3 Fourier Transform Infrared-Spectroscopy 198\u003c\/p\u003e \u003cp\u003e11.3.4 Raman Spectroscopy 200\u003c\/p\u003e \u003cp\u003e11.3.5 X-Ray Diffraction 201\u003c\/p\u003e \u003cp\u003e11.3.6 Thermogravimetric Analysis (TGA) and Differential Scanning Calorimetry (DSC) 202\u003c\/p\u003e \u003cp\u003e11.3.7 Amino Acid Racemization 202\u003c\/p\u003e \u003cp\u003e11.4 DNA 204\u003c\/p\u003e \u003cp\u003e11.5 Changes to the Bone at Different Temperatures 205\u003c\/p\u003e \u003cp\u003e11.5.1 100°C Exposure 205\u003c\/p\u003e \u003cp\u003e11.5.2 200°C Exposure 206\u003c\/p\u003e \u003cp\u003e11.5.3 300°C Exposure 206\u003c\/p\u003e \u003cp\u003e11.5.4 400°C Exposure 207\u003c\/p\u003e \u003cp\u003e11.5.5 500°C Exposure 207\u003c\/p\u003e \u003cp\u003e11.5.6 600°C Exposure 207\u003c\/p\u003e \u003cp\u003e11.5.7 700°C Exposure 207\u003c\/p\u003e \u003cp\u003e11.5.8 800°C Exposure 208\u003c\/p\u003e \u003cp\u003e11.5.9 900°C Exposure 208\u003c\/p\u003e \u003cp\u003e11.5.10 1000°C Exposure 208\u003c\/p\u003e \u003cp\u003e11\u003ci\u003e.\u003c\/i\u003e6 Conclusion 208\u003c\/p\u003e \u003cp\u003eAcknowledgment 209\u003c\/p\u003e \u003cp\u003eReferences 209\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 DNA Profiling from Burnt Remains 213\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSara C. Zapico and Rebecca Stone-Gordon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction 213\u003c\/p\u003e \u003cp\u003e12.2 Research Studies on Burnt Remains 214\u003c\/p\u003e \u003cp\u003e12.3 Forensic Cases 218\u003c\/p\u003e \u003cp\u003e12.4 Alternative Approaches and New Technologies 221\u003c\/p\u003e \u003cp\u003e12.4.1 Assessment of DNA Damage 221\u003c\/p\u003e \u003cp\u003e12.4.2 Alternatives for DNA Extraction 222\u003c\/p\u003e \u003cp\u003e12.4.3 New Technologies 223\u003c\/p\u003e \u003cp\u003e12.5 Conclusions 225\u003c\/p\u003e \u003cp\u003eReferences 226\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Applying Colorimetry to the Study of Low Temperature Thermal \u003c\/b\u003e\u003cb\u003eChanges in Bone 229\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eChristopher W. Schmidt and Alexandria McDaniel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 229\u003c\/p\u003e \u003cp\u003e13.2 Colorimetry 230\u003c\/p\u003e \u003cp\u003e13.3 Challenges of Colorimetry 232\u003c\/p\u003e \u003cp\u003e13.4 Case Study 233\u003c\/p\u003e \u003cp\u003e13.5 Conclusion 236\u003c\/p\u003e \u003cp\u003eReferences 236\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 The Use of Histology to Distinguish Animal from Human Burnt Bone with Reference to Some Limitations 241\u003cbr\u003e\u003c\/b\u003e\u003ci\u003ePamela Mayne Correia; Kalyna Horocholyn and Kassandra Pointer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction 241\u003c\/p\u003e \u003cp\u003e14.2 Bone Tissue 242\u003c\/p\u003e \u003cp\u003e14.2.1 Primary Bone Tissue 243\u003c\/p\u003e \u003cp\u003e14.2.2 Secondary Bone 252\u003c\/p\u003e \u003cp\u003e14.3 Vertebrate Histology 254\u003c\/p\u003e \u003cp\u003e14.4 Burnt Bone Histology 256\u003c\/p\u003e \u003cp\u003e14.5 Case Study for Comparison of Histology of Cremated Bone 259\u003c\/p\u003e \u003cp\u003e14.5.1 Qualitative and Quantitative Analysis for Case Study 259\u003c\/p\u003e \u003cp\u003e14.6 Discussion 264\u003c\/p\u003e \u003cp\u003e14.7 Conclusion 266\u003c\/p\u003e \u003cp\u003eReferences 267\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Isotope Analysis from Cremated Remains 273\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eChristophe Snoeck\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Introduction 273\u003c\/p\u003e \u003cp\u003e15.2 Infrared Analyses 274\u003c\/p\u003e \u003cp\u003e15.3 Radiocarbon Dating 276\u003c\/p\u003e \u003cp\u003e15.4 Isotope Analyses 277\u003c\/p\u003e \u003cp\u003e15.4.1 Carbon and Oxygen Isotope Ratios 277\u003c\/p\u003e \u003cp\u003e15.4.2 Strontium Isotope Ratios and Concentrations 281\u003c\/p\u003e \u003cp\u003e15.5 Archaeological Case Studies 282\u003c\/p\u003e \u003cp\u003e15.5.1 Stonehenge 282\u003c\/p\u003e \u003cp\u003e15.5.2 Meuse Basin Belgium and the Netherlands 283\u003c\/p\u003e \u003cp\u003e15.6 Conclusions 285\u003c\/p\u003e \u003cp\u003eAcknowledgments 285\u003c\/p\u003e \u003cp\u003eReferences 285\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 The Application of Imaging to Heat-Induced Bone 291\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRachael M. Carew and David Errickson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 Introduction 291\u003c\/p\u003e \u003cp\u003e16.2 Technological Progression 292\u003c\/p\u003e \u003cp\u003e16.3 The Current Technology 294\u003c\/p\u003e \u003cp\u003e16.3.1 Two-Dimensional Imaging 294\u003c\/p\u003e \u003cp\u003e16.3.2 Three-Dimensional Imaging 295\u003c\/p\u003e \u003cp\u003e16.4 The Application of Imaging to Heat-Induced and Burnt Bodies 299\u003c\/p\u003e \u003cp\u003e16.4.1 Locating and Identifying Burnt Bone 299\u003c\/p\u003e \u003cp\u003e16.4.2 Visual Capture and Documentation for Recording and Archiving 300\u003c\/p\u003e \u003cp\u003e16.4.3 Quantifying and Analyzing Burnt Remains 301\u003c\/p\u003e \u003cp\u003e16.4.4 Reconstruction 302\u003c\/p\u003e \u003cp\u003e16.4.5 Ethical and Legal Considerations within the Forensic Context 305\u003c\/p\u003e \u003cp\u003e16.5 Discussion and Conclusion 306\u003c\/p\u003e \u003cp\u003eReferences 308\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 The First Reference Collection for the Research of Burnt Human Skeletal Remains Stemming from the 21st Century Identified Skeletal Collection (Portugal) 313\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eDavid Gonçalves; Calil Makhoul; Maria Teresa Ferreira and Eugénia Cunha\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17.1 Introduction 313\u003c\/p\u003e \u003cp\u003e17.1.1 The Challenge Posed by Burnt Skeletal Remains 313\u003c\/p\u003e \u003cp\u003e17.1.2 Changing the Paradigm 315\u003c\/p\u003e \u003cp\u003e17.1.3 The 21st Century Identified Skeletal Collection 320\u003c\/p\u003e \u003cp\u003e17.1.4 Preparing the Skeletons 321\u003c\/p\u003e \u003cp\u003e17.1.5 Composition of the Collection 323\u003c\/p\u003e \u003cp\u003e17.2 Research Potential 324\u003c\/p\u003e \u003cp\u003e17.3 Final Comments 327\u003c\/p\u003e \u003cp\u003eAcknowledgments 328\u003c\/p\u003e \u003cp\u003eReferences 328\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4 Case Studies\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Analysis of Burnt Human Remains: Statistical Perspectives from Casework in Forensic Anthropology 337\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eDouglas H. Ubelaker; Cassandra M. DeGaglia and Haley Khosrowshahi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18.1 Introduction 337\u003c\/p\u003e \u003cp\u003e18.2 Materials and Methods 337\u003c\/p\u003e \u003cp\u003e18.3 Results 339\u003c\/p\u003e \u003cp\u003e18.4 Discussion 342\u003c\/p\u003e \u003cp\u003e18.5 Conclusions 344\u003c\/p\u003e \u003cp\u003eLiterature Cited 344\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 The Challenge of Burnt Remains from the Brazilian “Microwave Oven” 345\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMelina Calmon Silva; Eugénia Cunha and Yara Vieira Lemos\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19.1 Introduction 345\u003c\/p\u003e \u003cp\u003e19.2 Brazilian Homicide Rates 346\u003c\/p\u003e \u003cp\u003e19.3 The Relationship between Homicide and Drugs 347\u003c\/p\u003e \u003cp\u003e19.4 The “Microwave Oven” Modality of Death \/ Disposability of Human Remains 348\u003c\/p\u003e \u003cp\u003e19.4 Phases of Rubber Tire Combustion 350\u003c\/p\u003e \u003cp\u003e19.5 The Challenges of Investigating “Microwave Oven” Deaths 351\u003c\/p\u003e \u003cp\u003e19.6 The Role of Forensic Anthropology 353\u003c\/p\u003e \u003cp\u003e19.6.1 Case Study 1 354\u003c\/p\u003e \u003cp\u003e19.6.2 Case Study 2 359\u003c\/p\u003e \u003cp\u003e19.7 Conclusion 365\u003c\/p\u003e \u003cp\u003eConflicts of Interest 366\u003c\/p\u003e \u003cp\u003eEthical Approval 366\u003c\/p\u003e \u003cp\u003eAcknowledgments 366\u003c\/p\u003e \u003cp\u003eReferences 367\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20 Recovery and Identification of Fatal Fire Victims from the 2018 Northern California Camp Fire Disaster 371\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eColleen Milligan; Alison Galloway; Ashley Kendell; Lauren Zephro; P. Willey and Eric Bartelink\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20.1 Overview of the Camp Fire 371\u003c\/p\u003e \u003cp\u003e20.2 Wildfire Burn Environments and Condition of Remains 374\u003c\/p\u003e \u003cp\u003e20.3 Field to Morgue: What’s Important for Identification Efforts? 375\u003c\/p\u003e \u003cp\u003e20.4 Morgue Identification 379\u003c\/p\u003e \u003cp\u003e20.5 Conclusions 381\u003c\/p\u003e \u003cp\u003eReferences 381\u003c\/p\u003e \u003cp\u003e\u003cb\u003e21 Recovery and Identification of Burnt Remains in a Military Theatre of Operations: The Warrior Six 383\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJulie Roberts\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21.1 Introduction 383\u003c\/p\u003e \u003cp\u003e21.1.1 Improvised Explosive Devices and Blast Injuries 384\u003c\/p\u003e \u003cp\u003e21.1.2 The Effects of Heat on Bone 384\u003c\/p\u003e \u003cp\u003e21.2 Background to the Case 385\u003c\/p\u003e \u003cp\u003e21.3 Assessment of the Vehicle and Recovered Remains 387\u003c\/p\u003e \u003cp\u003e21.4 Excavation Strategy and Methodology 390\u003c\/p\u003e \u003cp\u003e21.5 Examination of the Remains in the Temporary Mortuary 394\u003c\/p\u003e \u003cp\u003e21.6 Examinations in the Role 3 Hospital 398\u003c\/p\u003e \u003cp\u003e21.6.1 Soldier A 398\u003c\/p\u003e \u003cp\u003e21.6.2 Soldier B 398\u003c\/p\u003e \u003cp\u003e21.6.3 Soldier C 399\u003c\/p\u003e \u003cp\u003e21.6.4 Soldier D 399\u003c\/p\u003e \u003cp\u003e21.6.5 Soldier E 400\u003c\/p\u003e \u003cp\u003e21.6.6 Soldier F 400\u003c\/p\u003e \u003cp\u003e21.7 Post-mortem Examinations and Positive Identification in the UK 401\u003c\/p\u003e \u003cp\u003e21.8 Conclusions 403\u003c\/p\u003e \u003cp\u003eAcknowledgments 403\u003c\/p\u003e \u003cp\u003eReferences 403\u003c\/p\u003e \u003cp\u003e\u003cb\u003e22 Volcanoes Bones and Heat: The Case of the AD 79 Victims of Vesuvius 407\u003cbr\u003e\u003c\/b\u003e\u003ci\u003ePier paolo Petrone\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22.1 Introduction 407\u003c\/p\u003e \u003cp\u003e22.2 The AD 79 Eruption of Vesuvius 408\u003c\/p\u003e \u003cp\u003e22.3 The Date of the Eruption 410\u003c\/p\u003e \u003cp\u003e22.4 Historical and Archaeological Context of the Discovery 411\u003c\/p\u003e \u003cp\u003e22.5 Bioarchaeological and Taphonomic Study 413\u003c\/p\u003e \u003cp\u003e22.6 The Causes of Death 418\u003c\/p\u003e \u003cp\u003e22.7 The Most Recent Studies 420\u003c\/p\u003e \u003cp\u003e22.8 An Exceptional Discovery 427\u003c\/p\u003e \u003cp\u003e22.9 Conclusions 430\u003c\/p\u003e \u003cp\u003eReferences 431\u003c\/p\u003e \u003cp\u003eIndex 437\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":48866411020631,"sku":"9781119682608","price":130.5,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781119682608.jpg?v=1722278509"},{"product_id":"advances-in-medicinal-chemistry-research-9781536163681","title":"Advances in Medicinal Chemistry Research","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eAdvances in Medicinal Chemistry Research is a book addressed to undergraduate and postgraduate students, where recent advances in the discovery and development of effective agents against the most remarkable wide-reaching diseases are presented, divided into seven chapters. This first edition of Advances in Medicinal Chemistry Research offers insights into medicinal chemistry that arguably have the most significant impact on our lives than any other. It draws together research on therapeutic agents from natural, synthetic, and virtual screening sources as starting points for the design of drugs against obesity, multidrug-resistant bacteria, neglected tropical diseases, Alzheimer, and cancer. From the prediction of promising hits and identification of active compounds to the extraction of more complex molecules, this book explores a range of essential topics to support the development of novel, economical, and efficacious therapeutics for these diseases, which currently affect a billion people worldwide. Beginning with an overview of obesity, showing the current research landscape, the books shows the importance of natural and synthetic products as promising anti-obesity agents. Subsequently, the medicinal chemistry of modulation of bacterial resistance is presented, focusing on the MFS, RND, ABC, and MATE superfamilies. The book goes on to discuss such topics as antituberculosis, antileishmanial, and anti-hepatitis thiophene-containing compounds, under the medicinal chemistry point of view. Also, potent human glutaminyl cyclase inhibitors are deeply discussed and displayed as hopeful anti-Alzheimer's agents. The last three chapters are focused on the development of researches involving new anticancer agents, initializing with LBDD, SBDD, QSAR, and QM\/MM methods applied to the identification of novel promising anticancer compounds. Moreover, IDO1 inhibitors are exhaustively explored and analyzed as a new promise for the immunotherapy of cancer. Finally, a great update on Eg5 kinesin inhibitors is provided, exploring different chemical classes of synthetic and natural compounds, including miscellanea as a new approach for Eg5 inhibition. Combining the expertise of researchers from around the world, this volume aims to support and encourage researches for the development of novel, safe, and active agents against lipase enzyme, bacteria, neglected tropical diseases, Alzheimer, and cancer. The clear narrative truly engages the reader, holding their attention right from the opening of a chapter, and maintaining interest and understanding as a chapter leads into more complex material. Advances in Medicinal Chemistry Research is a book that reviews ongoing developments and recent cutting-edge advances in medicinal chemistry of the most relevant diseases found nowadays, underlining how medicinal chemistry research continues to make significant contributions to the discovery and development of new therapeutic entities. Key Features Chapters written by active specialists and leading experts deeply engaged in the research field of most deadly and limiting diseases for drug discovery. Draws together cutting-edge research advances in medicinal chemistry focused at the obesity, multidrug-resistant microorganisms, Alzheimer, and cancer in a single volume. Highlights the future potential of researches for the medicinal chemistry of most impactful diseases today. Contents addressed to medicinal chemistry, biochemistry, biology, and pharmacy students, professors, and researchers.","brand":"Nova Science Publishers Inc","offers":[{"title":"Default Title","offer_id":48886145974615,"sku":"9781536163681","price":138.39,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781536163681.jpg?v=1722538981"},{"product_id":"antimicrobial-resistance-opportunities-and-challenges-9781536179439","title":"Antimicrobial Resistance: Opportunities and","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThis book contains comprehensive and up-to-date reviews of multidrug resistance mechanisms. The book intends to provide a state-of-the-art collection of reviews and methods for both basic and clinician investigators who are interested in multidrug resistance mechanisms and reversal strategies. We believe that this information will be of value to clinicians, epidemiologists, microbiologists, virologists, parasitologists, public health authorities, medical students, and fellows in training. Each chapter begins with a summary of the concepts, so that those not actively working in the field can readily gain an overall picture of what follows. The book contains 13 chapters which deal with the antibiotic resistance mechanism in bacteria, fungus, virus and also methicillin resistance S.aureus. The book also explains the futuristic strategy to deal with the antibiotic resistance. We have endeavoured to provide this information in a style that is accessible to the broad community of persons who are concerned with the impact of drug resistance in our clinics and across broader global communities.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePreface; History of Drug-Resistant Microbes; Mechanism of Antibiotic Resistance in Bacteria; Infectious Pathogens, Pathogenesis, Antimicrobial Therapy, Antimicrobial Resistance, and Surveillance Measures; Fungal Resistance to Antibiotics; Antibiotic Resistance and Tolerance in Bacterial Biofilm; Methicillin Resistant Staphylococcus aureus (MRSA): An Overview; Mechanism of Drug Resistance in Mycobacterium tuberculosis; Viral Drug Resistance; Strategies for Circumventing Antimicrobial Resistance; Metallic Nanoparticles in Tackling of Antimicrobial Resistance; Plant Antimicrobials: An Alternative for Overcoming Microbial Resistance; Algae: Novel Cell Factories for Antimicrobial Compounds to Overcome Antibiotic Resistance; Microbial Resistance: A Worldwide Public Health Problem; Index.","brand":"Nova Science Publishers Inc","offers":[{"title":"Default Title","offer_id":48886172909911,"sku":"9781536179439","price":163.19,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781536179439.jpg?v=1722539080"},{"product_id":"drugs-easily-explained-9783031121876","title":"Drugs Easily Explained","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eBillions of people worldwide take medicines every day to treat important diseases. In many cases, however, neither the doctor nor the pharmacist has the time to explain to the patient why a particular drug should be taken, how the drug works and what side effects to expect. Of course, the patient can find \"everything\" about a particular drug on the Internet. But how reliable and understandable is this information? In addition, most Internet sources do not point out the interrelationships between different diseases and drug interactions. Written by an experienced and well-known textbook author, this book provides an overview of the most common diseases and the drugs used to treat them. The book is designed for a general audience. It provides patients with essential information about how medications work and what side effects and interactions to expect. Finally, the book gives patients advice on what they can do themselves to improve drug therapy and safety. Summaries, bullet points, tables and diagrams support the information process.\u003cbr\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eChapter 1. What Should I Know About Drugs?.- Chapter 2. Painkillers (analgesics).- Chapter 3. Drugs for Gastrointestinal Disorders.- Chapter 4. Drugs for Respiratory Diseases.- Chapter 5. Drugs for Cardiovascular Diseases.- Chapter 6. Drugs for Metabolic Disorders.- Chapter 7. Drugs for Her and Him.- Chapter 8. Drugs for Neurological Disorders.- Chapter 9. Drugs for Mental Disorders.- Chapter 10. Drugs for Eye Diseases.- Chapter 11. Drugs for Cancer and Autoimmune and Infectious Diseases.\u003c\/p\u003e\u003cbr\u003e","brand":"Springer International Publishing AG","offers":[{"title":"Default Title","offer_id":48889015304535,"sku":"9783031121876","price":18.74,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783031121876.jpg?v=1722552273"},{"product_id":"pharmaceutical-biotechnology-fundamentals-and-applications-9783031300226","title":"Pharmaceutical Biotechnology: Fundamentals and","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThis introductory text explains both the basic science, production, quality, dosage forms, administration, economic and regulatory aspects and the clinical applications of biotechnology-derived pharmaceuticals. It serves as a complete one-stop source for undergraduate\/graduate pharmacists and pharmaceutical science students. An additional important audience are pharmaceutical scientists in industry and academia, particularly those who have not received formal training in pharmaceutical biotechnology and are inexperienced in this field. The rapid growth and advances in the field made it necessary to revise this textbook in order to continue providing up-to-date information and introduce readers to cutting edge knowledge and technology of this field. This Sixth Edition completely updates the previous edition and includes additional coverage on new approaches such as oligonucleotides, siRNA, mRNA, gene therapy, cell therapies, monoclonal antibodies and vaccines. With more than 3-million-chapter downloads, the fifth edition of the textbook has achieved widespread distribution as a key educational resource for the field of pharmaceutical biotechnology. \u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eMolecular Biotechnology.- Biophysical and biochemical analysis of recombinant proteins.- Production and downstream processing of biotech products.- Formulation of biotech products, including biopharmaceutical considerations.- Pharmacokinetics and pharmacodynamics of peptide and protein drugs.- Immunogenicity of pharmaceutical proteins.- General considerations of monoclonal antibodies from structure to therapeutic application.- Genomics, Other “Omics” Technologies, Personalized Medicine and Additional Biotechnology-Related Techniques.- Dispensing biotechnology products: handling, professional education and product information.- Economic considerations in medical biotechnology.- Regulatory framework for biosimilars.- Vaccines.- Oligonucleotides and siRNA.- Gene therapy.- Stem cell technology.- \u003cb\u003eTherapeutic Applications.-\u003c\/b\u003e\u003ci\u003eEndocrinology\u003c\/i\u003e.- Insulin.- Follicle-stimulating hormone.-  Growth hormone.- \u003cb\u003eCardiovascular and Respiratory Applications.- \u003c\/b\u003eRecombinant coagulation factors and thrombolytics.- Recombinant human deoxyribonuclease.- \u003cb\u003eOncology.- \u003c\/b\u003eMonoclonal antibodies in oncology .- Hematopoetic growth factors.- I\u003cb\u003enflammation and Immunemodulation\u003c\/b\u003e.- Monoclonal antibodies in transplantation.- Monoclonal antibodies and antibody-based therapeutics in anti-inflammatory therapy.-  Interferons and interleukins.- \u003cb\u003eAnti-infectious diseases.- \u003c\/b\u003eMonoclonal antibodies.- Enzyme replacement therapy.\u003cbr\u003e\u003c\/p\u003e","brand":"Springer International Publishing AG","offers":[{"title":"Default Title","offer_id":48889016680791,"sku":"9783031300226","price":67.49,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783031300226.jpg?v=1722552282"},{"product_id":"advanced-organic-chemistry-9780387683546","title":"Advanced Organic Chemistry","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eAlkylation of Enolates and Other Carbon Nucleophiles.- Reactions of Carbon Nucleophiles with Carbonyl Compounds.- Functional Group Interconversion by Substitution, Including Protection and Deprotection.- Electrophilic Additions to Carbon-Carbon Multiple Bonds.- Reduction of Carbon-Carbon Multiple Bonds, Carbonyl Groups, and Other Functional Groups.- Concerted Cycloadditions, Unimolecular Rearrangements, and Thermal Eliminations.- Organometallic Compounds of Group I and II Metals.- Reactions Involving Transition Metals.- Carbon-Carbon Bond-Forming Reactions of Compounds of Boron, Silicon, and Tin.- Reactions Involving Carbocations, Carbenes, and Radicals as Reactive Intermediates.- Aromatic Substitution Reactions.- Oxidations.- Multistep Syntheses.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eFrom the reviews of the fifth edition:\u003c\/p\u003e \u003cp\u003e\u003c\/p\u003e \u003cp\u003e\"Advanced Organic Chemistry … the well-known textbook for graduate students – has now appeared in a 5th edition. … Carey \u0026amp; Sundberg will be interesting to all students who seek a detailed understanding of organic chemistry, and who wish to refresh and embellish their existing knowledge. On the strength of the scope and quality of the explanations, this pair of texts is recommended for use as the resource of first resort for specific research questions in one’s later career.\" (www.organische-chemie.ch, January, 2008)\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eAlkylation of Enolates and Other Carbon Nucleophiles.- Reactions of Carbon Nucleophiles with Carbonyl Compounds.- Functional Group Interconversion by Substitution, Including Protection and Deprotection.- Electrophilic Additions to Carbon-Carbon Multiple Bonds.- Reduction of Carbon-Carbon Multiple Bonds, Carbonyl Groups, and Other Functional Groups.- Concerted Cycloadditions, Unimolecular Rearrangements, and Thermal Eliminations.- Organometallic Compounds of Group I and II Metals.- Reactions Involving Transition Metals.- Carbon-Carbon Bond-Forming Reactions of Compounds of Boron, Silicon, and Tin.- Reactions Involving Carbocations, Carbenes, and Radicals as Reactive Intermediates.- Aromatic Substitution Reactions.- Oxidations.- Multistep Syntheses.","brand":"Springer-Verlag New York Inc.","offers":[{"title":"Default Title","offer_id":49083495154007,"sku":"9780387683546","price":49.49,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780387683546.jpg?v=1725549127"},{"product_id":"pharmacokinetics-basics-to-applications-9789811689529","title":"Pharmacokinetics: Basics to Applications","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThis textbook covers all the essential elements of pharmacokinetics, from basics to applications. It describes authoritative equations and methods on pharmacokinetic evaluation procedures with their importance. Each chapter of the book is supplemented with numerous illustrations and figures for easy understanding of the subject. The book presents mathematical techniques, step- by-step descriptive equations, and applicable statistical analysis methods for the easy understanding of the topic. Further, it covers the preclinical applications and methods of pharmacokinetic aspects. The book also contains mathematical problems and questions related to pharmacokinetics for students. Special emphasis is on recent pharmacokinetic methods and their applications for managing clinical data and biostatistical approaches based on the current literature. This book is primarily meant for researchers and students from academic institutions and to R\u0026amp;D professionals.\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eChapter 1: Fundamentals of Pharmacokinetics.- Chapter 2: Drug absorption.- Chapter 3:  The extent of drug absorption: bioavailability, clearance, bioequivalence, and protein-binding.- Chapter 4:  Pharmacokinetic models and drug distribution.- Chapter 5: Drug metabolism .- Chapter 6: Drug elimination and nonlinear kinetics.- Chapter 7: Pharmacokinetic drug-drug interactions.- Chapter 8: Pharmacokinetic applications.- Chapter 9: Pharmacokinetic sample collection and processing.- Chapter 10: Important bio-analytical instrumental techniques in pharmacokinetics.- Chapter 11: Statistics in pharmacokinetics.- Chapter 12: Pharmacokinetic software and tools.- Chapter 13: Pharmacokinetic laboratory-based experiments.- Chapter 14: Pharmacokinetic numerical problems with solutions.- Chapter 15: Questions, and questions \u0026amp; answers for practice.\u003c\/p\u003e","brand":"Springer Verlag, Singapore","offers":[{"title":"Default Title","offer_id":49084934127959,"sku":"9789811689529","price":54.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9789811689529.jpg?v=1725553789"},{"product_id":"chemical-biology-and-drug-discovery-9783662644119","title":"Chemical Biology: and Drug Discovery","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThe focus of this textbook is on application, rather than pure knowledge transfer of the results of all chemical biological work (which would also be beyond the scope of a book). It gives the reader, through the specific selection of chemical biological techniques and concepts, the necessary tools to be able to develop new ways of thinking and thus new therapeutic options in the complex field of chemical biology and drug development. The stated aim of this book is to provide concrete solutions and inspiration to students, (post)graduate students, and experienced scientists at universities as well as in industry in their problems. \u003c\/p\u003e\u003cp\u003eAfter an introduction to the problems addressed by chemical biology in drug discovery, the three levels of molecular biology dogma: DNA, RNA and proteins and their role as drug targets serve as the common thread of this book.\u003c\/p\u003e\u003cp\u003eThis book is a translation of the original German 1\u003csup\u003est\u003c\/sup\u003e edition \u003ci\u003eChemische Biologie \u003c\/i\u003eby Marco F. Schmidt, published by Springer-Verlag GmbH Germany, part of Springer Nature in 2020. The translation was done with the help of artificial intelligence (machine translation by the service DeepL.com). A subsequent human revision was done primarily in terms of content, so that the book will read stylistically differently from a conventional translation. Springer Nature works continuously to further the development of tools for the production of books and on the related technologies to support the authors.\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eForeword.- Introduction.- Part I: Chemical Biology and Drug Development.- Chemical Biology - a Holistic Science.- Drug Development.- From Genomics to Chemical Biology.- Part II: DNA.- DNA - blueprint of proteins.- Genomic Variation.- Gene Therapy and Genome Editing.- Part III: RNA.- RNA - information and function carrier.- RNA Interference in Drug Development.- Part IV: Proteins.- Peptides \u0026amp; proteins.- Proteins as drug targets.- Chemical genomics - From target protein to drug.- From target protein to macromolecular drug - Biologics.- Chemical proteomics: From drug to target protein.- Chemical genetics: validation of drug target by elucidation of signaling pathway.- Chemical biology - Addressing new drug targets.\u003cbr\u003e","brand":"Springer-Verlag Berlin and Heidelberg GmbH \u0026 Co. KG","offers":[{"title":"Default Title","offer_id":49372703949143,"sku":"9783662644119","price":52.24,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783662644119.jpg?v=1730163878"},{"product_id":"health-promotion-programs-9781119770886","title":"Health Promotion Programs","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eContents\u003cbr\u003e\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003ci\u003eIntroduction \u003c\/i\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003ePart One: Health Promotion Program Foundations\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003ci\u003eChapter 1\u003c\/i\u003e- What are Health Promotion Programs?\u003cbr\u003e\u003ci\u003eChapter 2\u003c\/i\u003e- Health Promotion, Equity, and Social Justice\u003cbr\u003e\u003ci\u003eChapter 3-\u003c\/i\u003e Theory in Health Promotion Programs \u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003ePart Two: Planning Health Promotion Programs \u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003ci\u003eChapter 4\u003c\/i\u003e- Assessing the Health Needs of a Defined Population \u003cbr\u003e\u003ci\u003eChapter 5\u003c\/i\u003e- Making Decisions to Create and Support a Program \u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003ePart Three: Implementing Health Promotion Programs \u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003ci\u003eChapter 6-\u003c\/i\u003e Implementation Tools, Program Staff, and Budgets \u003cbr\u003e\u003ci\u003eChapter 7-\u003c\/i\u003e Advocacy \u003cbr\u003e\u003ci\u003eChapter 8-\u003c\/i\u003e Communicating Health Information Effectively \u003cbr\u003e\u003ci\u003eChapter 9-\u003c\/i\u003e Where Money Meets Mission: Developing, Increasing and Sustaining Program Funding\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003ePart Four: Evaluating and Sustaining Health Promotion\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003ci\u003eChapter 10\u003c\/i\u003e- Evaluating and Improving Health Promotion Programs \u003cbr\u003e\u003ci\u003eChapter 11\u003c\/i\u003e- Using Big Data for Action and Impact \u003cbr\u003e\u003ci\u003eChapter 12\u003c\/i\u003e- Sustaining Health Promotion Programs \u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003ePart Five: Health Promotion Programs in Diverse Settings \u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003ci\u003eChapter 13\u003c\/i\u003e- School Health Education: Promoting Health and Academic Success\u003cbr\u003e\u003ci\u003eChapter 14\u003c\/i\u003e- Promoting Health in Colleges and Universities \u003cbr\u003e\u003ci\u003eChapter 15\u003c\/i\u003e- Patient-Centered Health Promotion Programs in Healthcare\u003cbr\u003e\u003ci\u003eChapter 16\u003c\/i\u003e- Health Promotion Programs in Workplace Settings \u003cbr\u003e\u003ci\u003eChapter 17\u003c\/i\u003e- Promoting Community Health: Local Health Departments and Community Health Organizations \u003cbr\u003e\u003cbr\u003e\u003ci\u003eIndex \u003c\/i\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49396207157591,"sku":"9781119770886","price":76.46,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781119770886.jpg?v=1730415100"},{"product_id":"laboratory-techniques-in-thrombosis-a-manual-9780792353171","title":"Laboratory Techniques in Thrombosis  a Manual","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThe first edition of this manual appeared in 1992 and was entitled ECAT Assay Procedures. It was the result of a unique cooperation between experts brought together by the European Concerted Action on Thrombosis and                            Disabilities (ECAT). The Concerted Action was at that time under the auspices of the Commission of the European Union. The second edition, like the first edition, deals with diagnostic tests within the field of thrombosis.                            However, the second edition has a broader scope because it is no longer limited by the frontiers of ECAT. Experts allover the world, in and outside ECAT, have contributed to this edition. The editors are very grateful for                            their contributions. The need for a new edition is obvious. Since 1992 new assays have been introduced for research, diagnosis, and therapy of thrombosis; for other assays improvements have been suggested, while a few others                            became\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003cstrong\u003e`\u003c\/strong\u003eThe objective towards standardization is largely met,  since world experts on each assay collaborated to evaluate and compare  the available methodologies and point to the advantages and  disadvantages of each one. This book is written for clinical  thrombosis and hemostasis laboratorians. Another attractive feature is  the degree of expertise recruited to produce these critical summaries  of existing methodologies. This book is a long overdue update of the  first edition in view of the multitude of newly developed  methodologies and the number of manufacturers involved.\u003cstrong\u003e'\u003c\/strong\u003e \u003cbr\u003e  \u003cstrong\u003eDemetra D. Callas, Loyola University Medical Center\u003c\/strong\u003e in  \u003cstrong\u003eDoody\u003c\/strong\u003e \u003cstrong\u003ePublishing Inc.\u003c\/strong\u003e \u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eList of Contributors. Nomenclature of Haemostasis Factors.  1. Introduction to Laboratory Assays in Haemostasis and  Thrombosis; J.Gram, J. Jespersen. 2. Good Medical  Laboratory Services - Guidelines; J.-C. Libeer. 3.  Blood Collection and Sample Preparation: Pre-analytical Variation;  I.D. Walker. 4. Quality Assessment of Haemostatic Assays  and External Quality Assessment Schemes; T.A.L. Woods, et  al. 5. Activated Partial Thromboplastin Time (APTT); L.  Poller. 6. Prothrombin Time (PT); L. Poller.  7. Endogenous Thrombin Potential; H.C. Hemker, S.  Béguin. 8. Fibrinogen; M.P.M. de Maat, et  al.9. Activated Factor VII; J.H. Morrissey. 10.  Factor VII Activity and Antigen; G. Mariani, et al. 11.  Factor VIII Clotting Activity; P.M. Mannucci, A. Tripodi.  12. Von Willebrand Factor; P.M. Mannucci, R.  Coppola. 13. Antithrombin Activity and Antigen; J.  Conard. 14. Protein C Activity and Antigen; R.M.  Bertina. 15. Protein S Antigen; R.M. Bertina. 16.  Protein S Activity Assays; E.M. Faioni. 17. Activated  Protein C (APC) Resistance; A. Tripodi. 18. Tissue Factor  Pathway Inhibitor (TFPI); P.M. Sandset. 19. Lupus  Anticoagulant; D.A. Triplett. 20. Heparin Cofactor II;  S.J. Bauman, F.C. Church. 21. Fibrinopeptide A  (FPA); A. Haeberli. 22. Thrombin-Antithrombin (TAT)  Complexes; J. Harenberg. 23. Prothrombin Fragment F 1\u0026amp;plus; 2; A. Haeberli. 24. Plasma Tissue-Type Plasminogen  Activator (t-PA) Activity; C. Kluft, et al. 25. Tissue  Type Plasminogen Activator Antigen (t-PA Ag); M.Ch. Alessi, I.  Juhan-Vague. 26. Plasminogen Activator Inhibitor-1(PAI-1)  Antigen; P.J. Declerk. 27. Plasminogen Activity; P.J.  Gaffney. 28. Plasma Plasmin Inhibitor* Activity (*Previously  \u0026amp;agr;2-Antiplasmin); C. Kluft, P. Meyer. 29.  Plasmin-\u0026amp;agr;2-Antiplasmin Complexes (Plasmin-Plasmin Inhibitor  Complexes); E. Hattey, et al. 30. Soluble Fibrin and  Degradation Products of Fibrinogen (FgDP), Fibrin (FbDP;D-dimer) and  Total of FgDP and FbDP (TDP); W. Nieuwenhuizen, R. Bos.  31. Venous Occlusion Test in Fibrinolysis Assays; J.  Jespersen. 32. List of Manufacturers. Index.","brand":"Springer","offers":[{"title":"Default Title","offer_id":49405068542295,"sku":"9780792353171","price":170.99,"currency_code":"GBP","in_stock":true}]},{"product_id":"disaster-victim-identification-in-the-21st-century-9781119652786","title":"Disaster Victim Identification in the 21st","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eA comprehensive examination of all critical aspects of Disaster Victim Identification (DVI)\u003c\/b\u003e  \u003cp\u003eAs the frequency of both natural and man-made mass fatality disasters increases worldwide, the establishment of clear standards and best practices within the field of Disaster Victim identification (DVI) is of vital importance. Whereas most countries assign jurisdiction to law enforcement agencies following Interpol guidelines, DVI is the responsibility of the medical examiner and coroner in the United States.  \u003c\/p\u003e\u003cp\u003e\u003ci\u003eDisaster Victim Identification in the 21st Century\u003c\/i\u003e is the first book of its kind to directly address the needs of DVI practitioners in the United States, covering the full spectrum of DVI from traditional methods such as fingerprints, odontology, and anthropology to advanced DNA identification technology. Approaching DVI from three perspectivesacademic, government, and private industrythis comprehensive volume examines the history and current state of the discipline, \u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eAbout the Editors xv\u003c\/p\u003e \u003cp\u003eNotes on the Contributors xvii\u003c\/p\u003e \u003cp\u003ePreface xxi\u003c\/p\u003e \u003cp\u003eSeries Preface xxiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Introduction 1\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJohn A Williams and Victor W Weedn\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 1\u003c\/p\u003e \u003cp\u003e1.2 This Book 3\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Historical Background 7\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eVictor W Weedn\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 History of Mass Disasters 7\u003c\/p\u003e \u003cp\u003e2.2 Early History of Mass Disaster Response 14\u003c\/p\u003e \u003cp\u003e2.2.1 The Portsmouth Christmas Fires and 1803 Portsmouth Federal Disaster Relief 16\u003c\/p\u003e \u003cp\u003e2.2.2 The 1835 Great Fire of New York City 16\u003c\/p\u003e \u003cp\u003e2.2.3 1865 Sultana Explosion 18\u003c\/p\u003e \u003cp\u003e2.2.4 The 1871 Fires 18\u003c\/p\u003e \u003cp\u003e2.2.5 American Red Cross (ARC) 19\u003c\/p\u003e \u003cp\u003e2.2.6 1889 Johnstown Flood 19\u003c\/p\u003e \u003cp\u003e2.2.7 1899 San Ciriaco Hurricane 20\u003c\/p\u003e \u003cp\u003e2.2.8 1900 Galveston Storm 20\u003c\/p\u003e \u003cp\u003e2.2.9 1906 San Francisco Earthquake 21\u003c\/p\u003e \u003cp\u003e2.2.10 1911 Triangle Shirtwaist Fire 21\u003c\/p\u003e \u003cp\u003e2.2.11 1912 Sinking of Titanic 22\u003c\/p\u003e \u003cp\u003e2.2.12 1918 Spanish Flu Pandemic 22\u003c\/p\u003e \u003cp\u003e2.2.13 1921–22 Russian (Povolzhye) Famine 23\u003c\/p\u003e \u003cp\u003e2.2.14 1927 Mississippi River Flood 24\u003c\/p\u003e \u003cp\u003e2.3 1930s and 1940s Federal Disaster Relief Legislation 24\u003c\/p\u003e \u003cp\u003e2.3.1 World War II Civilian Preparedness and Emergency Assets 25\u003c\/p\u003e \u003cp\u003e2.3.2 Post WWII Federal Disaster Relief Legislation 25\u003c\/p\u003e \u003cp\u003e2.3.3 Civil Defense Act of 1950 (P.L 81-920) 26\u003c\/p\u003e \u003cp\u003e2.3.4 Federal Disaster Relief Act of 1950 (P.L 81-875) 26\u003c\/p\u003e \u003cp\u003e2.4 1950s Federal Disaster Relief 28\u003c\/p\u003e \u003cp\u003e2.5 1960s Beginnings 28\u003c\/p\u003e \u003cp\u003e2.5.1 1960 Hurricane Donna 29\u003c\/p\u003e \u003cp\u003e2.5.2 1961 Hurricane Carla 29\u003c\/p\u003e \u003cp\u003e2.5.3 1962 Ash Wednesday Storm 29\u003c\/p\u003e \u003cp\u003e2.5.4 1964 Great Alaskan Earthquake 30\u003c\/p\u003e \u003cp\u003e2.5.5 1960s Federal Activism in the Wake of the Alaskan Earthquake 30\u003c\/p\u003e \u003cp\u003e2.5.6 1965 Palm Sunday Tornado Outbreak 30\u003c\/p\u003e \u003cp\u003e2.5.7 1965 Hurricane Betsy 31\u003c\/p\u003e \u003cp\u003e2.5.8 Disaster Relief Act of 1966 31\u003c\/p\u003e \u003cp\u003e2.5.9 1968 National Flood Insurance 31\u003c\/p\u003e \u003cp\u003e2.5.10 1969 Hurricane Camille 32\u003c\/p\u003e \u003cp\u003e2.6 Disaster Relief Acts of 1969 and 1970 32\u003c\/p\u003e \u003cp\u003e2.6.1 1971 San Fernando (Sylmar) Earthquake 32\u003c\/p\u003e \u003cp\u003e2.6.2 1972 Hurricane Agnes 33\u003c\/p\u003e \u003cp\u003e2.6.3 1974 Super Outbreak 33\u003c\/p\u003e \u003cp\u003e2.6.4 Disaster Relief Act Amendments of 1974 33\u003c\/p\u003e \u003cp\u003e2.7 National Emergencies Act of 1976 34\u003c\/p\u003e \u003cp\u003e2.8 National Earthquake Hazards Reduction Program (NEHRP) of 1977 34\u003c\/p\u003e \u003cp\u003e2.9 1979 Executive Orders 12127 \u0026amp; 12148 – Federal Emergency Management Agency (FEMA) 35\u003c\/p\u003e \u003cp\u003e2.9.1 1979 Three Mile Island (TMI) Nuclear Accident 36\u003c\/p\u003e \u003cp\u003e2.9.2 1980 Mount St Helens Volcanic Eruption 37\u003c\/p\u003e \u003cp\u003e2.10 Disaster Relief and Emergency Assistance Act of 1988 (The Stafford Act) 37\u003c\/p\u003e \u003cp\u003e2.10.1 FEMA under President George H W Bush (1989–1993) 38\u003c\/p\u003e \u003cp\u003e2.10.2 1989 Exxon Valdez Oil Spill 38\u003c\/p\u003e \u003cp\u003e2.10.3 1989 Hurricane Hugo 39\u003c\/p\u003e \u003cp\u003e2.10.4 1989 Loma Prieta Earthquake 39\u003c\/p\u003e \u003cp\u003e2.11 1992 Federal Response Plan (FRP) 40\u003c\/p\u003e \u003cp\u003e2.11.1 1992 Hurricane Andrew 40\u003c\/p\u003e \u003cp\u003e2.11.2 1992 Hurricane Iniki 41\u003c\/p\u003e \u003cp\u003e2.12 FEMA under President William J Clinton (1993–2001) 41\u003c\/p\u003e \u003cp\u003e2.12.1 1993 Midwest Floods 42\u003c\/p\u003e \u003cp\u003e2.12.2 1994 Northridge Earthquake 42\u003c\/p\u003e \u003cp\u003e2.12.3 1995 Oklahoma City Bombing 42\u003c\/p\u003e \u003cp\u003e2.13 1996 EMAC 43\u003c\/p\u003e \u003cp\u003e2.14 FEMA under President George W Bush (2001–2009) 43\u003c\/p\u003e \u003cp\u003e2.14.1 2001 Al Qaeda 9\/11 Terrorist Attacks 44\u003c\/p\u003e \u003cp\u003e2.15 Department of Homeland Security (DHS) 45\u003c\/p\u003e \u003cp\u003e2.15.1 2005 Hurricane Katrina 47\u003c\/p\u003e \u003cp\u003e2.16 Post-Katrina Emergency Management Reform Act of 2006 (PKEMRA) 48\u003c\/p\u003e \u003cp\u003e2.17 2008 National Response Framework (NRF) 49\u003c\/p\u003e \u003cp\u003e2.18 2011 National Disaster Recovery Framework 50\u003c\/p\u003e \u003cp\u003e2.18.1 2012 Hurricane Sandy 50\u003c\/p\u003e \u003cp\u003e2.18.2 Sandy Recovery Improvement Act of 2013 (SRIA) 50\u003c\/p\u003e \u003cp\u003e2.18.3 2017 Hurricane Harvey 51\u003c\/p\u003e \u003cp\u003e2.18.4 2017 Hurricane Maria 51\u003c\/p\u003e \u003cp\u003e2.19 The Disaster Recovery Reform Act of 2018 (DRRA) 52\u003c\/p\u003e \u003cp\u003e2.20 2020 COVID-19 Pandemic 52\u003c\/p\u003e \u003cp\u003e2.21 Summary of Federal Disaster Response 53\u003c\/p\u003e \u003cp\u003e2.22 History of Disaster Victim Identification 54\u003c\/p\u003e \u003cp\u003e2.22.1 Scientific Methods of Identification 55\u003c\/p\u003e \u003cp\u003e2.22.2 Military Identification Efforts 59\u003c\/p\u003e \u003cp\u003e2.22.3 Fbi Dvi Squad 61\u003c\/p\u003e \u003cp\u003e2.22.4 Interpol 61\u003c\/p\u003e \u003cp\u003e2.22.5 Other International Guidance 63\u003c\/p\u003e \u003cp\u003e2.22.6 Disaster Mortuary Operations Response Team (DMORT) 64\u003c\/p\u003e \u003cp\u003e2.22.7 National Association of Medical Examiners 65\u003c\/p\u003e \u003cp\u003e2.22.9 US Standards Setting Efforts 66\u003c\/p\u003e \u003cp\u003e2.22.8 Federal Direction 65\u003c\/p\u003e \u003cp\u003e2.23 Conclusion 68\u003c\/p\u003e \u003cp\u003eReferences 68\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Quality Assurance in Disaster Victim Identification: The Case for Standards 93\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJason M Wiersema and Michal L Pierce\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 93\u003c\/p\u003e \u003cp\u003e3.2 The Need for Standards in MDI 94\u003c\/p\u003e \u003cp\u003e3.3 The Need for Standards in DVI 96\u003c\/p\u003e \u003cp\u003e3.4 History of Standards Development in DVI 98\u003c\/p\u003e \u003cp\u003e3.5 Organization of Scientific Area Committees (OSAC) 99\u003c\/p\u003e \u003cp\u003e3.6 Discussion 100\u003c\/p\u003e \u003cp\u003e3.7 Adoption of Standards 102\u003c\/p\u003e \u003cp\u003e3.8 Conclusion 104\u003c\/p\u003e \u003cp\u003eReferences 104\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Medical Examiners, Coroners, and Public and Private Agencies 107\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJohn A Williams and Jason Wiersema\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 107\u003c\/p\u003e \u003cp\u003e4.2 The Medical Examiner\/Coroner System 109\u003c\/p\u003e \u003cp\u003e4.3 The US Federal Government and Mass Disasters 111\u003c\/p\u003e \u003cp\u003e4.4 Disaster Mortuary Operational Response Team 115\u003c\/p\u003e \u003cp\u003e4.5 Transportation Disaster Response 121\u003c\/p\u003e \u003cp\u003e4.6 State Reponses to Mass Fatalities 122\u003c\/p\u003e \u003cp\u003e4.7 The Private Sector 123\u003c\/p\u003e \u003cp\u003e4.8 Summary 123\u003c\/p\u003e \u003cp\u003eReferences 124\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 DVI Morgue Operations 127\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJohn A Williams\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction 127\u003c\/p\u003e \u003cp\u003e5.2 DVI Morgue Considerations 127\u003c\/p\u003e \u003cp\u003e5.2.1 Morgue Site Selection 128\u003c\/p\u003e \u003cp\u003e5.2.2 Incident Command System 129\u003c\/p\u003e \u003cp\u003e5.3 Workflow in the DVI Morgue 131\u003c\/p\u003e \u003cp\u003e5.4 DVI Morgue Stations 135\u003c\/p\u003e \u003cp\u003e5.4.1 Non-forensic Stations 135\u003c\/p\u003e \u003cp\u003e5.4.2 Forensic Stations 139\u003c\/p\u003e \u003cp\u003e5.5 Information Resource Center 141\u003c\/p\u003e \u003cp\u003e5.6 Identification and Reconciliation 142\u003c\/p\u003e \u003cp\u003e5.7 Summary 143\u003c\/p\u003e \u003cp\u003eReferences 143\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Forensic Odontology and Disaster Victim Identification 145\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eKenneth W Aschheim\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 145\u003c\/p\u003e \u003cp\u003e6.2 Methods of Identification of an Individual 145\u003c\/p\u003e \u003cp\u003e6.2.1 Non-Dental Methods of Identification 145\u003c\/p\u003e \u003cp\u003e6.2.2 Dental Identification 146\u003c\/p\u003e \u003cp\u003e6.3 Theoretical Basis for Comparative Dental Analysis 147\u003c\/p\u003e \u003cp\u003e6.3.1 Basic Theory 147\u003c\/p\u003e \u003cp\u003e6.3.2 The 32 Teeth Concept 149\u003c\/p\u003e \u003cp\u003e6.3.3 Logical Direction of Change 151\u003c\/p\u003e \u003cp\u003e6.3.4 Comparison Discrepancies 151\u003c\/p\u003e \u003cp\u003e6.3.5 Concordant Features 151\u003c\/p\u003e \u003cp\u003e6.4 The Antemortem Dental Record 153\u003c\/p\u003e \u003cp\u003e6.4.1 Tooth Numbering Systems 154\u003c\/p\u003e \u003cp\u003e6.5 Laws Governing the Transfer of Protected Dental Information 155\u003c\/p\u003e \u003cp\u003e6.5.1 Electronic Dental Record 156\u003c\/p\u003e \u003cp\u003e6.5.2 Issues Concerning Dental Data 156\u003c\/p\u003e \u003cp\u003e6.6 The Postmortem Dental Record 156\u003c\/p\u003e \u003cp\u003e6.7 The Dental Autopsy 157\u003c\/p\u003e \u003cp\u003e6.7.1 Visible Light Fluorescence 159\u003c\/p\u003e \u003cp\u003e6.7.2 Craniofacial Dissection 159\u003c\/p\u003e \u003cp\u003e6.7.3 Antemortem Radiographs 160\u003c\/p\u003e \u003cp\u003e6.7.4 Postmortem Radiographs 161\u003c\/p\u003e \u003cp\u003e6.7.5 Types of Imaging Devices 161\u003c\/p\u003e \u003cp\u003e6.7.5.1 Film 161\u003c\/p\u003e \u003cp\u003e6.7.5.2 Phosphorus Storage Plates (PSP) 162\u003c\/p\u003e \u003cp\u003e6.7.6 Digital Sensors 162\u003c\/p\u003e \u003cp\u003e6.7.7 Radiographic Sources 162\u003c\/p\u003e \u003cp\u003e6.7.8 Types of Dental Radiographs 163\u003c\/p\u003e \u003cp\u003e6.7.8.1 Intraoral Radiographs 163\u003c\/p\u003e \u003cp\u003e6.7.8.2 Extraoral Radiographs 164\u003c\/p\u003e \u003cp\u003e6.7.9 Radiographic Guidelines 166\u003c\/p\u003e \u003cp\u003e6.8 Intraoral and Extraoral Photographs 167\u003c\/p\u003e \u003cp\u003e6.8.1 Postmortem Photographs 168\u003c\/p\u003e \u003cp\u003e6.9 Study Casts 169\u003c\/p\u003e \u003cp\u003e6.10 Denture Labeling 170\u003c\/p\u003e \u003cp\u003e6.11 Dental Age Assessment 171\u003c\/p\u003e \u003cp\u003e6.12 Characterization of Dental Materials 172\u003c\/p\u003e \u003cp\u003e6.13 Reconciliation 172\u003c\/p\u003e \u003cp\u003e6.13.1 Source Conclusions 172\u003c\/p\u003e \u003cp\u003e6.13.2 Serial Unmasking 173\u003c\/p\u003e \u003cp\u003e6.13.3 Criteria for Comparison and Reconciliation 173\u003c\/p\u003e \u003cp\u003e6.13.4 Reporting 174\u003c\/p\u003e \u003cp\u003e6.13.5 Terminology 174\u003c\/p\u003e \u003cp\u003e6.14 Assembling the Forensic Odontology Team 174\u003c\/p\u003e \u003cp\u003e6.14.1 Leadership Team 176\u003c\/p\u003e \u003cp\u003e6.14.2 Administration Team 176\u003c\/p\u003e \u003cp\u003e6.14.3 Site Assessment Team 177\u003c\/p\u003e \u003cp\u003e6.14.4 Antemortem Team 177\u003c\/p\u003e \u003cp\u003e6.14.5 Postmortem Team 178\u003c\/p\u003e \u003cp\u003e6.14.6 Coding Team 178\u003c\/p\u003e \u003cp\u003e6.14.7 Information Technology Team 178\u003c\/p\u003e \u003cp\u003e6.14.8 Photographic Team 178\u003c\/p\u003e \u003cp\u003e6.14.9 Reconciliation (Comparison) Team 179\u003c\/p\u003e \u003cp\u003e6.14.10 Identification Review Board (IRB) 179\u003c\/p\u003e \u003cp\u003e6.15 Computer-Assisted Dental Identification 179\u003c\/p\u003e \u003cp\u003e6.15.1 Computer Assisted Post-Mortem Identification (CAPMI) 180\u003c\/p\u003e \u003cp\u003e6.15.2 WinID3 181\u003c\/p\u003e \u003cp\u003e6.15.3 Uvis\/Udim 183\u003c\/p\u003e \u003cp\u003e6.15.4 Dvi System International 186\u003c\/p\u003e \u003cp\u003e6.15.5 OdontoSearch 187\u003c\/p\u003e \u003cp\u003e6.16 Ethical Considerations 188\u003c\/p\u003e \u003cp\u003e6.17 Demobilization and After-Action Reports 189\u003c\/p\u003e \u003cp\u003e6.17.1 Demobilization 189\u003c\/p\u003e \u003cp\u003e6.17.2 Preservation of Dental Data 189\u003c\/p\u003e \u003cp\u003e6.17.2.1 Preservation of Antemortem Dental Data 189\u003c\/p\u003e \u003cp\u003e6.17.2.2 Preservation of Postmortem Dental Data 190\u003c\/p\u003e \u003cp\u003e6.17.3 Post-Action Follow-Up 190\u003c\/p\u003e \u003cp\u003e6.17.4 Planning and Training 190\u003c\/p\u003e \u003cp\u003e6.18 Conclusion 191\u003c\/p\u003e \u003cp\u003eReferences 191\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Fingerprints and DVI 195\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eBryan Johnson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 195\u003c\/p\u003e \u003cp\u003e7.2 Role of Fingerprints in DVI 197\u003c\/p\u003e \u003cp\u003e7.3 The DVI Process and Fingerprints 198\u003c\/p\u003e \u003cp\u003e7.4 Postmortem Fingerprinting Station 200\u003c\/p\u003e \u003cp\u003e7.5 Personnel and Postmortem Fingerprinting 203\u003c\/p\u003e \u003cp\u003e7.6 Postmortem Fingerprinting Process 204\u003c\/p\u003e \u003cp\u003e7.6.1 Inspection and Cleansing 205\u003c\/p\u003e \u003cp\u003e7.6.2 Rehydration 205\u003c\/p\u003e \u003cp\u003e7.6.2.1 Macerated Remains 209\u003c\/p\u003e \u003cp\u003e7.6.2.1.1 Tissue Injection 209\u003c\/p\u003e \u003cp\u003e7.6.2.1.2 Degloving 210\u003c\/p\u003e \u003cp\u003e7.6.2.1.3 Boiling Method 210\u003c\/p\u003e \u003cp\u003e7.6.2.2 Thermal Modification (Charred\/burned Skin) 213\u003c\/p\u003e \u003cp\u003e7.6.2.2.1 Tendon Release 214\u003c\/p\u003e \u003cp\u003e7.6.2.2.2 Break and Twist Method 214\u003c\/p\u003e \u003cp\u003e7.6.2.3 Desiccation (Mummification) 215\u003c\/p\u003e \u003cp\u003e7.6.2.3.1 Sodium Hydroxide Reconditioning 217\u003c\/p\u003e \u003cp\u003e7.6.2.3.2 Ammonium Hydroxide Reconditioning 217\u003c\/p\u003e \u003cp\u003e7.6.2.3.3 Detergent Soaking Reconditioning 218\u003c\/p\u003e \u003cp\u003e7.6.3 Collecting PM Prints 219\u003c\/p\u003e \u003cp\u003e7.6.3.1 Digital Capture 219\u003c\/p\u003e \u003cp\u003e7.6.3.2 Powder and Adhesive Lifters 220\u003c\/p\u003e \u003cp\u003e7.6.3.3 Ink and Paper 222\u003c\/p\u003e \u003cp\u003e7.6.3.4 Casting 224\u003c\/p\u003e \u003cp\u003e7.6.3.5 Photography 225\u003c\/p\u003e \u003cp\u003e7.7 Searching\/AM Records 226\u003c\/p\u003e \u003cp\u003e7.7.1 Database Searches 227\u003c\/p\u003e \u003cp\u003e7.7.2 AM Purported Knowns 228\u003c\/p\u003e \u003cp\u003e7.7.3 Palm Prints and Footprints 229\u003c\/p\u003e \u003cp\u003e7.8 Conclusion 230\u003c\/p\u003e \u003cp\u003eReferences 231\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 DNA Technology and the Future of Disaster Victim Identification 233\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eTaylor M Dickerson III\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 233\u003c\/p\u003e \u003cp\u003e8.2 STRs and Mini-STRs 235\u003c\/p\u003e \u003cp\u003e8.3 Lineage Markers 237\u003c\/p\u003e \u003cp\u003e8.4 Next Generation Sequencing 240\u003c\/p\u003e \u003cp\u003e8.5 Rapid DNA 241\u003c\/p\u003e \u003cp\u003e8.6 Conclusion 243\u003c\/p\u003e \u003cp\u003eReferences 243\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 The Victim Information Center and Data Collection: Its Evolving Role in DVI 249\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJason H Byrd\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction 249\u003c\/p\u003e \u003cp\u003e9.1.1 History of the Family Assistance Center 250\u003c\/p\u003e \u003cp\u003e9.2 Overall Function of the Victim Information Center 251\u003c\/p\u003e \u003cp\u003e9.2.1 Incident Operations 252\u003c\/p\u003e \u003cp\u003e9.2.2 Meeting the Needs of Families and Survivors 253\u003c\/p\u003e \u003cp\u003e9.2.3 Briefings and Communication 254\u003c\/p\u003e \u003cp\u003e9.3 Components of the Victim Information Center 255\u003c\/p\u003e \u003cp\u003e9.3.1 Temporary Reception Center 255\u003c\/p\u003e \u003cp\u003e9.3.2 Call Centers 255\u003c\/p\u003e \u003cp\u003e9.3.2.1 Missing Persons Call Center 256\u003c\/p\u003e \u003cp\u003e9.3.2.2 Air Carrier Call Center 256\u003c\/p\u003e \u003cp\u003e9.4 Accounting for the Victims 257\u003c\/p\u003e \u003cp\u003e9.4.1 Victim Information Program 257\u003c\/p\u003e \u003cp\u003e9.5 Considerations for the Victim Information Center 259\u003c\/p\u003e \u003cp\u003e9.5.1 Equipment and Personnel 259\u003c\/p\u003e \u003cp\u003e9.5.2 Function and Location 261\u003c\/p\u003e \u003cp\u003e9.5.3 Closing the Victim Information Center 262\u003c\/p\u003e \u003cp\u003e9.6 \u003ci\u003eAvailable \u003c\/i\u003eResources 263\u003c\/p\u003e \u003cp\u003eReferences 264\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Ethical and Legal Considerations 265\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eVictor W Weedn\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 265\u003c\/p\u003e \u003cp\u003e10.2 State Authority for Fatality Management 265\u003c\/p\u003e \u003cp\u003e10.3 Federal Medicolegal Death Investigations 267\u003c\/p\u003e \u003cp\u003e10.3.1 Assassination of the President or Other Federal Officials 267\u003c\/p\u003e \u003cp\u003e10.4 Legislatively Mandated Scientific Identification 267\u003c\/p\u003e \u003cp\u003e10.5 Missing Persons Acts and Presumptive Deaths 268\u003c\/p\u003e \u003cp\u003e10.6 Rights of the Dead 269\u003c\/p\u003e \u003cp\u003e10.7 Rights of Others in the Dead 269\u003c\/p\u003e \u003cp\u003e10.8 Constitutional Considerations in Responding to Disasters 270\u003c\/p\u003e \u003cp\u003e10.9 Emergency Powers 271\u003c\/p\u003e \u003cp\u003e10.10 Stafford Act 271\u003c\/p\u003e \u003cp\u003e10.11 Federal Executive Administration 274\u003c\/p\u003e \u003cp\u003e10.12 State and Local Executive Administration 276\u003c\/p\u003e \u003cp\u003e10.13 Military Assistance 276\u003c\/p\u003e \u003cp\u003e10.14 Transportation Incidents 278\u003c\/p\u003e \u003cp\u003e10.15 Terrorist Incidents 279\u003c\/p\u003e \u003cp\u003e10.16 Infectious Epidemics 279\u003c\/p\u003e \u003cp\u003e10.17 National Emergency Family Registry and Locator\u003c\/p\u003e \u003cp\u003eSystem\/National Call Center 280\u003c\/p\u003e \u003cp\u003e10.18 International Legal Considerations in DVI 281\u003c\/p\u003e \u003cp\u003e10.18.1 The US Department of State 281\u003c\/p\u003e \u003cp\u003e10.18.2 Nation-specific Laws 281\u003c\/p\u003e \u003cp\u003e10.18.3 Obligation to Identify Victims 282\u003c\/p\u003e \u003cp\u003e10.18.4 International Disaster Response Law 283\u003c\/p\u003e \u003cp\u003e10.18.5 International Treaties 284\u003c\/p\u003e \u003cp\u003e10.18.6 International Humanitarian Law 286\u003c\/p\u003e \u003cp\u003e10.18.7 International Human Rights Law 287\u003c\/p\u003e \u003cp\u003e10.18.8 Missing and Disappeared Treaties 288\u003c\/p\u003e \u003cp\u003e10.18.9 International Resources 288\u003c\/p\u003e \u003cp\u003e10.18.10 Aviation and Maritime Deaths 290\u003c\/p\u003e \u003cp\u003e10.18.11 Presumed Deaths 291\u003c\/p\u003e \u003cp\u003e10.18.12 Customs 292\u003c\/p\u003e \u003cp\u003e10.18.13 Telecommunications 292\u003c\/p\u003e \u003cp\u003e10.18.14 International Framework for Risk Reduction 292\u003c\/p\u003e \u003cp\u003e10.19 Ethical Considerations in DVI 293\u003c\/p\u003e \u003cp\u003e10.19.1 Community Resilience 295\u003c\/p\u003e \u003cp\u003e10.19.2 Equal Treatment 296\u003c\/p\u003e \u003cp\u003e10.19.3 Respectful Treatment of the Remains 296\u003c\/p\u003e \u003cp\u003e10.19.4 Respect for the Beliefs of the Deceased 296\u003c\/p\u003e \u003cp\u003e10.19.5 Respect for Loved Ones 296\u003c\/p\u003e \u003cp\u003e10.19.6 Respectful Communications 297\u003c\/p\u003e \u003cp\u003e10.19.7 Haitian Example [184–186] 297\u003c\/p\u003e \u003cp\u003e10.20 Conclusion 298\u003c\/p\u003e \u003cp\u003eReferences 299\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 DVI in the Changing Twenty-first Century 313\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eCynthia S Gavin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 313\u003c\/p\u003e \u003cp\u003e11.2 Trend Analysis 314\u003c\/p\u003e \u003cp\u003e11.2.1 Megatrend #1: Population Shift and Megacity Growth 315\u003c\/p\u003e \u003cp\u003e11.2.2 Megatrend #2: Change in Disaster Types that Result in MFIs 315\u003c\/p\u003e \u003cp\u003e11.2.3 Megatrend #3: Massive Technological Advancement 318\u003c\/p\u003e \u003cp\u003e11.2.4 Megatrend #4: Social Media and Social Expectations 320\u003c\/p\u003e \u003cp\u003e11.2.5 Megatrend #5: The Specialization of Ethics 321\u003c\/p\u003e \u003cp\u003e11.2.6 Megatrend #6: A New Dynamic Disaster Management System 322\u003c\/p\u003e \u003cp\u003e11.2.7 Megatrend #7: A New DVI Model 323\u003c\/p\u003e \u003cp\u003e11.2.8 Megatrend #8: Healthcare and the National and International Privatization of Medicine 325\u003c\/p\u003e \u003cp\u003e11.3 Forcefield Analysis 326\u003c\/p\u003e \u003cp\u003e11.3.1 Drivers of Change: Regulation and Legal Factors 326\u003c\/p\u003e \u003cp\u003e11.3.2 Drivers and Constrainers of Change: Politics 328\u003c\/p\u003e \u003cp\u003e11.3.3 Constrainers of Change 332\u003c\/p\u003e \u003cp\u003e11.3.4 A Neutral Context to Gain Insight regarding Driving and Constraining Forces 337\u003c\/p\u003e \u003cp\u003e11.4 DVI Futures in the Twenty-first Century 339\u003c\/p\u003e \u003cp\u003e11.4.1 The Quantum Forensics World 340\u003c\/p\u003e \u003cp\u003e11.4.2 The Modern Crowners World 341\u003c\/p\u003e \u003cp\u003e11.4.3 The Launch-Resistant Forensics World 342\u003c\/p\u003e \u003cp\u003e11.4.4 The Hey Buddy Innovator World 342\u003c\/p\u003e \u003cp\u003e11.5 Future DVI Strategy Performance 343\u003c\/p\u003e \u003cp\u003e11.5.1 DVI Strategies 343\u003c\/p\u003e \u003cp\u003e11.5.2 Stress-Testing Strategies Against DVI Futures 344\u003c\/p\u003e \u003cp\u003e11.6 SWOT Analysis 350\u003c\/p\u003e \u003cp\u003e11.6.1 Strengths 350\u003c\/p\u003e \u003cp\u003e11.6.2 Weaknesses 351\u003c\/p\u003e \u003cp\u003e11.6.3 Opportunities 351\u003c\/p\u003e \u003cp\u003e11.6.4 Threats 352\u003c\/p\u003e \u003cp\u003e11.7 Actionable Recommendations 352\u003c\/p\u003e \u003cp\u003e11.7.1 Refresh the ME\/C Mission Statement 352\u003c\/p\u003e \u003cp\u003e11.7.2 Create an Enduring DVI Vision 354\u003c\/p\u003e \u003cp\u003e11.7.3 Envision a Future Smart Independent Regional Forensic Science System and Move Toward Implementing This Model 356\u003c\/p\u003e \u003cp\u003e11.7.4 Develop Alternate DVI Standards 358\u003c\/p\u003e \u003cp\u003e11.8 Closing Thoughts 360\u003c\/p\u003e \u003cp\u003eReferences 362\u003c\/p\u003e \u003cp\u003eIndex 371 \u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49407110414679,"sku":"9781119652786","price":104.36,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781119652786.jpg?v=1730498213"},{"product_id":"disaster-response-and-recovery-9781119810032","title":"Disaster Response and Recovery","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eAbout the Author xvii\u003c\/p\u003e \u003cp\u003eForeword xix\u003c\/p\u003e \u003cp\u003ePreface xxi\u003c\/p\u003e \u003cp\u003eAcknowledgments xxv\u003c\/p\u003e \u003cp\u003eAbout the Companion Website xxvi\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Knowing What to Expect: Hazards, Vulnerability, and Disasters 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Understanding the Actors: Roles and Responsibilities of Relevant \u003c\/b\u003e\u003cb\u003eStakeholders 53\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Anticipating Attitudes and Behavior in Disasters: Myths, Exaggerations, and Realities 93\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Applying Alternative Management Approaches: Disaster Response and Recovery Theory 123\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Implementing Initial Response Measures: Hazard Detection, Warning, Evacuation and Sheltering 149\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Caring For the Injured, Dead, and Distraught: Overcoming Physical and Emotional Impacts 191\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Managing Public Information, Donations, and Volunteers: Expected Difficulties and Benefits 237\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Moving Beyond Immediate Needs: Damage Assessment, Disaster Declarations, and Debris Removal 277\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Promoting Recovery and Mitigation: Disaster Assistance, Rebuilding, and Vulnerability Reduction 317\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Overcoming Typical Challenges: Vital Considerations for Response and Recovery 357\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Harnessing Technology and Organization: Tools and Structures for Effective Operations 407\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Foreseeing the Future: Prior Lessons, Unaddressed Risks, and Rising Vulnerability 455\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Enhancing Disaster Resilience: Preparedness, Improvisation, Spontaneous Planning, Leadership, and Professionalism 517\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIndex 559\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49407159501143,"sku":"9781119810032","price":70.25,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781119810032.jpg?v=1730498379"},{"product_id":"herbal-drugs-for-the-management-of-infectious-diseases-9781119818724","title":"Herbal Drugs for the Management of Infectious","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cb\u003eHerbal Drug \u003ci\u003efor the\u003c\/i\u003e Management \u003ci\u003eof\u003c\/i\u003e Infectious Diseases\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eThe book is a comprehensive compilation of herbal drug applications for the treatment and management of infectious diseases and addresses issues related to development, challenges, and future prospects associated with the use of herbal medicine.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eThe use of herbal medicines has evolved in various cultures around the world over many millennia. In many developing Asian and African countries, the use of herbal medicines, as supplied by traditional medicinal practitioners, has always been popular. In the last two to three decades, many people in developed countries have begun to turn to alternative or complementary therapies, including the use of herbal medicines, nutraceuticals, functional foods, and other supplements. This resurgence in interest in plant-derived medicines is partly due to the growing dissatisfaction with allopathic medicines, as well as the perception that plant-derived medi\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003ePreface xvii\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Essential Oils as Potent Antimicrobial Agents 1\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eRakesh K. Sindhu, Prabhjot Kaur, Parneet Kaur, Sumitra Singh and Simona Cavalu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 2\u003c\/p\u003e \u003cp\u003e1.2 Essential Oils 3\u003c\/p\u003e \u003cp\u003e1.3 Chemical Composition of Essential Oils 5\u003c\/p\u003e \u003cp\u003e1.4 Mechanism of Action of Essential Oils as Antimicrobials 11\u003c\/p\u003e \u003cp\u003e1.5 Factors Affecting Antimicrobial Activity of Essential Oil 13\u003c\/p\u003e \u003cp\u003e1.6 Essential Oils as Combination Therapy 13\u003c\/p\u003e \u003cp\u003e1.7 Evaluation of Antimicrobial Efficacy of Essential Oils 14\u003c\/p\u003e \u003cp\u003e1.8 Conclusion and Future Perspectives 16\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Herbal Antibiotics for Treating Drug-Resistant Bacteria 23\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eHaixia Chen and Shuqin Li\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 24\u003c\/p\u003e \u003cp\u003e2.2 Resistance Mechanism of Strains 25\u003c\/p\u003e \u003cp\u003e2.3 The Classification of Herbal Secondary Metabolites for Drug Resistance 28\u003c\/p\u003e \u003cp\u003e2.4 Mechanism 41\u003c\/p\u003e \u003cp\u003e2.5 Conclusion and Perspectives 44\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Phytopharmaceuticals for the Management of Fungal Infections 55\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eKampanart Huanbutta and Tanikan Sangnim\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 55\u003c\/p\u003e \u003cp\u003e3.2 Nature of Fungi and Classification of Fungal Disease 56\u003c\/p\u003e \u003cp\u003e3.3 Epidemiology of Fungal Infection 58\u003c\/p\u003e \u003cp\u003e3.4 Limitations of Modern Medicines 60\u003c\/p\u003e \u003cp\u003e3.5 Medicinal Plants With Antifungal Activities 61\u003c\/p\u003e \u003cp\u003e3.6 Phytopharmaceuticals With Antifungal Activities 63\u003c\/p\u003e \u003cp\u003e3.7 Activity and Mechanism of Action of Antifungal Drugs and Phytopharmaceuticals 68\u003c\/p\u003e \u003cp\u003e3.8 Conclusion and Future Prospect of Phytopharmaceuticals for the Management of Fungal Infections 72\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Herbal Bioactives for the Management of Influenza Viral Infection 85\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eShaveta Bhardwaj, Jobanpreet Kaur, Atinderpal Kaur, Satvinder Kaur, Anu Jindal and Inderbir Singh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 86\u003c\/p\u003e \u003cp\u003e4.2 Various Herbal Bioactives With Anti-Influenza Property 87\u003c\/p\u003e \u003cp\u003e4.3 Mechanism of an Anti-Influenza Effect 91\u003c\/p\u003e \u003cp\u003e4.4 Conclusion 93\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Herbal Bioactives for Treating Respiratory Infections 101\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eChandrakantsing V. Pardeshi, Sagar R. Pardeshi, Jitendra B. Naik, Atul A. Shirkhedkar and Sanjay J. Surana\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction 101\u003c\/p\u003e \u003cp\u003e5.2 Overview of Respiratory Tract Infections 103\u003c\/p\u003e \u003cp\u003e5.3 Herbal Bioactives for the Management of RTIs 108\u003c\/p\u003e \u003cp\u003e5.4 Bioactives and Their Derivatives Against Novel Coronavirus Disease 112\u003c\/p\u003e \u003cp\u003e5.5 Emerging Drug Delivery Strategies for Biomedicines in the Management of RTIs 113\u003c\/p\u003e \u003cp\u003e5.6 Clinical Status: Opportunities and Challenges 120\u003c\/p\u003e \u003cp\u003e5.7 Patent Perspectives 120\u003c\/p\u003e \u003cp\u003e5.8 Future Perspectives 122\u003c\/p\u003e \u003cp\u003e5.9 Conclusion 122\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Herbal Bioactives for the Treatment of Gastrointestinal Tract Disorders 133\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eManish Kumar, Inderjeet Verma, Rakesh Kumar Sindhu and Rishabh Srivastava\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 134\u003c\/p\u003e \u003cp\u003e6.2 Classification of GIT Disorders 134\u003c\/p\u003e \u003cp\u003e6.3 The Science of Herbal Medicine 135\u003c\/p\u003e \u003cp\u003e6.4 Need of Herbal Medicine 143\u003c\/p\u003e \u003cp\u003e6.5 Indirect Adverse Effects of Herbal Therapy 144\u003c\/p\u003e \u003cp\u003e6.6 Herbal Bioactive-Based Formulation 144\u003c\/p\u003e \u003cp\u003e6.7 Recent Patents for Herbal Drug Delivery Systems 148\u003c\/p\u003e \u003cp\u003e6.8 Future Perspective 148\u003c\/p\u003e \u003cp\u003e6.9 Conclusion 148\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Herbal Drugs for the Treatment of Ocular Infections 157\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eA. A. Shirkhedkar, Mukesh S. Patil, A. S. Patil and Inderbir Singh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 158\u003c\/p\u003e \u003cp\u003e7.2 Eye Essential Anatomy and Physiology 159\u003c\/p\u003e \u003cp\u003e7.3 Preparation and Method of Use 161\u003c\/p\u003e \u003cp\u003e7.4 Modern Investigations and Findings 163\u003c\/p\u003e \u003cp\u003e7.5 Patents Recently Issued on Herbal Formulations 170\u003c\/p\u003e \u003cp\u003e7.6 Conclusion 171\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Phytopharmaceuticals for Treating Sexually Transmitted Diseases 179\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eKenneth Chinedu Ugoeze\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 180\u003c\/p\u003e \u003cp\u003e8.2 Disease 180\u003c\/p\u003e \u003cp\u003e8.3 Infectious Diseases 181\u003c\/p\u003e \u003cp\u003e8.4 Types of Infectious Diseases 181\u003c\/p\u003e \u003cp\u003e8.5 Treatment of Sexually Transmitted Diseases 190\u003c\/p\u003e \u003cp\u003e8.6 Phytochemicals 194\u003c\/p\u003e \u003cp\u003e8.7 Phytopharmaceuticals 195\u003c\/p\u003e \u003cp\u003e8.8 Future View of Phytopharmaceuticals: The Need for Patenting 225\u003c\/p\u003e \u003cp\u003e8.9 Summary 226\u003c\/p\u003e \u003cp\u003e8.10 Conclusion 229\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Herbal Bioactives for Treating Infectious Skin Diseases 263\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eDarshan R. Telange, Saurabh B. Ganorkar and Atul A. Shirkhedkar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 History of Treating Skin Diseases With Herbs 264\u003c\/p\u003e \u003cp\u003e9.2 Herbal Bioactives for Treating Infectious Skin Diseases\u003c\/p\u003e \u003cp\u003e9.3 Herbs of Choice for Skin Infections 271\u003c\/p\u003e \u003cp\u003e9.4 Herbal Bioactive--Based Formulations for Skin Infections 280\u003c\/p\u003e \u003cp\u003e9.5 Patent Perspective 282\u003c\/p\u003e \u003cp\u003e9.6 Futuristic View 283\u003c\/p\u003e \u003cp\u003e9.7 Conclusion 284\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Plant-Based Vaccines: Challenges and Opportunities 291\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eNavgeet Kaur, Anju Goyal and Rakesh K. Sindhu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 292\u003c\/p\u003e \u003cp\u003e10.2 Production Process of Plant-Based Vaccines 293\u003c\/p\u003e \u003cp\u003e10.3 Current Scenario of the Vaccines 297\u003c\/p\u003e \u003cp\u003e10.4 Challenges 299\u003c\/p\u003e \u003cp\u003e10.5 Conclusion and Future Prospects 300\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Herbal Medicines for HIV Infection and AIDS 307\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eThongtham Suksawat and Pharkphoom Panichayupakaranant\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 308\u003c\/p\u003e \u003cp\u003e11.2 Pathophysiology of HIV Infections 309\u003c\/p\u003e \u003cp\u003e11.3 Current Treatments for HIV\/AIDS 310\u003c\/p\u003e \u003cp\u003e11.4 Targeting for Novel Drug Therapy Against HIV\/AIDS 311\u003c\/p\u003e \u003cp\u003e11.5 Herbal Extract and Phytochemicals with Anti-HIV Effects 312\u003c\/p\u003e \u003cp\u003e11.6 Patents of Herbal and Phytochemical Products for Anti--HIV-1 Infections 330\u003c\/p\u003e \u003cp\u003e11.7 Conclusions 332\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Anthelmintic Potential of Herbal Drugs 341\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eKalpana Nagpal, Pravin Pawar, Ritu Rathi, Nishant Gaur and Inderbir Singh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction 342\u003c\/p\u003e \u003cp\u003e12.2 Drugs Used as Anthelmintics 342\u003c\/p\u003e \u003cp\u003e12.3 Active Principles Derived From Medicinal Plants as Anthelmintic Compounds 349\u003c\/p\u003e \u003cp\u003e12.4 Conclusion 352\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Herbal Drugs for the Management and Treatment of Herpes Simplex Infections 359\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eWiwit Suttithumsatid and Pharkphoom Panichayupakaranant\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 360\u003c\/p\u003e \u003cp\u003e13.2 Pathophysiology of HSV Infections 360\u003c\/p\u003e \u003cp\u003e13.3 Current Treatments for HSV Infection 361\u003c\/p\u003e \u003cp\u003e13.4 Targeting for Novel Drug Therapy Against Herpes Simplex Infection 363\u003c\/p\u003e \u003cp\u003e13.5 Herbal Extracts and Phytochemicals With Anti-HSV Activity 363\u003c\/p\u003e \u003cp\u003e13.6 Recommended Herbal Extracts Used for Herpes Simplex Infection and Futuristic View 381\u003c\/p\u003e \u003cp\u003e13.7 Patents on Herbal Medicine for Anti-Herpes Simplex Infections 381\u003c\/p\u003e \u003cp\u003e13.8 Conclusions 383\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Herbs and Plants Used for the Management and Treatment of Hepatitis Infections 389\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eOmonike O. Ogbole, Temitayo A. Ajayi and Oluwatoyin A. Odeku\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction 390\u003c\/p\u003e \u003cp\u003e14.2 Hepatitis 391\u003c\/p\u003e \u003cp\u003e14.3 Herbal Medicine and Control of Viral Infection 397\u003c\/p\u003e \u003cp\u003e14.4 Major Classes of Medicinal Plants Having Activity Against Hepatitis Virus 398\u003c\/p\u003e \u003cp\u003e14.5 The Common Classes of Bioactive Compounds with Anti-Hepatitis Virus Activities 406\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Herbal Bioactives for Treating Urinary Tract Infections 427\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eKashish Wilson, Manish Kumar, Prerna Sharma, Harkiran Nehra and Inderjeet Verma\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Introduction 428\u003c\/p\u003e \u003cp\u003e15.2 Discussion on Medicinal Plants 431\u003c\/p\u003e \u003cp\u003e15.3 Causes of UTI 431\u003c\/p\u003e \u003cp\u003e15.4 Symptoms of a UTI 432\u003c\/p\u003e \u003cp\u003e15.5 Management 432\u003c\/p\u003e \u003cp\u003e15.6 Herbs Employed for Therapy of Urinary Tract Infection 433\u003c\/p\u003e \u003cp\u003e15.7 Causative Agents in Infection of Urinary Tract 436\u003c\/p\u003e \u003cp\u003e15.8 Mechanism of Herbs 438\u003c\/p\u003e \u003cp\u003e15.9 Future Prospective 438\u003c\/p\u003e \u003cp\u003e15.10 Conclusion 439\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Herbs Used in Parasitic Infection--Malaria 443\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eM.G. Kalaskar, B. Duraiswami, S.J. Surana and A.A. Shirkhedkar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 Introduction 444\u003c\/p\u003e \u003cp\u003e16.2 Parasitic Infections 445\u003c\/p\u003e \u003cp\u003e16.3 Antiparasitic Medicinal Plants and Their Mode of Action 450\u003c\/p\u003e \u003cp\u003e16.4 Antimalarial Herb 452\u003c\/p\u003e \u003cp\u003eReferences 509\u003c\/p\u003e \u003cp\u003eIndex 519\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49407162057047,"sku":"9781119818724","price":170.1,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781119818724.jpg?v=1730498389"},{"product_id":"research-ethics-for-scientists-9781119837886","title":"Research Ethics for Scientists","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003ePreface xi\u003c\/p\u003e \u003cp\u003eAcknowledgments xii\u003c\/p\u003e \u003cp\u003eAbout the Companion Website xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 1 Research Ethics: The Best Ethical Practices Produce the Best Science 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eJudge yourself 6\u003c\/p\u003e \u003cp\u003eMorality vs. ethics 6\u003c\/p\u003e \u003cp\u003eOnward and upward 8\u003c\/p\u003e \u003cp\u003eInauspicious beginnings 8\u003c\/p\u003e \u003cp\u003eHow science works 10\u003c\/p\u003e \u003cp\u003eNothing succeeds like success 13\u003c\/p\u003e \u003cp\u003eSummary 14\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 2 How Honest Is Science? 15\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eJudge yourself 16\u003c\/p\u003e \u003cp\u003eSanctionable research misconduct: fabrication, falsification, and plagiarism 16\u003c\/p\u003e \u003cp\u003e“Scientists behaving badly” 17\u003c\/p\u003e \u003cp\u003eDo scientists behave worse with experience? 20\u003c\/p\u003e \u003cp\u003eJudge yourself 20\u003c\/p\u003e \u003cp\u003eCrime and punishment 21\u003c\/p\u003e \u003cp\u003eJudge yourself 25\u003c\/p\u003e \u003cp\u003eDiscussion questions 27\u003c\/p\u003e \u003cp\u003eSummary 28\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 3 Research Misconduct: Plagiarize and Perish 29\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIdeas 31\u003c\/p\u003e \u003cp\u003eSentences 32\u003c\/p\u003e \u003cp\u003ePhrases 32\u003c\/p\u003e \u003cp\u003eA hoppy example 33\u003c\/p\u003e \u003cp\u003eWhat is plagiarism, really? 34\u003c\/p\u003e \u003cp\u003eJudge yourself 34\u003c\/p\u003e \u003cp\u003eHow many consecutive identical and uncited words constitute plagiarism? 35\u003c\/p\u003e \u003cp\u003eSelf- plagiarism and recycling 36\u003c\/p\u003e \u003cp\u003eJudge yourself 37\u003c\/p\u003e \u003cp\u003eJudge yourself 44\u003c\/p\u003e \u003cp\u003eTools to discover plagiarism 46\u003c\/p\u003e \u003cp\u003eiThenticate 46\u003c\/p\u003e \u003cp\u003eReferences cited 48\u003c\/p\u003e \u003cp\u003eSelf- plagiarism and ethics revisited 51\u003c\/p\u003e \u003cp\u003eJudge yourself 51\u003c\/p\u003e \u003cp\u003eIs plagiarism getting worse? 52\u003c\/p\u003e \u003cp\u003eThe [true] case study: the plagiarizing novelist who also plagiarized her confession to plagiarism and the author of the website “Plagiarism Today” 54\u003c\/p\u003e \u003cp\u003eSummary 55\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 4 Finding the Perfect Mentor 56\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eCaveat 57\u003c\/p\u003e \u003cp\u003eChoosing a mentor 58\u003c\/p\u003e \u003cp\u003eJudge yourself 62\u003c\/p\u003e \u003cp\u003eChoosing a graduate project 69\u003c\/p\u003e \u003cp\u003eJudge yourself 69\u003c\/p\u003e \u003cp\u003eMentors for assistant professors 69\u003c\/p\u003e \u003cp\u003eHow to train your mentor 75\u003c\/p\u003e \u003cp\u003eDiscussion questions 78\u003c\/p\u003e \u003cp\u003eDiscussion questions 80\u003c\/p\u003e \u003cp\u003eSummary 81\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 5 Becoming the Perfect Mentor 82\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eGrants and contracts are a prerequisite to productive science 84\u003c\/p\u003e \u003cp\u003eJudge yourself 85\u003c\/p\u003e \u003cp\u003ePublications are the fruit of research 86\u003c\/p\u003e \u003cp\u003eOn a personal level 87\u003c\/p\u003e \u003cp\u003eJudge yourself 88\u003c\/p\u003e \u003cp\u003eCommon and predictable mistakes scientist make at key stages in their training and careers and how being a good mentor can make improvements 88\u003c\/p\u003e \u003cp\u003eDiscussion questions 104\u003c\/p\u003e \u003cp\u003eSummary 105\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 6 Research Misconduct: Fabricating Data and Falsification 106\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eWhy cheat? 107\u003c\/p\u003e \u003cp\u003eJudge yourself 110\u003c\/p\u003e \u003cp\u003eThe case of Jan Hendrik Schön, “Plastic Fantastic” 110\u003c\/p\u003e \u003cp\u003eThe case of Woo- Suk Hwang: dog cloner, data fabricator 111\u003c\/p\u003e \u003cp\u003eThe case of Diederik Stapel, psychological serial fabricator 113\u003c\/p\u003e \u003cp\u003eJudge yourself 114\u003c\/p\u003e \u003cp\u003eDetection of image and data misrepresentation 116\u003c\/p\u003e \u003cp\u003eJudge yourself 120\u003c\/p\u003e \u003cp\u003eLessons learnt 121\u003c\/p\u003e \u003cp\u003eSummary 121\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 7 Research Misconduct: Falsification and Whistleblowing 122\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eReporting and adjudicating research misconduct 123\u003c\/p\u003e \u003cp\u003eA “can of worms” indeed: the case of Elizabeth “Betsy” Goodwin 125\u003c\/p\u003e \u003cp\u003eJudge yourself 128\u003c\/p\u003e \u003cp\u003eJudge yourself 129\u003c\/p\u003e \u003cp\u003eJudge yourself 131\u003c\/p\u003e \u003cp\u003eJudge yourself 137\u003c\/p\u003e \u003cp\u003eJudge yourself 140\u003c\/p\u003e \u003cp\u003eCultivating a culture of openness, integrity, and accountability 140\u003c\/p\u003e \u003cp\u003eSummary 141\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 8 Publication Ethics of Authorship: Who Is an Author on a Scientific Paper and Why 142\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eThe importance of the scientific publication 143\u003c\/p\u003e \u003cp\u003ePredatory publishing 145\u003c\/p\u003e \u003cp\u003eJudge yourself 146\u003c\/p\u003e \u003cp\u003eWho should be listed as an author on a scientific paper? 146\u003c\/p\u003e \u003cp\u003eJudge yourself 150\u003c\/p\u003e \u003cp\u003eHow to avoid authorship quandaries and disputes 151\u003c\/p\u003e \u003cp\u003eAuthorship for works other than research papers 153\u003c\/p\u003e \u003cp\u003eThe difference between authorship on scientific papers and inventorship on patents 154\u003c\/p\u003e \u003cp\u003eOther thoughts on authorship and publications 155\u003c\/p\u003e \u003cp\u003eJudge yourself 157\u003c\/p\u003e \u003cp\u003eSummary 162\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 9 Grant Proposals: Ethics and Success Intertwined 163\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eWhy funding is crucial 164\u003c\/p\u003e \u003cp\u003eJudge yourself 168\u003c\/p\u003e \u003cp\u003ePath to success in funding 168\u003c\/p\u003e \u003cp\u003eFair play and collaboration 170\u003c\/p\u003e \u003cp\u003eJudge yourself 171\u003c\/p\u003e \u003cp\u003eJudge yourself 173\u003c\/p\u003e \u003cp\u003eRecordkeeping and fiscal responsibility 173\u003c\/p\u003e \u003cp\u003ePushing the limits on proposals 174\u003c\/p\u003e \u003cp\u003eSummary 179\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 10 Peer Review and the Ethics of Privileged Information 180\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eThe history of peer review 181\u003c\/p\u003e \u003cp\u003eThe nature of journals and the purpose of peer review 182\u003c\/p\u003e \u003cp\u003eOpen- access journals vs. subscription journals 182\u003c\/p\u003e \u003cp\u003eWhich papers to review? 188\u003c\/p\u003e \u003cp\u003eOpen reviews and discussion 189\u003c\/p\u003e \u003cp\u003eJudge yourself 190\u003c\/p\u003e \u003cp\u003eGrant proposals 190\u003c\/p\u003e \u003cp\u003eConfidentiality and privileged information 191\u003c\/p\u003e \u003cp\u003eReviewers 192\u003c\/p\u003e \u003cp\u003eJudge yourself 192\u003c\/p\u003e \u003cp\u003eFinal thoughts 193\u003c\/p\u003e \u003cp\u003eSummary 195\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 11 Data and Data Management: The Ethics of Data 196\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eStewardship of data 197\u003c\/p\u003e \u003cp\u003eJudge yourself 199\u003c\/p\u003e \u003cp\u003eJudge yourself 204\u003c\/p\u003e \u003cp\u003eJudge yourself 208\u003c\/p\u003e \u003cp\u003eThe land of in- between: ethics of data presented at professional meetings 208\u003c\/p\u003e \u003cp\u003eJudge yourself 213\u003c\/p\u003e \u003cp\u003eRaw data, processed data, and data analysis: ways to go right and wrong 213\u003c\/p\u003e \u003cp\u003eSummary 213\u003c\/p\u003e \u003cp\u003eDiscussion questions 215\u003c\/p\u003e \u003cp\u003eDiscussion questions 216\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 12 Conflicts of Interest 217\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eThe dynamic landscape of conflicts of interest 218\u003c\/p\u003e \u003cp\u003ePotential conflicts of interest for university scientists 219\u003c\/p\u003e \u003cp\u003eJudge yourself 226\u003c\/p\u003e \u003cp\u003eConflicts of interest within labs or universities 226\u003c\/p\u003e \u003cp\u003eJudge yourself 228\u003c\/p\u003e \u003cp\u003eDiscussion questions 232\u003c\/p\u003e \u003cp\u003eDiscussion questions 237\u003c\/p\u003e \u003cp\u003eSummary 238\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 13 What Kind of Research Science World Do We Want? 239\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eA culture of discipline and an ethic of entrepreneurship 241\u003c\/p\u003e \u003cp\u003eJudge yourself 243\u003c\/p\u003e \u003cp\u003eToo much pressure? 243\u003c\/p\u003e \u003cp\u003eIntegrity awareness through ethics education 246\u003c\/p\u003e \u003cp\u003eAccountability 246\u003c\/p\u003e \u003cp\u003eTruth will win 247\u003c\/p\u003e \u003cp\u003eWe scientists 248\u003c\/p\u003e \u003cp\u003eSummary 249\u003c\/p\u003e \u003cp\u003eReferences 250\u003c\/p\u003e \u003cp\u003eIndex 256\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49407167267159,"sku":"9781119837886","price":38.9,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781119837886.jpg?v=1730498408"},{"product_id":"pharma-and-profits-9781119881339","title":"Pharma and Profits","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eAcknowledgments ix\u003c\/p\u003e \u003cp\u003eIntroduction x\u003cbr\u003e\u003cbr\u003eChapter 1 The $1000 Pill: the Fiscal Consequences of Curing Hepatitis C 1\u003c\/p\u003e \u003cp\u003eChapter 2 Enter the Payers: Fda Approval Does Not Guarantee Commercial Success 10\u003c\/p\u003e \u003cp\u003eChapter 3 Pandemic: mRNA Vaccines And The Race For A Cure 19\u003c\/p\u003e \u003cp\u003eChapter 4 Federal Investment in R\u0026amp;d: Why the Government Does Not Deserve a Piece of Biopharma’s Profits? 34\u003c\/p\u003e \u003cp\u003eChapter 5 Insulin: the True Cost of a 100- Year- Old Drug 44\u003c\/p\u003e \u003cp\u003eChapter 6 The Costly Alzheimer’s Disease Drug: a Questionable Breakthrough 50\u003c\/p\u003e \u003cp\u003eChapter 7 Gene Therapy: How Much Is a Life Worth? 60\u003c\/p\u003e \u003cp\u003eChapter 8 Proving the Value of Expensive Drugs: Should We Pay For Drugs Whose Ultimate Value Is Unknown? 70\u003c\/p\u003e \u003cp\u003eChapter 9 Generic Drugs: Built- in Cost Controls 74\u003c\/p\u003e \u003cp\u003eChapter 10 About Those Soaring Pharma Profits: Are They Driving Healthcare Costs? 80\u003c\/p\u003e \u003cp\u003eChapter 11 Schemes to Lower Drug Prices: the Impact of Reduced Resources on R\u0026amp;d 84\u003c\/p\u003e \u003cp\u003eFinal Thoughts 96\u003c\/p\u003e \u003cp\u003eIndex 98\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49407181160791,"sku":"9781119881339","price":19.51,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781119881339.jpg?v=1730498457"},{"product_id":"handbook-of-space-pharmaceuticals-9783030055257","title":"Handbook of Space Pharmaceuticals","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThis handbook, directed at medical professionals and students who are involved in developing the space industry or are academicians doing research in this area, covers current pharmaceutical knowledge about the difference in medication efficacy in space versus on Earth and includes trial results and best practices for the space research and travel industry. The well-known contributors come from an interdisciplinary background and address all aspects of the subject, from the physiological impact of spaceflight to the effects of radiation.\u003c\/p\u003e\u003cbr\u003eAs the commercial space industry expands its operations in industry and tourism, the field of space pharmaceuticals is growing commensurately. Existing pharmacological research from space is thoroughly covered in this book, and Earth applications are also described. Potential pharmacological solutions are posed along with the known challenges and examples from existing studies, which are detailed at length. This major reference work is a comprehensive and important medical resource for all space industry players.\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eSection I: Principles of Pharmaceuticals.- Section II: Effects of Spaceflight on Human Physiology and its Consequences on Drug Treatment.- Section III: Model Organisms for Pharmaceutical Research in Space.- Section IV: Simulated Microgravity for Pharmaceutical Research.- Section V: Translating Knowledge from Spaceflight Research to Earth Applications.- Section VI: Nutritional and Alternative Approaches to Treatment in Space.","brand":"Springer Nature Switzerland AG","offers":[{"title":"Default Title","offer_id":49415612957015,"sku":"9783030055257","price":522.49,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783030055257.jpg?v=1730527514"},{"product_id":"formulating-poorly-water-soluble-drugs-9783030887186","title":"Formulating Poorly Water Soluble Drugs","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThe objective of this third edition is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist’s approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound’s physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at a minimum a working knowledge of each of the above mentioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cb\u003eContents \u003c\/b\u003e\u003c\/p\u003e  \u003cp\u003e1.      \u003cb\u003eRoute-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs \u003c\/b\u003e……………….. Zachary Warnken, Hugh D.C. Smyth, and Robert O. Williams III \u003c\/p\u003e  \u003cp\u003e2.      \u003cb\u003eOptimizing the Formulation of Poorly Water-Soluble Drugs\u003c\/b\u003e………………………….. Xiangyu Ma, Daniel Ellenberger, Kevin P. O’Donnell, and Robert O. Williams III \u003c\/p\u003e  \u003cp\u003e3.      \u003cb\u003eSolid-State Techniques for Improving Solubility \u003c\/b\u003e……………………………………….. Miguel O. Jara,  Justin R. Hughey, Siyuan Huang, and Robert O. Williams III \u003c\/p\u003e  \u003cp\u003e4.      \u003cb\u003eMechanical Particle-Size Reduction Techniques\u003c\/b\u003e…………………………..……….…… Javier O. Morales, Alan B. Watts, and Jason T. McConville \u003c\/p\u003e  \u003cp\u003e5.      \u003cb\u003eCo-solvent and Complexation Systems \u003c\/b\u003e…………………………………………….... Junhuang Jiang and Robert O. Williams III \u003c\/p\u003e  \u003cp\u003e6.      \u003cb\u003eInjectable Formulations of Poorly Water-Soluble Drugs \u003c\/b\u003e………………………….…... Hannah L. O’Mary and Zhengrong Cui,\u003c\/p\u003e  \u003cp\u003e7.      \u003cb\u003eLipid-Based Formulations\u003c\/b\u003e…………………………………………………................... Daniel A. Davis Jr., Han-Hsuan Peng, and Robert O. Williams III \u003c\/p\u003e  \u003cp\u003e8.      \u003cb\u003eStructured Development Approach for Amorphous Systems \u003c\/b\u003e……………………….... Susanne Page, Reto Maurer, Nicole Wyttenbach, and Felix Ditzinger\u003c\/p\u003e  9.      \u003cb\u003eMelt Extrusion\u003c\/b\u003e………………………………………………………………………. Stephen A. Thompson, Daniel A. Davis Jr., James C. DiNunzio, Charlie Martin,\u003cbr\u003e Robert O. Williams III, and Feng Zhang \u003cp\u003e\u003c\/p\u003e  \u003cp\u003e10.  \u003cb\u003eSpray-Drying Technology\u003c\/b\u003e…………..………..………..………..……………………….. Dave A. Miller, Daniel Ellenberger, Tiago Porfirio, and Marco Gil \u003c\/p\u003e  \u003cp\u003e11.  \u003cb\u003ePharmaceutical Cryogenic Technologies \u003c\/b\u003e………………………………………….... Sawittree Sahakijpijarn, Chaeho Moon, and Robert O. Williams III \u003c\/p\u003e  \u003cp\u003e12.  \u003cb\u003ePrecipitation Technologies for Nanoparticle Production \u003c\/b\u003e……………………………. Tuangrat Praphawatvet and Robert O. Williams III \u003c\/p\u003e  \u003cp\u003e13.  \u003cb\u003eEmerging Technologies to Increase the Bioavailability of Poorly Water-Soluble Drugs \u003c\/b\u003e…\u003cb\u003e\u003cbr\u003e \u003c\/b\u003eDaniel A. Davis Jr., Rishi Thakkar, Mohammed Maniruzzaman, Dave A. Miller, Robert O. Williams III\u003c\/p\u003e  14.  \u003cb\u003eScientific and Regulatory Considerations for Development and Commercialization of Poorly Water-Soluble Drugs\u003c\/b\u003e…………………………………………………………………. .Zedong Dong and Hasmukh Patel \u003cp\u003e\u003c\/p\u003e","brand":"Springer Nature Switzerland AG","offers":[{"title":"Default Title","offer_id":49415655293271,"sku":"9783030887186","price":189.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783030887186.jpg?v=1730527674"},{"product_id":"hazardous-environmental-micro-pollutants-health-impacts-and-allied-treatment-technologies-9783030965228","title":"Hazardous Environmental Micro-pollutants, Health","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThis volume discusses hazardous environmental micropollutants, their impacts on human health, and possible means to mitigate their associated risks. The book features chapters that cover a variety of topics related to environmental micropollutants, which include dusts, infectious particles, heavy metals, organophosphates, atmospheric toxic organic micropollutants, fungal spores, pollutants from E-waste, antibiotic waste, and more. In addition impacts on human health and the environment, economic issues are addressed, with potential policy solutions offered. This work is timely, as hazardous micropollutants in soil, water and air are becoming more common, and this environmental contamination is leading to increasing instances of suboptimal human health outcomes. The book will be of interest to students and researchers in environmental pollution and remediation technology, microbiologists, and environmental regulators.\u003cbr\u003e \u003cp\u003e\u003cb\u003e \u003c\/b\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eChapter 1-Environmental Micropollutants.- Chapter 2-Infectious Diseases, Challenges and their Impacts on Human Health under Changing Climate.- Chapter 3-Marble Dust as an Environmental and Occupational Hazard.- Chapter 4-Impacts of Micropollutants on Economy and Main Spheres of Environment: Soil, Air and Water.- Chapter 5-Micropollutants Impacts and Preventive Measures to Reduce Diseases Burden among School Children.- Chapter 6-Emerging Organic Contaminants, Pharmaceuticals and Personal Care Products (PPCPs): A Threat to Water Quality.- Chapter 7-Environmental and Health Effects of Heavy Metals and their Treatment Methods.- Chapter 8-Organophosphates Pollution Status and their Remediation through Microbial Interaction in 21\u003csup\u003est\u003c\/sup\u003e Century.- Chapter 9-Atmospheric Toxic Organic Micropollutants.- Chapter 10-Impact of Aerial Fungal Spores on Human Health.- Chapter 11-Health Risks Associated with Arsenic Contamination and its Biotransformation Mechanisms in Environment: A Review.- Chapter 12-E-waste Threaten to Environment and Public Health.- Chapter 13-Manufacturing and use of flame retardant chemicals and their impact on the environment and public health.- Chapter 14-Mycotoxins in Environment and Its Health Implications.- Chapter 15-Antibiotics; Multipronged Threat to Our Environment.- Chapter 16-Microplastic pollution and Their Health Impacts.- Chapter 17-Treatment Technologies for the Environmental Micropollutant.","brand":"Springer Nature Switzerland AG","offers":[{"title":"Default Title","offer_id":49415667745111,"sku":"9783030965228","price":98.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783030965228.jpg?v=1730527717"},{"product_id":"inorganic-polyphosphates-from-basic-research-to-medical-application-9783031012365","title":"Inorganic Polyphosphates: From Basic Research to","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThis volume focuses on the biomedical aspects of inorganic polyphosphates, a family of unique bio-inorganic polymers.\u003c\/p\u003e\u003cp\u003eIn recent years, great advances have been made in understanding the development, metabolism, and physiological role of inorganic polyphosphates. These energy-rich polymers, which consist of long chains of phosphate units, are evolutionary old molecules. The acidocalcisomes, conserved organelles from bacteria to humans, as well as the mitochondria play a central role in polyphosphate production and storage. Polyphosphates have been assigned multiple functions, some of which are closely related to medically important processes, such as blood coagulation and fibrinolysis, energy metabolism, cell cycle regulation, apoptosis, chaperon function, microvascularization, stress response, neurodegeneration and aging. The development of bioinspired polyphosphate particles, in combination with suitable hydrogel-forming polymers enabled the development of new strategies in regenerative medicine, in particular for hard and soft tissue repair, but also in drug delivery and antimicrobial defense. \u003c\/p\u003e\u003cp\u003eThis book not only highlights the basic research in this area, but also discusses possible applications. Therefore, it appeals to scientists working in cell biology, biochemistry, and biomedicine and practicioners alike.\u003c\/p\u003e\u003cbr\u003e\u003cp\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e1.\tMitochondrial polyP production \u003cbr\u003eProf. Dr. Andrey Y. Abramov, University College London, London, UK\u003cbr\u003ea.abramov@ucl.ac.uk \u003c\/p\u003e\u003cp\u003e2.\tPolyphosphate in thrombosis and inflammation \u003cbr\u003eProf. Dr. James H. Morrissey and Dr. Stephanie Smith, University of Michigan Medical School, Ann Arbor MI, USA\u003cbr\u003ejim@tf7.org or jhmorris@umich.edu\u003c\/p\u003e\u003cp\u003e3.\tPolyphosphate in mitochondrial energy metabolism and pathology\u003cbr\u003eProf. Dr. Evgeny Pavlov, NYU College of Dentistry, New York NY, USA\u003cbr\u003eep37@nyu.edu\u003c\/p\u003e\u003cp\u003e4.\tPolyphosphate in plasma and human pathologies \u003cbr\u003eProf. Dr. Felix Ruiz, Facultad de Medicina, Universidad de Cádiz, Cádiz, Spain\u003cbr\u003efelix.ruiz@uca.es\u003c\/p\u003e\u003cp\u003e5.\tPolyP in neurodegeneration and aging\u003cbr\u003eProf. Dr. Maria E. Solesio, Rutgers University, Camden NJ, USA\u003cbr\u003em.solesio@rutgers.edu\u003c\/p\u003e\u003cp\u003e6.\tEffects of polyphosphate on function of leukocytes\u003cbr\u003eDr. Patrick Suess, University of Michigan Medical School, Ann Arbor MI, USA\u003cbr\u003epsuess@med.umich.edu\u003c\/p\u003e\u003cp\u003e7.\tPolyP and Vtc complex\u003cbr\u003eProf. Dr. Andreas Mayer, University of Lausanne, Epalinges, Switzerland\u003cbr\u003eandreas.mayer@unil.ch\u003c\/p\u003e\u003cp\u003e8.\tPolyP in antiviral protection\u003cbr\u003eProf. Dr. Dr. h.c. Werner E. G. Müller, Prof. Dr. Xiaohong Wang, Prof. Dr. Dr. Heinz C. Schröder, University Medical Center of Johannes Gutenberg University Mainz\u003cbr\u003ewmueller@uni-mainz.de\u003c\/p\u003e\u003cp\u003e9.\tPolyphosphate in biomimetic implant materials\u003cbr\u003eProf. Dr. Dr. Heinz C. Schröder, Prof. Dr. Xiaohong Wang, Prof. Dr. Dr. h.c. Werner E. G. Müller, University Medical Center of Johannes Gutenberg University Mainz\u003cbr\u003ewmueller@uni-mainz.de\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e","brand":"Springer International Publishing AG","offers":[{"title":"Default Title","offer_id":49415674790231,"sku":"9783031012365","price":98.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783031012365.jpg?v=1730527744"},{"product_id":"plant-molecular-farming-applications-and-new-directions-9783031127939","title":"Plant Molecular Farming: Applications and New","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eMolecular farming is a biotechnological approach that includes the genetic adjustment of agricultural products to create proteins and chemicals for profitable and pharmaceutical purposes. Plant molecular farming describes the manufacture of recombinant proteins and other biologically active product in plants. This approach depends on a genetic transformation of plants that can be accomplished by the methods of stable gene transfer, such as gene transfer to nuclei and chloroplasts, and unstable transfer methods like viral vectors. The requirement for recombinant proteins in terms of quality, quantity, and diversity is increasing exponentially This demand is traditionally met by recombinant protein construction technologies and the engineering of orthodox expression systems based on bacteria or mammalian cell cultures. However, majority of developing countries cannot afford the high costs of medicine derived from such existing methods. Hence, we need to produce not only the new drugs but also the cheaper versions of those already present in the market. Plant molecular farming is considered as a cost-effective technology that has grown and advanced tremendously over the past two decades.\u003c\/p\u003e  \u003cp\u003eThis book summarizes the advances and challenges of plant molecular farming for all those who are working on or have an interest in this rapidly emerging area of research.\u003cbr\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e​Chapter. 1. Molecular Farming in Plants: Introduction and Applications\u003c\/p\u003e\u003cp\u003eChapter. 2. Tools and Techniques Used in Plant Molecular Farming\u003c\/p\u003e\u003cp\u003eChapter. 3. Production of plant natural products in heterologous microbial species\u003c\/p\u003e\u003cp\u003eChapter. 4. Sustainable Manufacturing of Vaccines, Antibodies, and other Pharmaceuticals\u003c\/p\u003e\u003cp\u003eChapter. 5. Limitations, Biosafety, ethics, regulatory issues in molecular farming in plants\u003c\/p\u003e\u003cp\u003eChapter. 6. Conclusion and Perspectives\u003c\/p\u003e","brand":"Springer International Publishing AG","offers":[{"title":"Default Title","offer_id":49415685865815,"sku":"9783031127939","price":37.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783031127939.jpg?v=1730527785"},{"product_id":"nanozymes-in-medicine-9783031205804","title":"Nanozymes in Medicine","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThis​ book reviews the latest advances and biomedical applications of nanozymes, which are artificial nanomaterials exhibiting enzymatic properties similar to natural enzymes, but with less limitations than natural enzymes. Nanozymes display advantages such as facile synthesis, easy surface modification, improved stability, higher catalytic power, and target-specific binding.  Nanozymes containing metals, metal oxides, carbon, and metal sulfide are actually used for cancer therapy, biomolecules sensing, bioimaging, disease diagnostics and diabetes management. The book discloses underlying mechanisms, concepts, recent trends, constraints, and prospects for nanomedicine using nanozymes.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e1. Nano cerium oxide in medicine, agriculture and the industry\u003c\/p\u003e\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e2.      Synthesis and sensing applications of peroxidase-mimic nanozyme\u003c\/p\u003e\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e3.      Nanozymes for glucose sensing and diabetes management\u003c\/p\u003e\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e4.      Nanozymes for bioimaging and disease diagnostics\u003c\/p\u003e\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e5.      Nanozymes for improving anticancer therapy\u003c\/p\u003e\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e6.      Enzyme-based nanomedicine for cancer therapy\u003c\/p\u003e\u003cp\u003e7.      Synthesis of two-dimensional metal, metal oxide and metal hydroxide nanomaterials for biosensing\u003c\/p\u003e\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e8.      Biological applications of nanozymes\u003c\/p\u003e\u003cbr\u003e","brand":"Springer International Publishing AG","offers":[{"title":"Default Title","offer_id":49415696875863,"sku":"9783031205804","price":132.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783031205804.jpg?v=1730527821"},{"product_id":"differential-diagnosis-by-laboratory-medicine-a-quick-reference-for-physicians-9783540430575","title":"Differential Diagnosis by Laboratory Medicine: A","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThis extensive handbook helps clinicians and physicians make a precise diagnosis as well as the right decisions for patient treatment. Up-to-date and comprehensive information for differential diagnosis is presented in a well-structured manner. The different sections describe more than 1950 conditions and around 1200 drugs. It also includes a comprehensive section on international reference values of clinical-biochemical and laboratory parameters. The detailed parameter index and an extensive list of frequently used synonyms and abbreviations enable the reader to quickly locate the information they are looking for.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eFrom the reviews:\u003c\/p\u003e \u003cp\u003e\u003c\/p\u003e \u003cp\u003e\"This is a very important reference text which should be in the library of every hospital department, including emergency wards and outpatients clinics. It is a concise, clearly written Vademecum, which gives quick information. Useful not only to students and house staff but also to all other personnel. … The authors, especially the Slovak team, should be congratulated for assembling such a wealth of information. Note, the book is inexpensive.\" (PER - Pediatric Endocrinology Reviews, Vol. 1 (3), 2004)\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eto Laboratory Medicine.- Blood — Plasma — Serum.- Acid-base Balance.- Amniotic Fluid.- Bronchoalveolar Lavage Fluid.- Cerebrospinal Fluid.- Gastric Fluid.- Hair.- Hematology.- Pericardial Fluid.- Peritoneal Fluid.- Pleural Fluid.- Saliva.- Seminal Fluid.- Sputum.- Stool.- Sweat.- Synovial fluid.- Tears.- Urine.- Biochemical\/Laboratory Findings in Clinical Units and Conditions.- Medicaments — Interfering Factors.- Reference Ranges.- English Synonymous Vocabulary.- Literature Used.- Register.","brand":"Springer-Verlag Berlin and Heidelberg GmbH \u0026 Co. KG","offers":[{"title":"Default Title","offer_id":49419501764951,"sku":"9783540430575","price":159.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783540430575.jpg?v=1730538552"},{"product_id":"charakterisierung-des-wirkmechanismus-von-selektiven-serotonin-wiederaufnahme-inhibitoren-ssri-bei-infektion-mit-sars-cov-2-9783658430702","title":"Charakterisierung des Wirkmechanismus von","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e​Die auftretenden Varianten von SARS-CoV-2 beschleunigen durch ihre höheren Übertragungsraten die globale COVID-19-Pandemie, wodurch dringend neue therapeutische Angriffsziele benötigt werden. Hierbei wurde die antivirale Wirkung von Fluoxetin - einem Antidepressivum - gegen SARS-CoV-2 entdeckt. Mithilfe biochemischer und bildgebenden Methoden wurde der antivirale Wirkmechanismus von Fluoxetin näher analysiert und die saure Ceramidase als SARS-CoV-2 Wirtsfaktor charakterisiert. Veröffentlichte Studien zeigten, dass auch Aspirin eine antivirale Wirkung gegen Erkältungsviren, wie Rhinoviren und Influenzaviren zeigt. Diese antivirale Wirkung wurde in Bezug auf SARS-CoV-2 in Zellkultur und einem patienten-nahen 3D-Infektionsmodell untersucht und bestätigt. Um die Pathologie einer SARS-CoV-2-Infektion zu verstehen, wurde der Eintrittsweg des Virus in das Gehirn untersucht. Im Gegensatz zu anderen Viren überwindet SARS-CoV-2 die Blut-Hirnschranke ohne T-Zellen oder Makrophagen. Ebenso wurde der Einbau eines lipophilen Fluoreszenzfarbstoffs in die Virusmembran etabliert, womit die direkte Markierung verschiedener Viren trotz ihrer unterschiedlicher Membranzusammensetzung möglich ist. Mit superauflösender Mikroskopie (SIM) wurde der virale Eintritt verschiedener umhüllter Viren visualisiert.\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eEinleitung.- Materialien.- Methoden.- Ergebnisse.- Diskussion.- Eigene Publikationsliste.- Literaturverzeichnis.","brand":"Springer Fachmedien Wiesbaden","offers":[{"title":"Default Title","offer_id":49420152144215,"sku":"9783658430702","price":47.49,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783658430702.jpg?v=1730540969"},{"product_id":"biotechnology-of-anti-diabetic-medicinal-plants-9789811635281","title":"Biotechnology of Anti-diabetic Medicinal Plants","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThis book is a unique overview of insights on the genetic basis of anti-diabetic activity, chemistry, physiology, biotechnology, mode-of-action, as well as cellular mechanisms of anti-diabetic secondary metabolites from medicinal plants. The World Health Organization estimated that 80% of the populations of developing countries rely on traditional medicines, mostly plant drugs, for their primary health care needs. There is an increasing demand for medicinal plants having anti-diabetic potential in both developing and developed countries. The expanding trade in medicinal plants has serious implications on the survival of several plant species, with many under threat to become extinct. This book describes various approaches to conserve these genetic resources. It discusses the whole spectrum of biotechnological tools from micro-propagation for large-scale multiplication, cell-culture techniques to the biosynthesis and enhancement of pharmaceutical compounds in the plants. It also discusses the genetic transformation as well as short- to long-term conservation of plant genetic resources via synthetic seed production and cryopreservation, respectively. The book is enriched with expert contributions from across the globe.\u003c\/p\u003e  \u003cp\u003eThis reference book is useful for researchers in the pharmaceutical and biotechnological industries, medicinal chemists, biochemists, botanists, molecular biologists, academicians, students as well as diabetic patients, traditional medicine practitioners, scientists in medicinal and aromatic plants, Ayurveda, Siddha, Unani and other traditional medical practitioners.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e1 In vitro approach and quantification of ‘puerarin and genistein’ - Valuable antidiabetic compounds from Pueraria tuberosa.- 2 In Vitro Exploitation of Medicinal Plants for Continuous Supply of Antidiabetic Bioactive Compounds.- 3 Lower plants as potential source of antidiabetic compounds: The present knowledge and future prospects.- 4 Tissue culture mediated biotechnological intervention in Centella asiatica: A potential antidiabetic plant.- 5 In Vitro Approaches for Mass-Propagation of Stevia rebaudiana.- 6 Swertia chirayita, an endangered anti-diabetic plant: trends in biotechnological interventions.- 7 In vitro propagation and biotechnological improvement strategies of plants with high-intensity sweetener and anti-diabetic activities.- 8 In Vitro Culture Techniques and Metabolite Engineering for Enhanced Anti-Diabetic Secondary Metabolite Production.- 9 Saffron: A prized herb with therapeutic potential against diabetes.- 10 New Insights to Enhance the Desired Anti-Diabetic Compounds in Medicinal and Aromatic Plants Exposed to Abiotic Stress Factors.- 11 Boosting of bioactive secondary metabolites in antidiabetic plants through elicitation: A simple technology for better future.- 12 Rhizobium rhizogenes mediated genetic transformation of antidiabetic plants.- 13 Production of anti-diabetic lignans in flax cell cultures.- 14 Artificial seed development of selected anti-diabetic plants, their storage and regeneration: Progress and prospect.- 15 Cryopreservation of Anti-diabetic plants.\u003cp\u003e\u003c\/p\u003e \u003cbr\u003e\u003cp\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003e\u003c\/b\u003e\u003c\/p\u003e \u003cbr\u003e","brand":"Springer Verlag, Singapore","offers":[{"title":"Default Title","offer_id":49427827687767,"sku":"9789811635281","price":116.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9789811635281.jpg?v=1730565813"},{"product_id":"probiotic-research-in-therapeutics-volume-4-probiotics-in-neurodegenerative-disorders-9789811667596","title":"Probiotic Research in Therapeutics: Volume 4:","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eHumans have numerous microorganisms residing in the body, especially in the gut, far exceeding the human body's normal mammalian cells. Recent research links the gut microbiome, the population of microorganisms living in the gastrointestinal tract, with brain diseases. This volume explores the concept and possibility of its extension to manage a galaxy of CNS diseases, including Parkinson's, Alzheimer's, Autism spectrum disorders, depression, insomnia, and chronic fatigue syndrome. This volume elaborates about communication channels between gut and brain via the vagus nerve, short-chain fatty acids including omega acids, and other inflammasomes.\u003cbr\u003eIn contrast to the available books on the topic, this title is more versatile and endeavors to bring together scientific pre-clinical, and clinical claims on the probable psychobiotic implication of probiotic therapy. The book will appeal similar to the general public, students, experienced researchers, and academicians. It is endeavored to address an aspect of probiotic usage beyond gut disorders. We hope that it would be helpful to people studying the human nervous system and related conditions with their treatments.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e","brand":"Springer Verlag, Singapore","offers":[{"title":"Default Title","offer_id":49427833160023,"sku":"9789811667596","price":125.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9789811667596.jpg?v=1730565832"},{"product_id":"probiotic-research-in-therapeutics-volume-5-metabolic-diseases-and-gut-bacteria-9789811684432","title":"Probiotic Research in Therapeutics: Volume 5:","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThis volume focuses on the potential use of probiotics in treating metabolic disorders such as diabetes mellitus, metabolic acidosis, and gut dysbiosis. Chapters draw an association between gut microbiota and its diversity with metabolic diseases like diabetes, obesity, related liver and gut disorders; gut-brain axis; increased inflammation, and a compromised immune system resulting from these manifestations and scope of intervention with probiotics. Special attention is laid on describing the mechanisms of action of such beneficial effects of probiotic administration. The ability of probiotics to decrease metabolic endotoxemia by restoring the disrupted intestinal mucosal barrier is also included.\u003cbr\u003eThe volume is a comprehensive compilation describing the scope and application of probiotic and prebiotic therapy in treating metabolic disorders. Readers will discover how probiotics are not just confined to the microbiology industry but are showing promising results in the medical and pharmaceutical sectors.\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e","brand":"Springer Verlag, Singapore","offers":[{"title":"Default Title","offer_id":49427835650391,"sku":"9789811684432","price":161.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9789811684432.jpg?v=1730565840"},{"product_id":"pharmacokinetics-basics-to-applications-9789811689499","title":"Pharmacokinetics: Basics to Applications","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThis textbook covers all the essential elements of pharmacokinetics, from basics to applications. It describes authoritative equations and methods on pharmacokinetic evaluation procedures with their importance. Each chapter of the book is supplemented with numerous illustrations and figures for easy understanding of the subject. The book presents mathematical techniques, step- by-step descriptive equations, and applicable statistical analysis methods for the easy understanding of the topic. Further, it covers the preclinical applications and methods of pharmacokinetic aspects. The book also contains mathematical problems and questions related to pharmacokinetics for students. Special emphasis is on recent pharmacokinetic methods and their applications for managing clinical data and biostatistical approaches based on the current literature. This book is primarily meant for researchers and students from academic institutions and to R\u0026amp;D professionals.\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eChapter 1: Fundamentals of Pharmacokinetics.- Chapter 2: Drug absorption.- Chapter 3:  The extent of drug absorption: bioavailability, clearance, bioequivalence, and protein-binding.- Chapter 4:  Pharmacokinetic models and drug distribution.- Chapter 5: Drug metabolism .- Chapter 6: Drug elimination and nonlinear kinetics.- Chapter 7: Pharmacokinetic drug-drug interactions.- Chapter 8: Pharmacokinetic applications.- Chapter 9: Pharmacokinetic sample collection and processing.- Chapter 10: Important bio-analytical instrumental techniques in pharmacokinetics.- Chapter 11: Statistics in pharmacokinetics.- Chapter 12: Pharmacokinetic software and tools.- Chapter 13: Pharmacokinetic laboratory-based experiments.- Chapter 14: Pharmacokinetic numerical problems with solutions.- Chapter 15: Questions, and questions \u0026amp; answers for practice.\u003c\/p\u003e","brand":"Springer Verlag, Singapore","offers":[{"title":"Default Title","offer_id":49427836830039,"sku":"9789811689499","price":79.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9789811689499.jpg?v=1730565844"},{"product_id":"antibody-drug-conjugates-and-cellular-metabolic-dynamics-9789811956379","title":"Antibody-Drug Conjugates and Cellular Metabolic","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThis book summarizes the related research achievements in Antibody-drug conjugates (ADCs) and their cell metabolism kinetics. The book has three main parts. The first part describes the basic theory of ADCs, including the basic concept and structure of ADCs, and the relationship between the targets of ADCs and their specific functions. The second part mainly introduces the endocytosis and intracellular metabolism of ADCs, including the relationship between endocytosis and ADC activity, the endocytosis and intracellular transport of ADCs, the distribution and metabolism of ADC in vivo. Then it discusses the new formats and research technology of ADCs, including the application of miniaturized antibodies in ADC synthesis, novel carriers for ADC design, the technology and application of site-specific conjugation, and approaches for analyzing the drug: antibody ratio (DAR), the study of pharmacokinetics of ADCs. This book combines the basic theory with the research technology. It can be used as a reference book for students, teachers and researchers of biomedical field.\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eAntibody-Drug Conjugates Basic Concepts and Structures.- Relationship between target and specific action of antibody-drugs conjugates.- The internalization and therapeutic activity of antibody drug conjugate.- The internalization and intracellular trafficking of ADC.- Distribution and metabolism of antibody-drug conjugates.- Application of Antibody fragments in ADCs.- Novel Targeting Carriers in Antibody-drug Conjugates.- Site-specified Conjugating Technology and Application.- Determination of drug-to-antibody ratio of ADCs.- Pharmacokinetic study of antibody-drug conjugates.","brand":"Springer Verlag, Singapore","offers":[{"title":"Default Title","offer_id":49427849773399,"sku":"9789811956379","price":113.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9789811956379.jpg?v=1730565888"},{"product_id":"pharmaceutical-applications-of-supramolecules-9783031218996","title":"Pharmaceutical Applications of Supramolecules","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThis book outlines the use of supramolecules as different pharmaceutical drugs. Supramolecular chemistry in pharmaceutical sciences is quite a young and rapidly developing field. Supramolecular assemblies might offer an alternative for existing pharmaceutical formulations, as they facilitate the improvement of physicochemical and pharmacological properties i.e., higher bioavailability, better biocompatibility and drug-targeting, fewer multidrug-resistances. This book offers an overview of the recent advances in supramolecular structures and discusses the future aspects and challenges related to the development of these molecules, providing also a perspective on how to overcome these issues. \u003c\/p\u003eDivided into 13 chapters contributed by experts in their field, the book provides a deeper understanding of intermolecular forces playing pivotal roles in mediating the interactions between chemical molecules and biological systems by focusing on different applications of supramolecular compounds. In this book, readers will find valuable insights into the preparation of supramolecules and the latest research and development trends of supramolecules as anticancer drugs, including liquid-crystalline supramolecular assemblies, and as antimicrobial, antiviral, anti-inflammatory and cardiovascular drugs. Particular attention is given to the application of supramolecules in the fields of biomedicine, bioimaging, and vaccine development.\u003cp\u003e\u003c\/p\u003e\u003cp\u003e \u003c\/p\u003eGiven its breadth, this book will appeal to a wide readership from researchers and students interested in these fields to professionals in the pharma industry.\u003cp\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eTable of Contents (13 Chapters)\u003cbr\u003e1. Supramolecules in pharmaceutical science: A brief overviewNidhi Goel* and Naresh Kumar*\u003cbr\u003e2. Basic strategy and methods of preparation for supramoleculesVikrant Jayant, Shakeel Alvi and Rashid Ali*\u003cbr\u003e3. Research and development of supramolecules as anticancer drugsManjit and Brahmeshwar Mishra*\u003cbr\u003e4. Research and development of liquid-crystalline supramolecular assemblies as anticancer drugsAtsushi Yoshizawa*\u003cbr\u003e5. Progressive approach of supramolecules towards the advancement of antimicrobial drugsManju Sharma, Nidhi Aggarwal, Sonika Chibh, Avneet Kour, Samraggi Choudhury and Jiban Jyoti Panda*\u003cbr\u003e6. Promising functional supramolecules in antiviral drugsKanika Arora, Aakriti Singh, Aaqib Javaid and Shyam lal Mudavath*\u003cbr\u003e7. Role of supramolecules in anti-inflammatory drugsPatil Shivprasad Suresh, Anmol and Upendra Sharma*\u003cbr\u003e8. Recent advancements of supramolecules in the evolution of cardiovascular drugsMerve Kiremit and Ayse B. Tekinay*\u003cbr\u003e9. Development of supramolecules in the field of nanomedicinesAbhishesh Kumar Mehata and M. S. Muthu*\u003cbr\u003e10. Supramolecular self-assembled peptide-based nanostructures and their applications in biomedicineUttam Ghosh and Goutam Ghosh*\u003cbr\u003e11. Recent advancement of supramolecules in the field of bioimagingUttam Ghosh , Naresh Kumar and Goutam Ghosh*\u003cbr\u003e12. Role of supramolecules in vaccine developmentNaresh Kumar* and Nidhi Goel*\u003cbr\u003e13. Supramolecules: Future challenges and perspectivesNidhi Goel* and Naresh Kumar*","brand":"Springer International Publishing AG","offers":[{"title":"Default Title","offer_id":50470476939607,"sku":"9783031218996","price":132.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783031218996.jpg?v=1744898440"},{"product_id":"biochemistry-and-cell-biology-of-ageing-part-iv-clinical-science-9783031265754","title":"Biochemistry and Cell Biology of Ageing: Part IV,","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThis book provides an up-to-date overview of key areas of ageing research and bridges the gap between the subcellular events and the reality of ageing as seen in clinical practice.\u003c\/p\u003e\u003cp\u003eTo this end, the reader learns about the historical development and progression of clinical ageing research. All chapters address the biochemistry or cell biology of various ageing events (to the extent that the data are available) and work their way to the clinical understanding we have of ageing. The focus of this volume is on how dietary restriction, virus infection and chronic inflammation affect the ageing process. Additionally, this book discusses how phosphate metabolism and metabolic dysfunction contribute to ageing events and how various organs and tissues (e.g. tendons, ears, heart muscle, and the endocrine system) age. \u003c\/p\u003e\u003cp\u003e \u003c\/p\u003e\u003cp\u003eThis book follows on from Parts I, II and III of \u003ci\u003eBiochemistry and Cell Biology of Ageing\u003c\/i\u003e within the Subcellular Biochemistry book series and aims to bring the subcellular and clinical areas into closer contact by including interesting and significant biomedical ageing topics that were not included in the earlier volumes. Comprehensive and cutting-edge, this book is a valuable resource for experienced researchers and early career scientist alike, who are interested in learning more about the fascinating and challenging question of why and how our cells age.\u003c\/p\u003e\u003cbr\u003e\u003cp\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cb\u003e​See Attachments\u003c\/b\u003e","brand":"Springer International Publishing AG","offers":[{"title":"Default Title","offer_id":50470477267287,"sku":"9783031265754","price":142.49,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783031265754.jpg?v=1744898441"},{"product_id":"aromatic-and-medicinal-plants-of-drylands-and-deserts-9781032169729","title":"Aromatic and Medicinal Plants of Drylands and","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThe description and analysis of the Mexican and other countries desertic plants from the point of view of their use in traditional medicine and their potential use in integrative medicine is the overall theme of this book. Aromatic and Medicinal Plants of Drylands and Deserts: Ecology, Ethnobiology and Potential Uses describes the historic use of drylands plants, botanical and geological classification, also describes the endemic plants used in traditional medicine, going through the most relevant aspects of biomedicine and integrative medicine. The chemical and bioactive compounds from desertic medicinal and aromatic plants and the analytic techniques to determine chemical and bioactive compounds from the medicinal and aromatic plants are reviewed. Ethnobiology is detailed in the present book as well as the importance of the integrative medicine for the ancient and actual cultures. The book represents an effort to keep the ethnobiological knowledge of communities for the use of tra\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003ePreface\u003cbr\u003eChapter 1\u003cbr\u003e Introduction to plant taxonomy: vascular and non-vascular plants with medicinal use. \u003cbr\u003e Muro-Pérez G., Sánchez-Salas J., Cano-Villegas O., López-García R., Valenzuela-Núñez L. M.\u003c\/p\u003e\u003cp\u003eChapter 2 \u003cbr\u003e Mexican desertic medicinal plants: biology, ecology, and distribution. \u003cbr\u003e Hernández-Herrera J. A., Valenzuela-Núñez L. M., Encina-Domínguez J. A., Martínez-Sifuentes A. R., Lara-Reimers E. A., Navarrete-Molina C.\u003c\/p\u003e\u003cp\u003eChapter 3\u003cbr\u003e Mexican Desert: Health and biotechnological properties potential of some cacti species (Cactaceae).\u003cbr\u003e Trujillo J., Pérez-Miranda S., Ramírez-Hernández A., Muñiz-Ramírez A., García-Campoy A.H., Ramírez-Rodríguez Y. \u003c\/p\u003e\u003cp\u003eChapter 4 Potential of plants from the arid zone of Coahuila in Mexico for the extraction of essential oils.\u003c\/p\u003e\u003cp\u003e Solís-Quiroz O. S., González-Machado A. C., Aguirre-Joya J. A., Aguillón-Gutiérrez D. R., Ramírez-Moreno A., Torres-León C.\u003c\/p\u003e\u003cp\u003eChapter 5 Ethnopharmacology of important Aromatic Medicinal plants of the Caatinga, Northeastern Brazil.\u003c\/p\u003e\u003cp\u003e Olaitan-Balogun S., Medeiros-Bandeira M. A., do Nascimento-Magalhães K., Lima-Soares I. \u003cbr\u003eChapter 6 Plants of the Chihuahuan Semi-desert for the Control of Phytopathogens.\u003cbr\u003e Cándido-del Toro C. A., Arredondo-Valdés R., Govea-Salas M., Anguiano-Cabello J. C., Segura-Ceniceros E. P., Ramos-González R., Ascacio-Valdés J. A., Laredo Alcalá E. I., Iliná A.\u003c\/p\u003e\u003cp\u003eChapter 7 Phytochemical compounds from desert plants to management of plant-parasitic nematodes.\u003c\/p\u003e\u003cp\u003e Marco Tucuch-Pérez A., Arredondo-Valdés R., Hernández-Castillo F. D., Ochoa-Fuentes Y. M., Laredo Alcalá E. I., Anguiano-Cabello J. C.\u003c\/p\u003e\u003cp\u003eChapter 8 Plant phytochemicals from the Chihuahuan semi-desert with possible herbicidal actions.\u003c\/p\u003e\u003cp\u003e Barroso-Ake A. C., Arredondo-Valdés R., Ramos-González R., Laredo-Alcalá E. I., Aguilar-González C. N., Ascacio-Valdés J. A., Govea-Salas M., Iliná A., Tucuh-Peréz M. A.\u003c\/p\u003e\u003cp\u003eChapter 9 ¬Chemical and bioactive compounds from Mexican desertic medicinal plants. \u003c\/p\u003e\u003cp\u003e López-Romero J. C., Torres-Moreno H., Ireta-Paredes A. R., Charles-Rodríguez A. V., Flores-López M. L.\u003c\/p\u003e\u003cp\u003eChapter 10 Edible coating based on chia (Salvia hispanica L.) functionalized with Rhus microphylla fruit extract to improve the cucumber (Cucumis sativus L.) shelf life.\u003c\/p\u003e\u003cp\u003e Charles-Rodríguez AV., Reyes-de la Luz M., Guía-García J. L., Peña-Ramos F.M., Robledo-Olivo A., Hench-Cabrera A. F., Flores-López M. L.\u003c\/p\u003e\u003cp\u003eChapter 11 Larrea tridentata: bioactive compounds, biological activities and its potential use in phytopharmaceuticals improvement.\u003c\/p\u003e\u003cp\u003e López-Romero J. C., Torres-Moreno H, Rodríguez-Martínez K. L., Suárez-García A. del C., Beltrán-Martínez M. E., García-Dávila J.\u003c\/p\u003e\u003cp\u003eChapter 12 Toxicological aspects of medicinal plants that growth in drylands and polluted environments.\u003c\/p\u003e\u003cp\u003e Pérez-Morales R., Téllez López M. A., Olivas Calderón E. H., González-Zamora A.\u003c\/p\u003e","brand":"Taylor \u0026 Francis Ltd","offers":[{"title":"Default Title","offer_id":51018876715351,"sku":"9781032169729","price":147.25,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781032169729.jpg?v=1750778492"},{"product_id":"good-laboratory-practices-for-forensic-chemistry-9783319097244","title":"Good Laboratory Practices for Forensic Chemistry","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eGood Laboratory Practices for Forensic Chemistry\u003c\/i\u003e acknowledges the limitations that often challenge the validity of data and resultant conclusions. Eight chapters examine current practices in analytical chemistry as well as business practices, guidelines and regulations in the pharmaceutical industry to offer improvements to current practices in forensic chemistry. It discusses topics ranging from good manufacturing practices (GMP), good laboratory practices (GLP), the International Conference on Harmonisation (ICH), quality assurance (QA), and quality risk management (QRM), among others. This book is a guide for scientists, professors, and students interested in expanding their knowledge of forensic chemistry.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e.- 1 Introduction\u003c\/p\u003e\u003cp\u003e.- 2 What is Science \u003c\/p\u003e\u003cp\u003e.- 3 Forensic Chemistry \u003c\/p\u003e\u003cp\u003e.- 4 Code of Federal Regulations (21CFR) Guidance’s\u003c\/p\u003e\u003cp\u003e.- 5 International Committee on Harmonization (ICH)\u003c\/p\u003e\u003cp\u003e.- 6 International Organization for standards\u003c\/p\u003e\u003cp\u003e.- 7 Statistical Considerations\u003c\/p\u003e\u003cp\u003e.- 8 Conclusions.\u003c\/p\u003e","brand":"Springer International Publishing AG","offers":[{"title":"Default Title","offer_id":51021156680023,"sku":"9783319097244","price":33.74,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783319097244.jpg?v=1750785319"},{"product_id":"polymer-gels-science-and-fundamentals-9789811338687","title":"Polymer Gels: Science and Fundamentals","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThis book exclusively focuses on the science and fundamentals of polymer gels, as well as the numerous advantages that polymer gel-based materials offer. It presents a comprehensive collection of chapters on the recent advances and developments in the core science and fundamentals of both synthetic and natural polymer-based gels, and pays particular attention to applications in the various research fields of biomedicine and engineering. Key topics addressed include: polysaccharide-based gels and their fundamentals; stimuli-responsive polymer gels; polymer gels applied to enzyme and cell immobilization; chitosan-based gels for cancer therapy; natural polymeric and gelling agents; radiation dosimetry; polymeric gels as vehicles for enhanced drug delivery across the skin; transport in and through gel; and polymer gel nanocomposites and functional gels. The book’s extensive and highly topical coverage will appeal to researchers working in a broad range of fields in industry and academia alike.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eBrea Gum Gel Capacity.- An Overview on Polymer Gels Applied to Enzyme and Cell Immobilization.- Xylan-Based Gels and Their Fundamentals.- Stimuli-Responsive Polymer Gels for Protein Delivery.- Polysaccharide-Based Polymergels.- Chitosan Based Gels for Cancer Therapy.- Natural Polymeric and Gelling Agents.- Radiation Dosimetry - A Different Prospective of Polymer Gel.- Polymeric Gels: Vehicles for Enhanced Drug Delivery Across Skin.- Graphene Oxide - Polymer Gels.- Transport in and Through Gel.- Strategizing Advance Application of Polymer Gels by Incorporation of Fillers.- Polymer Gels: New Materials for the Future.- Polymer Gel-Clay (Nano)Composites.- Functional Gels.- Molecular Distinction Between Structures of Nanoporous Siloxane Polymers.- Stimuli Responsive Polysaccharides Based Gels: Fundamental and Pharmaceutical Aspects.- Polymer Gel for Islet Encapsulation for Diabetes Therapy.\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e","brand":"Springer Verlag, Singapore","offers":[{"title":"Default Title","offer_id":51021454737751,"sku":"9789811338687","price":151.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9789811338687.jpg?v=1750785991"},{"product_id":"drug-discovery-and-development-traditional-medicine-and-ethnopharmacology-9788119072859","title":"Drug Discovery and Development: Traditional","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThe pharmaceutical industry is currently facing a significant innovation deficit, despite the potential offered by advances in genomics, high throughput screening, and combinatorial and asymmetric synthesis for drug discovery. The number of new molecules registered annually has actually decreased, contrary to expectations, and post-marketing failures of blockbuster drugs have become a major concern. On the other hand, there is a growing global trend towards the use of traditional medicine, including complementary and alternative therapies. Ethnopharmacology and traditional medicines have played a significant role in the past in the discovery of natural products, and there are two clear areas where ethnopharmacology can make a significant contribution to future drug research. First, as a discovery engine for new targets, leads, and second, the use of quality-assured and standardized traditional medicines. This book provides a historical perspective, future prospects, and the significance of ethnopharmacology in drug research, as well as important steps in botanical drug discovery and development, including bioprospecting, quality control, standardization, pharmaceutics, stability, pharmacokinetics, and bioavailability, with examples from ethnopharmacology and herbal medicine. The book also includes an excellent overview of Good Laboratory and Good Clinical Practices, as well as very useful summary steps for filing IND or NDA for botanical products. Additionally, the book provides the regulators perspective on validating claims and how ethnopharmacological or traditional medicines may require a different approach.","brand":"New India Publishing Agency","offers":[{"title":"Default Title","offer_id":51045573198167,"sku":"9788119072859","price":40.36,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9788119072859.jpg?v=1750965061"},{"product_id":"drug-discovery-and-development-traditional-medicine-and-ethnopharmacology-9788189422295","title":"Drug Discovery and Development: Traditional","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eWhile biotechnological advances, genomics and high throughput screenings or combinatorial and asymmetric syntheses are opening new opportunities in drug discovery, the industry is facing serious innovation deficit. The total number of new molecules registered per year has dropped in contrast to expected increase. Post marketing failures of blockbuster drugs have become major concerns of industries. On the other side, globally there is a major shift to sue of traditional medicine involving complementary and alternative therapies. Ethnopharmacology and traditional medicines have contributed in past significantly in the process of natural product drug discovery. There are two clear tracks where ethnopharmacology has potential to contribute in future drug research. First, as a discovery engine to provide new targets, leads, and second, use of quality assured and standardized traditional medicines. In this scenario, it is important to understand the mechanisms of drug discovery and pharmaceutical development with a focus on herbal drugs and neutraceutical. This book provides historical perspective, future prospects and significance of ethnopharmacology in drug research. It also provides important steps in botanical drug discovery and development including bioprospecting, quality control, standardization, pharmaceutics, stability, pharmacokinetics, and bioavailability with examples from ethnopharmacology and herbal medicine. One of the important feature of this book is to give an excellent insight to Good Laboratory and Good Clinical Practices along with very useful summary steps involved in filing IND or NDA of botanical products. The book also gives Regulators' perspective of validating claims and how ethnopharmacological or traditional medicines need different approach.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eSection I. Discovery: 1. Overview of medical and drug development. 2. TM\/CAM and ethnopharmacology. 3. Natural product and drug discovery. 4. Innovation and drug discovery. 5. Bioprospecting and IPR. Section II. Development 6. Safety and regulatory issues. 7. Quality control and standardization. 8. Herbal pharmaceutics: stability and pharmacokinetics. 9. Preclinical and clinical evaluation. 10. Regulatory guidance to industry. 11. Validating of health claims and pharmacoepidemiology.Section III. Technology: 12. Biotechnology in herbal drug research. 13. Microarrays and high throughput screening. 14. Pharmacogenomics and ethnopharmacology. 15. Ethnoinformatics and AyuSoft. 16. Systems approaches and reverse pharmacology. 17. Future perspectives.","brand":"New India Publishing Agency","offers":[{"title":"Default Title","offer_id":51045594267991,"sku":"9788189422295","price":65.0,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9788189422295.jpg?v=1750965124"},{"product_id":"drug-discovery-and-development-from-targets-and-molecules-to-medicines-9789811555367","title":"Drug Discovery and Development: From Targets and","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003eThis book describes the processes that are involved in the development of new drugs. The authors discuss the history, role of natural products and concept of receptor interactions with regard to the initial stages of drug discovery. In a single, highly readable volume, it outlines the basics of pharmacological screening, drug target identification, and genetics involved in early drug discovery. The final chapters introduce readers to stem therapeutics, pharmacokinetics, pharmacovigilance, and toxicological testing. \u003c\/p\u003e  \u003cp\u003eGiven its scope, the book will enable research scholars, professionals and young scientists to understand the key fundamentals of drug discovery, including stereochemistry, pharmacokinetics, clinical trials, statistics and toxicology.\u003c\/p\u003e\u003cbr\u003e\u003cp\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eChapter 1: Historical Perspective of Drug Discovery and DevelopmentChapter2: Natural Products and Drug DiscoveryChapter 3: The Concept Of Receptors And Molecules Interaction In Drug  Discovery And DevelopmentChapter 4: Chemical Structure and Stereochemistry Chapter 5:Biased Agonism:Renewing GPCR's targetabilityChapter 6: Computer Aided Drug DiscoveryChapter 7: Pharmacological screening of novel chemical entitiesChapter 8:Drug Target Identification and Validation:Chapter 9: Genetics and Drug DiscoveryChapter 10: Stem Cells and Therapeutics Chapter 11: Pharmacokinetics Chapter 12: Regulatory Toxicological TestingChapter 13: Nanotoxicology and Regulatory Requirements\tChapter 14: Clinical Trials in Industrial Drug DevelopmentChapter 15:PharmacovigilanceChapter 16: Regulatory Process for New Drug Approval in IndiaChapter 17: Pharma Industry, Academia, Regulatory Authorities, and End-user Interaction in the Chapter 18: Statistics\u003cbr\u003e","brand":"Springer Verlag, Singapore","offers":[{"title":"Default Title","offer_id":51047312064855,"sku":"9789811555367","price":189.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9789811555367.jpg?v=1750971068"},{"product_id":"advances-in-qsar-modeling-applications-in-pharmaceutical-chemical-food-agricultural-and-environmental-sciences-9783319860183","title":"Advances in QSAR Modeling: Applications in","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThe book covers theoretical background and methodology as well as all current applications of Quantitative Structure-Activity Relationships (QSAR). Written by an international group of recognized researchers, this edited volume discusses applications of QSAR in multiple disciplines such as chemistry, pharmacy, environmental and agricultural sciences addressing data gaps and modern regulatory requirements. Additionally, the applications of QSAR in food science and nanoscience have been included – two areas which have only recently been able to exploit this versatile tool. This timely addition to the series is aimed at graduate students, academics and industrial scientists interested in the latest advances and applications of QSAR.\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePerformance parameters and validation practices in QSAR modeling.- Towards interpretable QSAR models.- The use of topological indices in QSAR and QSPR modeling.- The Maximum Common Substructure (MCS) search as a new tool for SAR and QSAR.- The universal approach for structural and physico-chemical interpretation of QSAR\/QSPR models.- Generative Topographic Mapping approach.- Monte Carlo methods for solution of tasks in Environmental Sciences.- QSAR in Environmental Research.- QSAR applications for environmental chemical prioritization: Biotransformation of chemicals.- QSAR modeling in environmental risk assessment: application to the prediction of pesticide toxicity.- Counter propagation artificial neural network (CP ANN) models for prediction of carcinogenicity of non congeneric chemicals for regulatory uses.- Strategy for identification of critical nanomaterials properties linked to biological impacts: interlinking of experimental and computational approaches.- QSAR\/QSPR modeling in the design of drug candidates with balanced pharmacodynamics and pharmacokinetic properties.- Molecular modeling of food chemicals as potential bioactive compounds.- On application QSARs in Food and Agricultural Sciences: History and Recent Developments.","brand":"Springer International Publishing AG","offers":[{"title":"Default Title","offer_id":51360367116631,"sku":"9783319860183","price":999.99,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783319860183.jpg?v=1754127445"},{"product_id":"space-pharmacology-9781461433958","title":"Space Pharmacology","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eSpace Pharmacology is a review of the current knowledge regarding the use of pharmaceuticals during spaceflights. Every section begins with a topic overview, and is followed by a discussion of published data from spaceflight, and from ground experiments meant to model the spaceflight situation.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eChapter 1: Introduction.- Chapter 2: Absorption.- Chapter 3: Distribution.- Chapter 4: Metabolism and Excretion.- Chapter 5: Central Nervous System.- Chapter 6: Cardiovascular System.- Chapter 7: Gastrointestinal System.- Chapter 8: Musculoskeletal System.- Chapter 9: Multiple Systems Spaceflight Effects.- Chapter 10: Conclusions - Special Challenges of Long Duration Exploration.- References.- Abbreviations.\u003c\/p\u003e","brand":"Springer-Verlag New York Inc.","offers":[{"title":"Default Title","offer_id":51742559207767,"sku":"9781461433958","price":49.49,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781461433958.jpg?v=1758385232"},{"product_id":"essential-pharmaceutics-9783030317478","title":"Essential Pharmaceutics","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003eParticularly in healthcare fields, there is growing movement away from traditional lecture style course towards active learning and team-based activities to improve learning and build higher level thinking through application of complex problems with a strong foundation of facts and data. Essential Pharmaceutics is suited to this modern teaching style, and is the first book of its kind to provide the resources and skills needed for successful implementation of an active learning pharmaceutics course.This text offers a format that is specifically suited for integration in an active learning, team-based classroom setting. It is ideal for self-learning for the beginning pharmaceutics student, based upon the extensive utilization of figures, tables, and its overview of essential topics in pharmaceutics. Also unique to this text is the integration of case studies based upon modern pharmaceutical products which are designed to reinforce importance pharmaceutical concepts and teach essential skills in literature review and patent searching. Case studies covering all topics covered in the text have been developed by the authors that allow application of the content in the flipped-classroom pharmaceutical course.\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePreface:Designing a Flipped-Classroom Pharmaceutics Course.- Guide to Patent and Literature Searching in Pharmaceutics.- Preformulation.- Capsules and Tablets.- Modified Release Solid Oral Dosage Forms.- Solution-Based Dosage Forms and Sterile Products .- Suspensions.- Emulsions.- Ophthalmic Delivery.- Nasal Dosage Forms.- Topical and Transdermal Dosage Forms.- Suppositories and Inserts.- Pulmonary Drug Delivery .- Regulations in Drug Product Development. \u003cbr\u003e","brand":"Springer Nature Switzerland AG","offers":[{"title":"Default Title","offer_id":51742844125527,"sku":"9783030317478","price":54.99,"currency_code":"GBP","in_stock":true}]}],"url":"https:\/\/bookcurl.com\/collections\/medicinal-chemistry.oembed?page=3","provider":"Book Curl","version":"1.0","type":"link"}